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A B S T R A C T
Background
Medicinal plant products are used orally for treating osteoarthritis. Although their mechanisms of action have not yet been elucidated in
full detail, interactions with common inflammatory mediators provide a rationale for using them to treat osteoarthritic complaints.
Objectives
To update a previous Cochrane review to assess the benefits and harms of oral medicinal plant products in treating osteoarthritis.
Search methods
We searched electronic databases (CENTRAL, MEDLINE, EMBASE, AMED, CINAHL, ISI Web of Science, World Health Organization Clinical
Trials Registry Platform) to 29 August 2013, unrestricted by language, and the reference lists from retrieved trials.
Selection criteria
Randomised controlled trials of orally consumed herbal interventions compared with placebo or active controls in people with
osteoarthritis were included. Herbal interventions included any plant preparation but excluded homeopathy or aromatherapy products,
or any preparation of synthetic origin.
Data collection and analysis
Two authors used standard methods for trial selection and data extraction, and assessed the quality of the body of evidence using the
GRADE approach for major outcomes (pain, function, radiographic joint changes, quality of life, withdrawals due to adverse events, total
adverse events, and serious adverse events).
Main results
Forty-nine randomised controlled studies (33 interventions, 5980 participants) were included. Seventeen studies of confirmatory design
(sample and eDect sizes pre-specified) were mostly at moderate risk of bias. The remaining 32 studies of exploratory design were at
higher risk of bias. Due to diDering interventions, meta-analyses were restricted to Boswellia serrata (monoherbal) and avocado-soyabean
unsaponifiables (ASU) (two herb combination) products.
Five studies of three diDerent extracts from Boswellia serrata were included. Moderate-quality evidence from two studies (85 participants)
indicated that 90 days treatment with 100 mg of enriched Boswellia serrata extract improved symptoms compared to placebo. Mean pain
was 40 points on a 0 to 100 point VAS scale (0 is no pain) with placebo, enriched Boswellia serrata reduced pain by a mean of 17 points
(95% confidence interval (CI) 8 to 26); number needed to treat for an additional beneficial outcome (NNTB) 2; the 95% CIs did not exclude
a clinically significant reduction of 15 points in pain. Physical function was 33 points on the Western Ontario and McMaster Universities
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Osteoarthritis Index (WOMAC) 0 to 100 point subscale (0 is no loss of function) with placebo, enriched Boswellia serrata improved function
by 8 points (95% CI 2 to 14); NNTB 4. Assuming a minimal clinically important diDerence of 10 points, we cannot exclude a clinically
important benefit in some people. Moderate-quality evidence (one study, 96 participants) indicated that adverse events were probably
reduced with enriched Boswellia serrata (18/48 events versus 30/48 events with placebo; relative risk (RR) 0.60, 95% CI 0.39 to 0.92). Possible
benefits of other Boswellia serrata extracts over placebo were confirmed in moderate-quality evidence from two studies (97 participants)
of Boswellia serrata (enriched) 100 mg plus non-volatile oil, and low-quality evidence from small single studies of a 999 mg daily dose of
Boswellia serrata extract and 250 mg daily dose of enrichedBoswellia serrata. It was uncertain if a 99 mg daily dose of Boswellia serrata
oDered benefits over valdecoxib due to the very low-quality evidence from a small single study. It was uncertain if there was an increased
risk of adverse events or withdrawals with Boswellia serrata extract due to variable reporting of results across studies. The studies reported
no serious adverse events. Quality of life and radiographic joint changes were not measured.
Six studies examined the ASU product Piasclidine®. Moderate-quality evidence from four studies (651 participants) indicated that ASU
300 mg produced a small and clinically questionable improvement in symptoms, and probably no increased adverse events compared to
placebo aLer three to 12 months treatment. Mean pain with placebo was 40.5 points on a VAS 0 to 100 scale (0 is no pain), ASU 300 mg
reduced pain by a mean of 8.5 points (95% CI 1 to 16 points); NNTB 8. ASU 300 mg improved function (standardised mean diDerence (SMD)
-0.42, 95% CI -0.73 to -0.11). Function was estimated as 47 mm (0 to 100 mm scale, where 0 is no loss of function) with placebo, ASU 300
mg improved function by a mean of 7 mm (95% CI 2 to 12 mm); NNTB 5 (3 to 19). There were no diDerences in adverse events (5 studies,
1050 participants) between ASU (53%) and placebo (51%) (RR 1.04, 95% CI 0.97 to 1.12); withdrawals due to adverse events (1 study, 398
participants) between ASU (17%) and placebo (15%) (RR 1.14, 95% CI 0.73 to 1.80); or serious adverse events (1 study, 398 participants)
between ASU (40%) and placebo (33%) (RR 1.22, 95% CI 0.94 to 1.59). Radiographic joint changes, measured as change in joint space width
(JSW) in two studies (453 participants) did not diDer between ASU 300 mg treatment (-0.53 mm) and placebo (-0.65 mm); mean diDerence
of -0.12 (95% CI -0.43 to 0.19). Moderate-quality evidence from a single study (156 participants) confirmed possible benefits of ASU 600 mg
over placebo, with no increased adverse events. Low-quality evidence (1 study, 357 participants) indicated there may be no diDerences in
symptoms or adverse events between ASU 300 mg and chondroitin sulphate. Quality of life was not measured.
All other herbal interventions were investigated in single studies, limiting conclusions. No serious side eDects related to any plant product
were reported.
Authors' conclusions
Evidence for the proprietary ASU product Piasclidine® in the treatment of osteoarthritis symptoms seems moderate for short term use, but
studies over a longer term and against an apparently active control are less convincing. Several other medicinal plant products, including
extracts of Boswellia serrata, have moderate-quality evidence for trends of benefits that warrant further investigation in light of the fact
that the risk of adverse events appear low.
There is no evidence that Piasclidine® significantly improves joint structure, and limited evidence that it prevents joint space narrowing.
Structural changes were not tested for with any other herbal intervention.
Further investigations are required to determine optimum daily doses producing clinical benefits without adverse events.
P L A I N   L A N G U A G E   S U M M A R Y
Oral herbal therapies for treating osteoarthritis
Background: what is osteoarthritis and what is herbal therapy?
Osteoarthritis (OA) is a disease of the joints (commonly knees, hips, hands). When joints lose cartilage, bone grows to try to repair the
damage. Instead of making things better, however, the bone grows abnormally and makes things worse. For example, the bone can become
misshapen and make the joint painful and limit movement. OA can aDect your physical function, particularly your ability to use your joints.
Herbal medicines are defined as being finished, labelled medicinal products that contain as active ingredients aerial or underground parts
of plants or other plant material, or combinations thereof, whether in the crude state or as plant preparations (for example extracts, oils,
tinctures).
Study characteristics
This summary of an update of a Cochrane review presents what we know from research about the eDects of herbal therapies consumed
orally by people with osteoarthritis. ALer searching for all relevant studies to August 2013, we included 45 new studies since the last
review, giving a total of 49 studies (on 33 herbal interventions) that included 5980 participants, most with mild to moderate symptomatic
osteoarthritis of the knee or hip. Thirty-three diDerent medicinal plant products were compared with placebo or active intervention
controls and many comparisons had single studies only; thus, we have restricted reporting of results here to multiple studies of Boswellia
serrata (monoherbal) and avocado-soyabean unsaponifiables (ASU) (two herb combination) products.
Key results
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Boswellia serrata
Pain on a scale of 0 to 100 points (lower scores mean reduced pain):
- people who used 100 mg of enriched Boswellia serrata extract rated their pain 17 points lower (range 8 to 26 points lower) (17% absolute
improvement) at 90 days compared with placebo;
- people who used enriched Boswellia serrata extract 100 mg rated their pain as 23 points;
- people who used a placebo preparation rated their pain as 40 points.
Physical function on a scale of 0 to 100 points (lower scores means better physical function):
- people who used 100 mg of enriched Boswellia serrata extract rated their physical function 8 points better (2 to 14 points better) on a 100
point scale (8% absolute improvement) at 90 days compared with placebo;
- people who used 100 mg of enriched Boswellia serrata extract rated their physical function as 25 points;
- people who used placebo rated their physical function as 33 points.
Avocado-soyabean unsaponifiables (ASU) product Piascledine®
Pain on a scale of 0 to 100 points (lower scores mean less pain):
- people who used ASU 300 mg rated their pain 8 points lower (1 to 16 points lower) on a 100 point scale (8% absolute improvement) at
3 to 12 months compared with placebo;
- people who used ASU 300 mg rated their pain as 33 points;
- people who used placebo rated their pain as 41 points.
Physical function on a scale of 0 to 100 mm scale (lower scores means better physical function):
- people who used ASU 300 mg rated their physical function 7 mm better (2 to 12 mm better) on a 100 mm scale (7% absolute improvement)
at 3 to 12 months compared with placebo;
- people who used ASU 300 mg rated their physical function as 40 mm;
- people who used placebo rated their physical function as 47 mm.
Quality of the evidence
There is moderate-quality evidence that in people with osteoarthritis Boswellia serrata slightly improved pain and function. Further
research may change the estimates.
There is moderate-quality evidence that avocado-soybean unsaponifiables (ASU) probably improved pain and function slightly, but may
not preserve joint space. Further research may change the estimates.
We are uncertain whether other oral herbal products improve osteoarthritis pain or function, or slow progression of joint structure damage
because the available evidence is limited to single studies or studies that cannot be pooled, and some of these studies are of low to very
low quality. Quality of life was not measured.
Herbal therapies may cause side eDects, however we are uncertain if there is an increased risk of these.
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Summary of findings for the main comparison.   Boswellia serrata for treating osteoarthritis
Boswellia serrata for treating osteoarthritis
Patient or population: patients with treating osteoarthritis
Settings: Community: India
Intervention: Boswellia serrata 999 mg
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Control Boswellia serrata
Relative ef-
fect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Pain
Global pain 0-3 (higher scores
mean worse)
Follow-up: mean 8 weeks
Mean pain in the con-
trol group at the end of
treatment was 2.50 (0 to
3 scale).
Mean pain in the interven-
tion groups was
2.24 lower
(2.64 to 1.84 lower).
- 30
(1 study)
⊕⊕⊝⊝
low1,2,3,4
Absolute improvement
in pain was 56% (46% to
66%); Relative improve-
ment in pain was 80%
(66% to 94%)5; NNTB = 1
(95% CI 1 to 2).
Function
Loss of function 0-3 (higher
scores mean worse)
Follow-up: mean 8 weeks
Mean disability in the
control group at the end
of treatment was 2.46 (0
to 3 scale).
Mean disability in the in-
tervention groups was
2.16 lower
(2.56 to 1.76 lower).
- 30
(1 study)
⊕⊕⊝⊝
low1,2,3,4
Absolute improvement in
function was 54% (44% to
64%); Relative improve-
ment was 76% (62% to
90%)5; NNTB = 1 (95% CI 1
to 3).
Adverse events
Participants (n) reported ad-
verse effects
Follow-up: mean 8 weeks
No (n=0) participants
in the control group re-
ported adverse events.
0 per 1000
Two (n=2) participants in
the intervention group re-
ported adverse events.
0 per 1000
RR 5.00 
(0.26 to 96.13)
30
(1 study)
⊕⊕⊝⊝
low1,2,3,4
Absolute risk of adverse
events was 13% higher
in the Boswellia serrata
group (6% lower to 33%
higher); Relative percent-
age change 400% worsen-
ing (74% to 9513% wors-
ening); NNT n/a.6
Adverse events
Participants (n) withdrew due
to adverse effects
See comment See comment Not estimable 30
(1 study)
See comment Reported NIL withdrawals
due to adverse events.
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Adverse events
Participants (n) reported seri-
ous adverse events
See comment See comment Not estimable - See comment Serious adverse events
not reported as discrete
outcome.
Radiographic joint changes See comment See comment Not estimable - See comment Radiographic joint
changes not measured.
Quality of life See comment See comment Not estimable - See comment Quality of life not mea-
sured.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Criteria for diagnosis of OA not specified.
2 Exploratory study design; power, eDect, and sample size not determined a priori.
3 Ethical oversight not reported.
4 Downgrade estimate due to single study.
5 Control group baseline pain (SD) 2.80 (0.41), baseline disability 2.86 (0.35), from Kimmatkar 2003.
6 Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial
oDice). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/). Assumed a minimal clinically important diDerence of 1 point
of a 0 to 3 point scale (pain, function).
 
 
Summary of findings 2.   Boswellia serrata (enriched) 100 mg for treating osteoarthritis
Boswellia serrata (enriched) 100 mg for treating osteoarthritis
Patient or population: patients with treating osteoarthritis
Settings: Community: India
Intervention: Boswellia serrata (enriched) 100 mg
Illustrative comparative risks* (95% CI)Outcomes
Assumed risk Corresponding risk
Relative ef-
fect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
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Control Boswellia serrata (en-
riched) 100mg
Pain
Global pain VAS 0-100 (higher
scores mean worse)
Follow-up: mean 90 days
Weighted mean pain in
the control groups at
the end of treatment
was 40.02 (0 to 100
scale).
The weighted mean pain
in the intervention groups
was
16.57 lower
(26.47 to 8.47 lower)
- 85
(2 studies)
⊕⊕⊕⊝
moderate2
Absolute improvement
in pain was 17% (8% to
26%); Relative improve-
ment in pain was 29%
(15% to 43%)3; NNTB 2
(95% CI 1 to 6).
Function
WOMAC-VAS (Function)1 0-100
(higher scores mean worse)
Follow-up: mean 90 days
Weighted mean dis-
ability in the control
groups at the end of
treatment was 33.13 (0
to 100 scale).
The weighted mean dis-
ability in the intervention
groups was
8.21 lower
(14.21 to 2.22 lower)
- 85
(2 studies)
⊕⊕⊕⊝
moderate2
Absolute improvement
was 8% (14% to 2%); Rel-
ative improvement was
20% (5% to 34%)3; NNTB 4
(95% CI 2 to 18).
Adverse events
Adverse event episodes (n) re-
ported
Follow-up: mean 90 days
625 per 1000 375 per 1000
(211 to 577)
RR 0.60 
(0.39 to 0.92)
96
(1 study)
⊕⊕⊕⊝
moderate4
Absolute risk of adverse
events was 25% lower
in the Boswellia serrata
group (6% to 44% low-
er); Relative percentage
change 40% improvement
(61% improvement to 9%
worsening); NNT = 4 (95%
CI 3 to 22).
Adverse events
Participants (n) withdrew due to
adverse effects
See comment See comment Not estimable 96
(1 study)
See comment Reported NIL withdrawals
due to adverse events.
Adverse events
Participants (n) reported serious
adverse events
See comment See comment Not estimable 96
(1 study)
See comment Reported NIL serious ad-
verse events.
Radiographic joint changes See comment See comment Not estimable - See comment Radiographic joint
changes not measured.
Quality of life See comment See comment Not estimable - See comment Quality of life not mea-
sured.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Sengupta 2008, Sengupta 2010, Vishal 2011: WOMAC scores presented as subscale scores only. Overall WOMAC not reported.
2 Confirmatory study design: statistical power 80%, alpha set at 0.05, but downgraded due to potential imprecision due to small number of participants; and lower limit of 95%
CI does not preclude clincially insignificant change
3 Control group baseline measures taken from Sengupta 2008, the study most heavily weighted in the meta-analyses. Control group baseline pain (SD) 56.88 (12.04), baseline
disability 41.3 (9.6).
4 Downgrade estimate due to potential imprecision, eg, small number of events and participants from a single study.
5 Number needed to treat (NNT) is not applicable (n/a) when result is not statistically significant. NNT for dichotomous outcomes calculated using Cates NNT calculator (http://
www.nntonline.net/visualrx/); NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial oDice). Assumed a minimal clinically important diDerence of 15
points on 0 to 100 mm pain scale, and 10 points on 0 to 100 mm function scale.
 
 
Summary of findings 3.   Boswellia serrata (enriched) 250 mg for treating osteoarthritis
Boswellia serrata (enriched) 250mg for treating osteoarthritis
Patient or population: patients with treating osteoarthritis
Settings: Community: India
Intervention:Boswellia serrata (enriched) 250mg
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Control Boswellia serrata (en-
riched) 250mg
Relative ef-
fect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Pain
Global pain VAS 0-100 (higher
scores mean worse)
Follow-up: mean 90 days
Mean pain in the con-
trol group at the end
of treatment was
41.76 (0 to 100 scale).
Mean pain in the inter-
vention group was
27.54 lower
(34.64 to 20.44 lower).
- 47
(1 study)
⊕⊕⊕⊝
moderate2
Absolute improvement in
pain was 28% (20% to 35%);
Relative improvement in pain
was 48% (36% to 61%)3 ; NNT
= 1 (95% CI 1 to 2).
Function
WOMAC-VAS (Function)1
(higher scores mean worse)
Follow-up: mean 90 days
Mean disability in the
control group at the
end of treatment was
34.07 (0 to 100 scale).
Mean disability in the in-
tervention group was
16.8 lower
(21.23 to 12.37 lower).
- 47
(1 study)
⊕⊕⊕⊝
moderate2
Absolute improvement in
disability was 17% (12% to
21%); Relative improvement
in disability was 41% (30% to
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51%)3; NNT = 1 (95% CI 1 to
2).
Adverse events
Adverse event episodes (n) re-
ported
Follow-up: mean 90 days
526 per 1000 474 per 1000
(302 to 653)
RR 0.90 
(0.62 to 1.30)
114
(1 study)
⊕⊕⊕⊝
moderate2
Absolute risk of adverse
events was 5% lower in the
Boswellia serrata group (24%
lower to 13% higher); Rela-
tive percentage change 10%
improvement (38% improve-
ment to 30% worsening); NNT
n/a.4
Adverse events
Participants (n) withdrew due to
adverse effects
See comment See comment Not estimable 114
(1 study)
See comment Reported NIL withdrawals
due to adverse events.
Adverse events
Participants (n) reported serious
adverse events
See comment See comment Not estimable 114
(1 study)
See comment Reported NIL serious adverse
events.
Radiographic joint changes See comment See comment Not estimable - See comment Radiographic joint changes
not measured.
Quality of life See comment See comment Not estimable - See comment Quality of life not measured.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Sengupta 2008: WOMAC scores presented as subscale scores only. Overall WOMAC not reported.
2 Downgrade estimate due to single study.
3 Control group baseline pain (SD) 56.88 (12.04), baseline disability 41.3 (9.6), from Sengupta 2008.
4 Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial
oDice). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/).
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Summary of findings 4.   Boswellia serrata (enriched) plus non-volatile oil for treating osteoarthritis
Boswellia serrata (enriched) plus non-volatile oil for treating osteoarthritis
Patient or population: patients with treating osteoarthritis
Settings: Community: India
Intervention: Boswellia serrata (enriched) 100mg plus non-volatile oil
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Control Boswellia serrata (en-
riched) plus non-volatile
oil
Relative ef-
fect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Pain
Global pain VAS 0-100 (higher
scores mean worse)
Follow-up: 30-90 days1
Weighted mean pain in
the control groups at
the end of treatment
was 38.90 (0 to 100
scale).
Weighted mean pain in
the intervention groups
was
16.09 lower
(20.37 to 11.81 lower).
- 97
(2 studies)
⊕⊕⊕⊝
moderate2
Absolute improvement
in pain was 16% (12%
to 20%); Relative im-
provement in pain was
34%(25% to 42%)3;
NNTB 2 (1 to 4)4
Function
WOMAC-VAS (Function)5 nor-
malised units
(higher scores mean worse)
Follow-up: 30-90 days
Weighted mean dis-
ability in the control
groups at the end of
treatment was 34.90 (0
to 100 scale).
Weighted mean disability
in the intervention groups
was
15.01 lower
(19.21 to 10.81 lower).
- 97
(2 studies)
⊕⊕⊕⊝
moderate2
Absolute improvement
in disability was 15%
(11% to 19%); Relative
improvement in dis-
ability was 37% (27% to
47%)3; NNTB 2 (1 to 3).
Adverse events
Participants (n) reported adverse
events
Follow-up: 30-90 days
42 per 1000 41 per 1000
(6 to 241)
RR 0.98 
(0.14 to 6.69)
97
(2 studies)
⊕⊕⊕⊝
moderate2
Absolute risk of adverse
events was 0% lower
in the Boswellia serra-
ta group (8% lower to
8% higher); Relative per-
centage change 2% im-
provement (86% im-
provement to 569%
worsening); NNT n/a.5
Adverse events
Participants (n) withdrew due to
adverse effects
See comment See comment Not estimable - See comment Reported NIL with-
drawals due to adverse
events.
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Adverse events
Participants (n) reported serious
adverse events
See comment See comment Not estimable - See comment Reported NIL serious ad-
verse events.
Radiographic joint changes See comment See comment Not estimable - See comment Radiographic joint
changes not measured.
Quality of life See comment See comment Not estimable - See comment Quality of life not mea-
sured.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Vishal 2011: 30 day intervention. Sengupta 2010: 90 day intervention.
2 Vishal 2011: Exploratory study design; power, eDect, and sample size not determined a priori.
3 Control group baseline measures taken from Vishal 2011, the study most heavily weighted in the meta-analyses. Control group baseline pain 47.6 (9.7), baseline disability 40.6
(9.5).
4 Number needed to treat to benefit (NNTB), and harm (NNTH) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using
Wells Calculator (CMSG editorial oDice). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/).
5 Sengupta 2010, Vishal 2011: WOMAC scores presented as subscale scores only. Overall WOMAC not reported.
 
 
Summary of findings 5.   Boswellia serrata compared to valdecoxib for treating osteoarthritis
Boswellia serrata compared to valdecoxib for treating osteoarthritis
Patient or population: patients with treating osteoarthritis
Settings: Community: India
Intervention: Boswellia serrata 999 mg
Comparison: valdecoxib
Illustrative comparative risks* (95% CI)Outcomes
Assumed risk Corresponding
risk
Relative ef-
fect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
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Valdecoxib Boswellia serrata
Pain
WOMAC-VAS (Pain)
(higher scores mean worse)
Follow-up: mean 6 months
Mean pain in the
valdecoxib group
at the end of treat-
ment was 17.08 (0
to 100 scale).
Mean pain in the in-
tervention groups
was
0.51 lower
(7.26 lower to 6.24
higher).
- 58
(1 study)
⊕⊝⊝⊝
very low1,2,3
Absolute improvement in pain was 1%
(7% improvement to 6% worsening);
Relative improvement in pain was 1%4;
NNT n/a.5
Function
WOMAC-VAS (Function)5
(higher scores mean worse)
Follow-up: mean 6 months
Mean disability
in the valdecox-
ib group at the
end of treatment
was 16.64 (0 to 100
scale).
Mean disability in
the intervention
groups was
2.49 higher
(4.07 lower to 9.05
higher).
- 58
(1 study)
⊕⊝⊝⊝
very low1,2,3
Absolute worsening in disability was 3%
(4% improvement to 9% worsening);
Relative improvement in disability was
4%4; NNT n/a.5
Adverse events
Participants (n) reported ad-
verse events
Follow-up: mean 6 months
61 per 1000 121 per 1000
(23 to 448)
RR 2.0
(0.39 to 10.18)
66
(1 study)
⊕⊝⊝⊝
very low1,2,3
Absolute risk of adverse events was 6%
higher in the Boswellia serrata group
(8% lower to 20% higher); Relative per-
centage change 100% worsening (61%
improvement to 918% worsening); NNT
n/a.5
Adverse events
Participants (n) withdrew due
to adverse effects
    RR 3.0
(0.13 to 71.07)
66
(1 study)
⊕⊝⊝⊝
very low1,2,3
Reported one (1) withdrawal possibly
due to adverse events.
Absolute risk of withdrawal due to
adverse events was 3% higher in the
Boswellia serrata group (5% lower
to 11% higher); Relative percentage
change 200% worsening (87% improve-
ment to 7007% worsening); NNT n/a.5
Adverse events
Participants (n) reported seri-
ous adverse events
See comment See comment Not estimable 66
(1 study)
See comment Reported NIL serious adverse events.
Radiographic joint changes See comment See comment Not estimable - See comment Radiographic joint changes not mea-
sured.
Quality of life See comment See comment Not estimable - See comment Quality of life not measured.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
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CI: Confidence interval; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Open trial. Medication regimens diDer between active control and intervention.
2 Downgrade estimate due to single study. Treatment eDect crosses midline (no eDect).
3 Exploratory study design; power, eDect, and sample size not determined a priori.
4 Baseline pain in valdecoxib group 49.2, baseline disability 51.6. Aggregate WOMAC scores converted to normalised scores for re-analysis.
5 Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial
oDice). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/).
 
 
Summary of findings 6.   Persea gratissma + Glycine max (ASU 300 mg) for treating osteoarthritis
Persea gratissma + Glycine max (ASU 300 mg) for treating osteoarthritis
Patient or population: patients with osteoarthritis
Settings: Community: France (3), Belgium (1).
Intervention: Persea gratissma + Glycine max (ASU 300 mg)
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Control Persea gratissma +
Glycine max (ASU 300mg)
Relative ef-
fect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Pain
Global pain VAS 0-100 (higher
scores mean worse)
Follow-up: 3 to 12 months
Weighted mean pain in
the control groups at
end of treatment was
40.53 (0 to 100 scale).
Weighted mean pain in
the intervention groups
was
8.47 lower
(15.90 to 1.04 lower)
- 651
(4 studies)
⊕⊕⊕⊝
moderate1
Absolute improvement in
pain was 8% (1% to 16%); Rel-
ative improvement in pain
was 15% (2% to 29%)2; NNTB
8 (4 to 77)3
Function
Multiple tools4
Follow-up: 3 to 12 months
Mean disability in
the control group at
end of treatment was
47.10 mm, on VAS 0 to
100 mm scale (higher
scores mean worse)5.
Mean disability in the in-
tervention groups was
7 mm lower
(12 mm to 2 mm lower6)
- 642
(4 studies)
⊕⊕⊕⊝
moderate1
SMD -0.42 (95% CI -0.73 to
-0.11), in favour of ASU 300mg
Absolute improvement in dis-
ability was 7% (2% to 12%);
Relative improvement in dis-
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ability was 13% (4% to 23%)7;
NNTB 5 (3 to 19)3
Adverse events
Participants (n) reported ad-
verse events
Follow-up: 3 to 36 months
510 per 1000 531 per 1000
(495 to 572)
RR 1.04 
(0.97 to 1.12)
1050
(5 studies)
⊕⊕⊕⊝
moderate1
Absolute risk of adverse
events is 2% higher in the
ASU group (2% lower to 7%
higher); Relative percentage
change 4% worsening (9% im-
provement to 12% worsen-
ing); NNT n/a3
Adverse events
Participants (n) withdrew due
to adverse effects
148 per 1000 169 per 100
(108 to 267)
RR 1.14
(0.73 to 1.80)
398
(1 study)
⊕⊕⊕⊝
moderate8
Absolute risk of participants
withdrawing due to adverse
events in 2% higher in ASU
group (5% lower to 9% high-
er); Relative percentage
change 14% worsening (27%
improvement to 90% worsen-
ing); NNT n/a.3,9
Adverse events
Participants (n) reported seri-
ous adverse events
325 per 1000 397 per 1000
(306 to 517)
RR 1.22
(0.94 to 1.59)
398
(1 study)
⊕⊕⊕⊝
moderate8
Absolute risk of serious ad-
verse events is 7% higher in
the ASU group (2% lower to
17% higher); Relative per-
centage change 22% worsen-
ing (6% improvement to 59%
worsening); NNT n/a.3,9
Radiographic joint changes
Change in Joint Space Width
(JSW) from baseline
(higher scores mean worse).
Follow up: 24 to 36 months.
Weighted mean JSW
change from baseline
in the control groups
at end of treatment
was 0.65.
Mean JSW change from
baseline in the interven-
tion groups was 0.12 low-
er (0.43 lower to 0.19 high-
er)
- 453
(2 studies)
⊕⊕⊕⊝
moderate8
Absolute change
NNT n/a.3,9
Quality of life See comment See comment Not estimable - See comment Quality of life not measured.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
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Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgrade due to heterogeneity, inconsistency
2 Calculations based on control group baseline pain measure taken from Blotman 1997, the most heavily weighted study in the meta-analysis. Control group baseline mean (SD)
pain 54.3 (11.9).
3 Number needed to treat to benefit (NNTB), or to harm (NNTH) = not applicable (n/a) when result is not statistically significant. NNT for dichotomous outcomes calculated using
Cates NNT calculator (http://www.nntonline.net/visualrx/)NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial oDice), assuming a minimal clinically
important diDerence of 15 mm on a 0 to 100 mm pain scale, and 10 mm on a 0 to 100 mm function scale.
4 Multiple tools: Disability VAS reported in one study only (Maheu 1998); WOMAC change score reported in one study (Maheu 2013); Lequesne algofunctional index reported in
four studies, but to avoid over-reporting, data were extracted on this outcome from three studies only (Appelboom 2001, Blotman 1997, Lequesne 2002)
5 From Maheu 1998: follow-up disability score in the control group 47.10 mm (VAS 0 to 100 mm scale)
6 Four trials pooled (Appelboom 2001, Blotman 1997, Lequesne 2002, Maheu 1998) using SMD, and re-expressed as MD by multiplying the SMD (95% CI) by the baseline SD in
the control group of Maheu 1998 (16.78).
7 Calculations based on data from Maheu 1998: control group baseline mean (SD) disability 52.5 (16.78), 0 to 100 mm VAS scale.
8 Downgrade estimate due to imprecision: few participants.
9 Treatment eDect crosses midline (no eDect).
 
 
Summary of findings 7.   Persea gratissma + Glycine max (ASU 600 mg) for treating osteoarthritis
Persea gratissma + Glycine max (ASU 600 mg) for treating osteoarthritis
Patient or population: patients with osteoarthritis
Settings: Community: Belgium
Intervention: Persea gratissma + Glycine max (ASU 600 mg)
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Control Persea gratissma +
Glycine max (ASU
600mg)
Relative ef-
fect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Pain
Global pain VAS 0-100
(higher scores mean worse)
Follow up: 3 months
Mean pain in the con-
trol group at the end
of treatment was
42.4 (0 to 100 scale).
Mean pain in the inter-
vention group was
14.2 lower
(20.82 to 7.58 lower)
- 156
(1 study)
⊕⊕⊕⊝
moderate1
Absolute improvement in
pain was 14% (21% to 8%);
Relative improvement in pain
was 26.5%2; NNT =
Function Mean disability in the
control group at the
Mean disability in the in-
tervention group was
- 156
(1 study)
⊕⊕⊕⊝
moderate1
Absolute improvement in dis-
ability was 1% (1% to 0%);
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Lequesne algofunctional index
0-24
(higher scores mean worse)
Follow-up: 3 months
end of treatment was
7.8 (0 to 24 scale).
1.3 lower
(2.38 to 0.22 lower)
Relative improvement in dis-
ability was 13.7%2; NNT =
Adverse events
Participants (n) reported adverse
events
Follow-up: 3 months
261 per 1000 278 per 1000
(165 to 431)
RR 1.07 
(0.66 to 1.74)
174
(1 study)
⊕⊕⊕⊝
moderate1
Absolute risk of adverse
events is 2% higher in the
ASU group (11% lower to 15%
higher); Relative percentage
change 7% worsening (34%
improvement to 74% worsen-
ing); NNT n/a.3
Adverse events
Participants (n) withdrew due to
adverse effects
See comment See comment Not estimable 174
(1 study)
See comment Withdrawals due to adverse
events not reported as a dis-
crete outcome in ASU 600mg
subgroup.
Adverse events
Participants (n) reported serious
adverse events
See comment See comment Not estimable 174
(1 study)
See comment Serious adverse events not re-
ported as a discrete outcome
in ASU 600mg subgroup.
Radiographic joint changes See comment See comment Not estimable - See comment Radiographic joint changes
not measured.
Quality of life See comment See comment Not estimable - See comment Quality of life not measured.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Single study.
2 Control group baseline mean (SD) pain 53.5 (13.9), baseline mean (SD) disability 9.5 (2.2), from Appelboom 2001.
3 Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial
oDice). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/).
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Summary of findings 8.   Persea gratissma + Glycine max (ASU 300 mg) compared to chondroitin sulphate for treating osteoarthritis
Persea gratissma + Glycine max (ASU 300 mg) compared to chondroitin sulphate for treating osteoarthritis
Patient or population: patients with osteoarthritis
Settings: Community: Czech Republic, Slovak Republic, Hungary, Poland, Romania
Intervention: Persea gratissma + Glycine max (ASU 300mg)
Comparison: chondroitin sulphate
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Chondroitin sulphate Persea gratissma +
Glycine max (ASU
300mg)
Relative ef-
fect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Pain
WOMAC-VAS (Pain)
(higher scores mean worse)
Follow-up: mean 6 months
Mean pain in the chon-
droitin sulphate group
at the end of treat-
ment was 22.88 (0 to
100 scale).
The mean pain in the in-
tervention group was
1.41 higher
(2.68 lower to 5.50 high-
er)
- 357
(1 study)
⊕⊕⊝⊝
low1,2
Absolute worsening of pain was
10% (10% improvement to 31%
worsening); Relative worsening
of pain was 3%3; NNT n/a.4
Function
WOMAC-VAS (Function)
(higher scores mean worse)
Follow-up: mean 6 months
Mean function in the
chondroitin sulphate
group at the end of
treatment was 25.14 (0
to 100 scale).
The mean disability in
the intervention group
was
1.63 higher
(2.51 lower to 5.77 high-
er)
- 357
(1 study)
⊕⊕⊝⊝
low1,2
Absolute worsening of disability
was 28% (43% improvement to
98% worsening); Relative wors-
ening of disability was 3%3; NNT
n/a.4
Adverse events
Participants (n) reported
adverse events
244 per 1000 210 per 1000
(139 to 304)
RR 0.86 
(0.59 to 1.26)
357
(1 study)
⊕⊕⊝⊝
low1,2
Absolute risk of adverse events
was 3% lower in the ASU group
(12% lower to 5% higher); Rela-
tive percentage change 14% im-
provement (41% improvement to
26% worsening); NNT n/a.4
Adverse events
Participants (n) withdrew
due to adverse effects
See comment See comment Not estimable 357
(1 study)
  Withdrawals due to adverse
events not reported as a discrete
outcome.
Adverse events
Participants (n) reported se-
rious adverse events
6 per 1000 17 per 1000
(2 to 158)
RR 2.92
(0.31 to 27.78)
357
(1 study)
⊕⊕⊝⊝
low1,2
Absolute risk of serious adverse
events was 1% higher in the ASU
group (1% lower to 3% high-
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er); Relative percentage change
192% worsening (69% improve-
ment to 2678% worsening); NNT
n/a.4
Radiographic joint
changes
See comment See comment Not estimable - See comment Radiographic joint changes not
measured.
Quality of life See comment See comment Not estimable - See comment Quality of life not measured.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 SIngle study. Treatment eDect crosses midline (no eDect).
2 Chondroitin sulfate might not be active control. Non-inferiority hypothesis may be flawed.
3 Chrondroitin sulfate group baseline pain 49.08, baseline disability 49.07. Aggregate WOMAC scores converted to normalised scores for re-analysis.
4 Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial
oDice). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/).
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B A C K G R O U N D
Oral herbal therapies for treating osteoarthritis
Herbal medicines have a long tradition in the treatment of
osteoarthritis. Although the mechanism of action of oral medicinal
plant products has not been fully elucidated, experimental studies
indicate interactions with mediators of inflammation and cartilage
destruction, providing a rational basis for the putative eDectiveness
of oral medicinal plant products in alleviating osteoarthritis. This
review is an update of an earlier review from 2000. Four of the
studies in the original review and 45 new studies are included in
this review, evaluating the eDects of 33 diDerent oral medicinal
plants or combinations of plants from Europe, Africa, Asia, and the
Americas. The review shows that oral medicinal plant products may
improve osteoarthritic complaints, but multiple studies providing
moderate to high evidence of eDectiveness are only available
for proprietary products from avocado-soyabean unsaponifiables
(ASU) and Boswellia serrata. For the other medicinal plant products
the quality and quantity of the studies are insuDicient to draw
definitive conclusions on eDectiveness. Although the included
studies did not report serious adverse events related to the
products, safety data are limited.
Herbal medicinal products are used in a variety of forms for
the treatment of osteoarthritis (OA) worldwide. Although their
mechanisms of action have not yet been elucidated in full
detail, interactions with mediators of inflammation and cartilage
destruction provide a rationale for using them to treat OA
complaints (Cameron 2009). The knowledge on herbal medicine
gleaned over centuries of medicinal use is collated in textbooks and
monographs (for example the German Commission E monographs
(Blumenthal 1998)). All include empirical knowledge. The more
recent Western monographs also include information on animal
studies and clinical trials, for example the monographs of
the European Scientific Cooperative on Phytotherapy (ESCOP
2003; ESCOP 2009), the monographs of the American Herbal
Pharmacopeia (www.herbal-ahp.org), and the World Health
Organization (WHO) monographs on selected medicinal plants
(http://apps.who.int/medicinedocs/en/d/Js2200e/). Whereas the
ESCOP and American and WHO monographs are not oDicial,
they provide scientific information on the safety, eDicacy,
and quality of medicinal plants and provide recommendations
for their use in clinical practice (for example the doses,
types of preparation). In contrast, the European Medicines
Agency (EMA) monographs (www.ema.europa.eu/ema/index.jsp?
curl=search.jsp&q=Herbal
+monographs&btnG=Search&mid=WC0b01ac05800240cf) serve as
guidance for application dossiers to obtain marketing
authorizations by the regulatory authorities of the individual
countries in the European Union. These monographs, however,
have not used an evidence-based approach. 
Description of the condition
Lawrence and Felson (Lawrence 2008) estimated that among US
adults, nearly 27 million had clinical OA in 2005 (up from the
estimate of 21 million for 1995). OA is characterized by degeneration
of the joints. Any joint of the body can be aDected, but the
most prominent joints include the hips, knees, and hands. Women
are aDected with OA more oLen than men and the prevalence
increases with increasing age. Overweight and heavy physical work
may explain OA in some cases, but non-mechanical factors and
genetic disposition are involved as well (van den Berg 2011; Zhang
2010a).  Primary OA has to be distinguished from secondary OA
that is induced, for example, by traumatic events and endocrine or
metabolic disorders. Both primary and secondary forms result in
impaired quality of life due to pain and physical disability (Schmitz
2010).
Description of the intervention
For the purpose of this review we have adopted the WHO guidelines
(www.who.int/medicines/areas/traditional/definitions/en/) for the
definition of medicinal plant products, that is, "Herbal medicines
include herbs, herbal materials, herbal preparations and finished
herbal products, that contain as active ingredients parts of plants,
or other plant materials, or combinations.
• Herbs: crude plant material such as leaves, flowers, fruit, seed,
stems, wood, bark, roots, rhizomes or other plant parts, which
may be entire, fragmented or powdered.• Herbal materials: in addition to herbs, fresh juices, gums, fixed
oils, essential oils, resins and dry powders of herbs. In some
countries, these materials may be processed by various local
procedures, such as steaming, roasting, or stir-baking with
honey, alcoholic beverages or other materials.• Herbal preparations:  the basis for finished herbal products
and may include comminuted or powdered herbal materials,
or extracts, tinctures and fatty oils of herbal materials.
They are produced by extraction, fractionation, purification,
concentration, or other physical or biological processes. They
also include preparations made by steeping or heating herbal
materials in alcoholic beverages and/or honey, or in other
materials.• Finished herbal products: herbal preparations made from one
or more herbs. If more than one herb is used, the term mixture
herbal product can also be used. Finished herbal products and
mixture herbal products may contain excipients in addition to
the active ingredients. However, finished products or mixture
products to which chemically defined active substances have
been added, including synthetic compounds and/or isolated
constituents from herbal materials, are not considered to be
herbal."
The WHO also notes that "in some traditions, materials of
inorganic or animal origin may also be present", however, in
this review we have applied the strict definition and excluded
herbal products combined with non-herbal materials (http://
apps.who.int/medicinedocs/en/d/Jh2945e/4.html).
How the intervention might work
There is evidence that pro-inflammatory cytokines play a
significant role in the pathogenesis of OA, in which articular
cartilage, subchondral bone, and synovial membrane are involved.
Cytokines including interleukin-1 (IL-1), tumour necrosis factor α
(TNFα), IL-6, and members of the IL-6 protein superfamily including
adiponectin, oncostatin M, and pre-B cell colony enhancing factor
(also known as visfatin), IL-7, IL-17, and IL-18 can promote articular
cartilage extracellular matrix protein degradation or synergize with
other cytokines to amplify and accelerate cartilage destruction.
Attempts to modify the progression of human OA in well
designed, controlled clinical trials with an IL-1 receptor antagonist
protein (IRAP) have not been successful (Malemud 2010). Anabolic
cytokines (also termed growth factors), including transforming
Oral herbal therapies for treating osteoarthritis (Review)
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growth factor-beta (TGF-β), insulin-like growth factor-1 (IGF-1),
and fibroblast growth factor-2 (FGF-2), have been characterized
as potential chondroprotective agents (Malemud 2010). Both
aging and the OA process itself induce deranged TGF-β receptor
expression, causing a shiL to dominant usage of activin receptor-
like kinase-1 (ALK-1) instead of ALK-5, and resulting in a TGF-β
mediated catabolic pathway (van den Berg 2011).
Recently, other cytokines were also identified as being involved
in the progressive breakdown of articular cartilage. Transcription
factor hypoxia-inducible factor-2α (HIF-2α), which is highly
enhanced in OA cartilage, has been shown to activate catabolic
metalloproteinases (MMP) including MMP-13. In addition, HIF-2α
suppresses chondrocyte autophagy, promoting chondrocyte
apoptosis. MMP-13 production is also activated via the chondrocyte
discoidin domain receptor (DDR-2) through interaction with
denatured collagen type II. The latter might occur in a proteoglycan
depleted pericellular matrix where DDR-2 expression is enhanced,
such as in OA cartilage. A disintegrin and metalloproteinase
with thrombospondin motifs (ADAMTS-5) was identified to
stimulate proteoglycan loss by interacting with transmembrane
proteoglycan syndecan-4. Furthermore, the alarmins (also know
as myeloid-related proteins), calcium binding proteins S100A8 and
S100A9, were identified as catabolic mediators (van den Berg
2011). An improved understanding of the balance between pro-
inflammatory, anabolic, and catabolic cytokines may eventually
result in the commercial development of disease-modifying OA
drugs (Malemud 2010). 
Inflammation and imbalance in complex cytokine interactions
cause morphological OA changes at the molecular level. Medicinal
plant products may inhibit inflammatory mediators and interact
with various cytokines, at least under experimental conditions
(Cameron 2009). The mechanism of action of the oral herbal
medicines is likely to be broader than that of non-steroidal anti-
inflammatory drugs. Some studies in animals indicate a promising
cartilage-protective eDect for some of the oral medicinal plant
products, including Piascledine® containing ASU (Mazieres 1993),
the Harpagophytum extract FB9195 (Chrubasik 2006; Hadhyiski
2006), and a Chinese herbal mixture SKI306X® (Choi 2002). In
a later, long term confirmatory study in humans, Piascledine®
showed no eDect on joint space loss (Lequesne 2002). It remains
to be demonstrated whether the experimental observations of
promising eDects on surrogate markers of cartilage destruction by
medicinal plant products are of clinical relevance.
Why it is important to do this review
Medicinal plant preparations are part of the armamentarium of
traditional treatments for people with OA. This review is important
to summarise the evidence of eDectiveness of medicinal plant
products used orally for OA, and to update the information on
these products. We have undertaken this research to investigate
the eDectiveness and adverse side eDects of these products so that
people with OA and their healthcare providers may make more
informed decisions about the usefulness of these interventions.
In the previous Cochrane review on herbal medicines for OA, oral
and topical herbal medicines were considered together. When
the update of this review became particularly large, a separation
of topical and oral medicinal plant products seemed advisable
because: (a) only oral products are purported to have any eDect
on joint structure, (b) topical herbal medicines may act as counter-
irritants via the skin (for example nettle, peppermint, Capsicum),
and (c) some products cannot be administered orally due to
systemic toxicity (Arnica, comfrey).
O B J E C T I V E S
To update an existing Cochrane systematic review to assess the
benefits and harms of oral medicinal plant products in treating
OA. Data were added from relevant randomised controlled trials
published in the period from January 2000 to August 2013.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled (placebo or active control) parallel and
crossover trials examining the eDects of oral herbal interventions
for treating OA.
Types of participants
All persons diagnosed with OA according to the American College
of Rheumatology (ACR) criteria (Altman 1986; Altman 1990; Altman
1991) or the equivalent European League Against Rheumatism
(EULAR) criteria (Zhang 2009; Zhang 2010a; Zhang 2010b). Studies
with samples defined according to vague descriptions (for example
'joint pain') were not considered. Studies with participant samples
defined according to incomplete or partial ACR and EULAR criteria
were included, and notes were provided to identify possible
weaknesses in sample selection in these studies.
Types of interventions
Any orally consumed herbal intervention compared with
an inert (placebo) or active control was included. Herbal
interventions included any plant preparation (whole, powder,
extract, standardised mixture) but excluded homeopathy or
aromatherapy products, or any preparation of synthetic origin.
In the methods published for the original review, herbal
therapies used in conjunction with other treatments or combined
with a non-herbal substance were also to be included if
the eDect of the non-herbal intervention was consistent
among all groups and quantifiable such that the eDect of
the herbal intervention could be determined. In this review,
however, we have confined interventions to those that comply
with the WHO definition of 'herbal' (www.who.int/medicines/
areas/traditional/definitions/en/). Accordingly, extracted single
compounds, synthetic reproductions of naturally occurring
compounds, and herbal therapies combined with non-herbal
substances are no longer herbal treatments. This definition is
important because non-herbal substances may interact with herbs
and change their eDects, potency, and safety profile. Even if the
non-herbal substance occurs in the same concentration in the
placebo control (as is the case in one excluded study, Park 2009),
the intervention-control comparison is not valid because the non-
herbal substance may interact uniquely with the herbs (for example
enhanced absorption of ingredients) and not with the placebo.
Types of outcome measures
The main outcome measures considered were consistent with
those used across Cochrane Musculoskeletal Group systematic
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reviews of interventions for OA: pain, function, adverse events, joint
structure changes, and quality of life (Altman 1996; Pham 2004).
To assess the benefits of treatment:
• pain, measured on a visual analogue scale (VAS) (0 to 100),
Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) pain subscale (0 to 4, or VAS 0 to 100), numerical rating
scale (0 to 3), or other pain scales;• physical function, measured by a VAS (0 to 100), WOMAC function
subscale (0 to 4, or VAS 0 to 100), algofunctional index (0 to 3),
time to perform functional tasks, or other validated functional
scales.
To assess the safety of treatment:
• number of participants reporting any adverse event.
Minor outcomes included:
• withdrawals due to adverse events;• serious adverse events;• radiographic joint changes measured as minimum joint space
width;• quality of life measured by the Short Form-36 (SF-36) or other
validated scales.
We extracted data from the last time point in each trial. Because
most interventions were not purported to be structure modifying,
we also extracted data from earlier time points in some studies to
allow data pooling with trials of shorter duration.
We included the following outcomes in the summary of findings
tables, derived from the list of outcomes recommended by the
Cochrane Musculoskeletal Group (CMSG) for inclusion in reviews
of interventions for osteoarthritis: pain; function; number of
participants experiencing any adverse event; withdrawals due
to adverse events; serious adverse events; radiographic joint
structure; and quality of life.
We did not extract data for re-analysis on any other outcome
measures, such as swelling, use of rescue medications, or blood
markers although these data were included in many of the included
studies.
Search methods for identification of studies
Electronic searches
For this review update we searched the following electronic
databases from the date of the last search in the previously
published version of the review (to November 2008) and updated
the search again on 21 May 2009, 14 December 2010, 16 May 2011,
12 December 2011, 15 June 2012, 25 and 27 February 2013, 15 March
2013, 7 May 2013, and finally on 29 August 2013:
1. Cochrane Central Register of Controlled Trials (CENTRAL), part
of The Cochrane Library (accessed 29 August 2013);
2. DARE, part of The Cochrane Library (accessed 29 August 2013);
3. MEDLINE (via Ovid) (2000 to 29 August 2013);
4. MEDLINE   (Ovid MEDLINE® In-Process & Other Non-Indexed
Citations) (to 29 August 2013);
5. EMBASE (via Ovid) (2000 to 29 August 2013);
6. CINAHL (via Ovid) (2000 to Week 5 2008); via EBSCOhost (2008 to
29 August 2013);
7. AMED (via Ovid) (1985 to 29 August 2013);
8. ISI Web of Knowledge (2000 to 29 August 2013);
9. Dissertation Abstracts, ProQuest (2000 to 29 August 2013);
10.WHO International Clinical Trials Registry Platform
(apps.who.int/trialsearch) (accessed 29 August 2013).
Thesaurus and free text searches appropriate to each database,
which combined terms describing osteoarthritis and terms
describing herbal medicine, were performed. No methodological
filter was applied and the search was not limited by language.
The full search strategies for each database are outlined in
Appendix 1.
Searching other resources
We searched reference lists of included trials for any other potential
studies. Unpublished research reports and theses (grey literature)
were sought directly from pharmaceutical companies (Steigerwald
Pharmaceuticals) (Bernhardt 1991; Huber 1991; Schadler 1988) and
university libraries (Guyader 1984).
Data collection and analysis
Selection of studies
This review was an update of a previous review. Two authors of the
original review (CL, TP) and two other colleagues (JG, AB) made
some contributions to this review and are acknowledged here as
investigators. Because these investigators did not contribute to the
totality of the review, they are identified in the Acknowledgements
rather than listed as authors of this review.
All titles and abstracts identified from electronic databases
and other searches were independently examined by three
investigators (MC, SC, CL). The full manuscript was retrieved for
each record that had the possibility of meeting the review criteria.
Three review authors (MC, SC, CL) independently assessed the
eligibility of retrieved studies for the review according to the
inclusion criteria.
Data extraction and management
Data were extracted from each eligible study by two review authors
acting independently. Because of the length of time taken to
complete this review and the associated review of topical medicinal
plant products for OA, the large number of studies included in
this update, and the inclusion of studies in languages other than
English, five investigators (MC, SC, AB, JG, TP) contributed to the
data extraction.
Two review authors (MC, SC) independently extracted the following
data from the included trials and entered the data in RevMan 5:
1) trial characteristics including size and location of the trial, and
source of funding;
2) characteristics of the study population including age; and
characteristics of the disease including diagnostic criteria and
disease duration;
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3) characteristics of the therapy in all trial arms including type and
dose of therapy;
4) risk of bias domains as outlined in 'Assessment of risk of bias in
included studies', below;
5) outcome measures, as the mean and standard deviation for
continuous outcomes, and number of events for dichotomous
outcomes (as outlined in Types of outcome measures).
If data on more than one pain scale were provided for a trial,
we referred to a previously described hierarchy of pain-related
outcomes (Juni 2006; Reichenbach 2007) and extracted data on the
pain scale that was highest on the following list:
1. global pain;
2. pain on walking;
3. WOMAC pain subscore;
4. composite pain scores other than WOMAC;
5. pain with activities other than walking;
6. rest pain or pain during the night;
7. WOMAC global algofunctional score;
8. Lequesne osteoarthritis index global score;
9. other algofunctional scale;
10.patient's global assessment;
11.physician's global assessment.
If data on more than one function scale were provided for a trial, we
extracted data according to the hierarchy:
1. global disability score;
2. walking disability;
3. WOMAC disability subscore;
4. composite disability scores other than WOMAC;
5. disability other than walking;
6. WOMAC global scale;
7. Lequesne osteoarthritis index global score;
8. other algofunctional scale;
9. patient’s global assessment;
10.physician’s global assessment.
If data on more than one quality of life scale were provided for a
trial, we extracted data according to the hierarchy:
1. SF-36;
2. EuroQoL;
3. Sickness Impact Profile (SIP);
4. Nottingham Health Profile (NHP).
To avoid multiple outcome reporting in the review, we adopted the
following rules to extract data.
• Where outcomes were reported at several time points, we
extracted the measure at the end of the intervention as the main
outcome. Studies of similar duration were analysed using end
of intervention data only. We also extracted data at interim time
points and reported these data for completeness but did not
include them in meta-analyses.
• Where trial authors reported both final values and change from
baseline values for the same outcome, we extracted the final
values.• Where trial authors reported data analysed based on the
intention-to-treat (ITT) sample and another sample (e.g. per
protocol, as-treated), we extracted ITT-analysed data.• For crossover trials, data were extracted only up to the
point of crossover given the potential for carry-over eDects of
these particular interventions and to bias the treatment eDect
following crossover.
Adverse events were measured as the number of patients
experiencing any adverse event, patients who were withdrawn or
dropped out because of adverse events, and patients experiencing
any serious adverse events. Serious adverse events were defined
as events resulting in in-patient hospitalisation, prolongation
of hospitalisation, persistent or significant disability, congenital
abnormality or birth defect of oDspring, life-threatening events, or
death.
If additional data were required, we contacted the trial authors
to obtain these data. Some data were converted to normalised
scales prior to extraction and reporting. Where data were imputed
or calculated (for example standard deviations calculated from
standard errors, P values, or confidence intervals; imputed from
graphs; or from the standard deviations in other trials) we reported
these adjustments (see Characteristics of included studies). Any
disagreements were resolved by consensus.
Assessment of risk of bias in included studies
Two review investigators (MC, SC) independently assessed the
risk of bias of each included trial against the key criteria:
random sequence generation; allocation concealment; blinding
of participants, personnel and outcome assessors; incomplete
outcome data; selective outcome reporting; and other sources of
bias in accordance with methods recommended by The Cochrane
Collaboration (Higgins 2011). Each of these criteria were explicitly
judged as: (a) low, (b) unclear (either lack of information or
uncertainty over the potential for bias), or (c) high risk of bias.
Potential disagreements were discussed and resolved by referring
to the original protocol and, if necessary, arbitration by member(s)
of the editorial group.
Measures of treatment e?ect
When possible, the analyses were based on ITT data (outcomes
provided for every randomised participant) from the individual
trials. For each trial, we presented outcome data as point estimates
with the mean and standard deviation for continuous outcomes
and risk ratio (RR) with corresponding 95% confidence interval for
dichotomous outcomes. Where possible, for continuous outcomes
we extracted the end of treatment scores rather than change from
baseline scores. For continuous data, results were presented as
mean diDerences (MD) and 95% confidence intervals (CI). We had
planned that when diDerent scales were used to measure the
same outcome or concept, standardised mean diDerence (SMD)
would be used. This was applicable to one analysis (ASU 300 mg
versus placebo) for function. Outcomes pooled using SMD were
re-expressed as a mean diDerence by multiplying the SMD by a
representative control group baseline standard deviation from one
trial using a familiar instrument.
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Unit of analysis issues
Where a study was defined as a crossover trial, data were extracted
only up to the point of crossover, given the potential for carry-over
eDects of these particular interventions to bias the treatment eDect
following crossover.
Dealing with missing data
For dichotomous outcomes we used the number randomised as
the denominator, making the assumption that any participants
missing at the end of treatment did not have a positive outcome.
For continuous outcomes with no standard deviation reported,
we calculated standard deviations (SD), if possible, from standard
errors (SEM), P values, or CIs. For four studies we converted the VAS
data from a 10 cm scale to a 100 mm scale (Chopra 2013; Gupta
2011; Kuptniratsaikul 2011; Piscoya 2001), and for three studies we
converted SEM to SD (Huber 1991; Maheu 2013; Piscoya 2001).
If no measures of variance were reported and the SD could not be
calculated, we had planned to impute SDs from other studies in the
same meta-analysis, using the average of the other SDs that were
available, provided only a small proportion of studies comprising
the meta-analysis had missing data. This imputation of missing
data was not required for any of the meta-analyses.
We contacted trial authors to obtain details of methods that were
missing from the trial reports. Details of author responses, as well as
data conversion and imputation, are explained in characteristics of
included studies and the associated table (see table Characteristics
of included studies).
Assessment of heterogeneity
We assessed included trials for clinical homogeneity in terms of
participants, interventions, and comparators. For studies judged
as clinically homogenous, we quantified the possible magnitude
of inconsistency (that is heterogeneity) across studies using the
I2 statistic with a rough guide to interpretation as follows: 0%
to 40% might not be important; 30% to 60% might represent
moderate heterogeneity; 50% to 90% may represent substantial
heterogeneity; 75% to 100% considerable heterogeneity (Deeks
2011).
Assessment of reporting biases
To examine the possibility of publication bias, we planned to
construct funnel plots if at least 10 studies were available for the
meta analysis of a primary outcome, however we identified too few
trials for this analysis.
We planned to assess the presence of small study bias in the overall
meta-analysis by checking if the random-eDects model estimate
of the intervention eDect was more beneficial than the fixed-eDect
model estimate, but again there were too few trials for this analysis.
Data synthesis
As far as data extraction was possible, descriptive results were
reported for all included studies. We pooled data from clinically
homogenous trials; that is with the same interventions, doses,
comparators, and outcomes. Where we could not combine data,
we have summarised the eDect estimates and 95% CIs of each trial
narratively. Meta-analyses are reported for multiple studies of ASU
and Boswellia serrata only, using the random-eDects model, based
on the assumption that clinical and methodological heterogeneity
was likely.
Summary of findings
See: 'Summary of findings' tables.
The main results (pain, function, joint structure, adverse events,
withdrawals due to adverse events, serious adverse events, quality
of life) of the review are presented in summary of findings tables
(Schunemann 2011a; Schunemann 2011b). The overall grading of
the evidence using the GRADE approach, classifying the evidence
for each herbal intervention as: (a) high, (b) moderate, (c) low, or
(d) very low, is included as an indication of our confidence in the
results of the studies.
Continuous outcomes pooled using SMDs were re-expressed as MD
by multiplying the SMD by a representative control group baseline
SD from a trial using a familiar instrument (Schunemann 2011b).
In the comments column of the summary of findings table we
reported the absolute per cent diDerence, the relative per cent
change from baseline, and the number needed to treat (NNT);
NNT was reported only when the outcome showed a statistically
significant diDerence).
For dichotomous outcomes, such as adverse events, the NNT
was calculated from the control group event rate and the
relative risk (RR) using the Visual Rx NNT calculator (Cates 2008).
The NNT for continuous measures was calculated using the
Wells calculator (available at the CMSG Editorial oDice, http://
musculoskeletal.cochrane.org/).
For dichotomous outcomes, the absolute risk diDerence was
calculated from the risk diDerence statistic in RevMan and the
result expressed as a percentage. For continuous outcomes, the
absolute benefit or change was calculated as the improvement
in the intervention group minus the improvement in the control
group, in the original units.
The relative per cent change for dichotomous data was calculated
as the RR - 1 and expressed as a percentage. For continuous
outcomes, the relative diDerence in the change from baseline was
calculated as the absolute benefit divided by the baseline mean of
the control group.
Subgroup analysis and investigation of heterogeneity
In order to explain the heterogeneity between the results of the
included studies, we have included some subgroup analyses by
type and length of intervention.
Data from studies of ASU compared with placebo have been
subgrouped according to dose (300 mg or 600 mg) and length of
intervention (three, six, or 36 months) (Appelboom 2001; Blotman
1997; Maheu 1998; Maheu 2013), or in the case of one study planned
over two years but not reported the data available aLer 12 months
of intervention (Lequesne 2002).
Data from studies of Boswellia serrata extracts have been
subgrouped by proprietary product because although these
products all contain Boswellia serrata extract we cannot be certain
that the active principles are identical (Kimmatkar 2003; Sengupta
2008; Sengupta 2010; Sontakke 2007; Vishal 2011).
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There were insuDicient data available on most oral herbal products
to justify subgroup analyses.
Sensitivity analysis
We planned a sensitivity analysis to investigate the robustness of
the treatment eDect on pain and function relative to allocation
concealment and participant blinding, by removing the trials that
reported inadequate or unclear allocation concealment and lack of
participant blinding from the meta-analysis to see if this changed
the overall treatment eDect. There were insuDicient data to perform
these analyses.
R E S U L T S
Description of studies
See: Characteristics of included studies.
See: Characteristics of excluded studies.
Note: proprietary names underlined; botanical names are set in
italics.
Forty-nine randomised controlled studies involving 5980 patients
with OA met the inclusion criteria for this review (45 studies were
identified for this review update and four studies were included in
the original review).
Most of the studies were of parallel design, with two groups
comparing a herbal intervention to a placebo (inert) control only
(n = 28). A further seven studies compared herbal interventions
to both active and placebo controls in three (or more) arm
designs (Adegbehingbe 2008; Bernhardt 1991; Biegert 2004;
Bliddal 2000; Chopra 2011; Piscoya 2001; Teekachunhatean 2004).
One study included a non-intervention control in a third arm
comparison against a herbal intervention and placebo (Badria
2002). Thirteen studies were head-to-head comparisons between
herbal products and active controls (Cao 2005; Chopra 2013; Jung
2004; Kuptniratsaikul 2009; Kuptniratsaikul 2011; Leblan 2000;
Majima 2012; Medhi 2009; Mehta 2007; Pavelka 2010; Sengupta
2008; Sengupta 2010; Sontakke 2007).
All studies including active controls used a non-inferiority design,
however in five of these studies we queried the activity of the
comparator agent (Cao 2005; Chopra 2011; Chopra 2013; Mehta
2007; Pavelka 2010).
Only seven studies used true crossover designs (Bliddal 2000;
Ferraz 1991; Kimmatkar 2003; Rein 2004a; Schadler 1988; Wigler
2003; Winther 2005), versus placebo, and one of these studies
included a third arm against an active control (Bliddal 2000). One
study was described as a crossover trial but the methodology
and reported results indicated that this study was conducted as
a parallel trial (Badria 2002), and in this review this study was
classified as a parallel design.
Eighteen studies were of confirmatory design (Altman 2001;
Appelboom 2001; Belcaro 2008; Biegert 2004; Blotman 1997;
Chopra 2004; Chopra 2013; Jung 2001; Jung 2004; Kuptniratsaikul
2009; Kuptniratsaikul 2011; Leblan 2000; Lequesne 2002; Maheu
1998; Maheu 2013; Pavelka 2010; Sengupta 2008; Sengupta 2010),
that is eDect size was estimated a priori, statistical power and alpha
level were set, and sample size recruitment undertaken according
to these calculations. The remaining 32 studies were of exploratory
design and were generally of poorer methodological quality.
Results of the search
This review was formed from the division of a broader review of
herbal therapies for the treatment of OA. In the original review
both topical and oral medicinal plant products were considered.
The search strategy for this updated review was structured from
the protocol used in the original review. The searches for this
review update have been repeated several times since 2005. It is not
possible, therefore, to give a precise account of the search results
as the number of records identified from all searches.
A full search was completed before the current review was divided
into two parts (December 2011). In that full search of all databases
we identified, aLer the removal of duplicates, 288 abstracts on
topical or oral herbal medicines in the treatment of OA.
In recent repeat searches (June 2012, February 2013, May 2013,
August 2013) we identified approximately 2500 citations, reduced
to 309 citations aLer removal of duplicates from previous searches,
and from these titles and abstracts we sought 99 items in full. Three
studies published as abstracts only were excluded because they
were identified as duplicate publications of full text manuscripts
already included in this review. A further seven studies currently
obtained only in abstract form are awaiting classification should full
text reports become available. See Figure 1 for our best estimate of
results from the searches.
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Figure 1.   Study flow diagram.
 
A total of 45 new studies, including four studies published between
1988 and 1997 that had been overlooked in the previous review
(Bernhardt 1991; Huber 1991; Schadler 1988; Schmelz 1997), were
identified for inclusion in the updated review (Adegbehingbe
2008; Altman 2001; Appelboom 2001; Badria 2002; Belcaro 2008;
Biegert 2004; Biller 2002; Bliddal 2000; Cao 2005; Cheras 2010;
Chopra 2004; Chopra 2011; Chopra 2013; Cisar 2008; Farid 2007;
Frerick 2001; Gupta 2011; Jung 2001; Jung 2004; Kimmatkar 2003;
Kuptniratsaikul 2009; Kuptniratsaikul 2011; Leblan 2000; Lequesne
2002; Maheu 2013; Majima 2012; Medhi 2009; Mehta 2007; Oben
2009; Pavelka 2010; Piscoya 2001; Rein 2004a; Schmid 2000;
Sengupta 2008; Sengupta 2010; Sontakke 2007; Teekachunhatean
2004; Vishal 2011; Warholm 2003; Wigler 2003; Winther 2005). These
new studies were added to the four studies of oral herbal products
included in the original review (Blotman 1997; Ferraz 1991; Maheu
1998; Mills 1996).
Included studies
See: Characteristics of included studies.
Thirty-three diDerent medicinal plant products were tested in the
included studies. Products were compared with placebo, active,
and non-intervention controls. Due to diDering study protocols and
diDerent herbal interventions, meta-analyses were restricted to
data from multiple studies of proprietary products from avocado-
soyabean unsaponifiables (ASU) and Boswellia serrata.
Monoherbal products studied were medicinal plant products
derived from Boswellia serrata (gum resin extracts), Curcuma
domestica (ethanolic root extract), the Malay jewel vine (Derris
scandens) (ethanolic stem extract), Garcinia kola (crude seed),
devil's claw (Harpagophytum procumbens) (aqueous or etholic
extractions or crude powdered plant material), Petiveria alliacea
(tipi tea) (aqueous extract), Pinus pinaster (polyphenol concentrate
from pine bark), Rosa canina lito (crude plant material from fruit
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and seed), Salix pupurea +daphnoides (ethanolic bark extract),
Uncaria guianensis (aqueous bark extract), Vitellaria paradoxa
(patented seed extract), and Zingiber o)icinale (acetone or carbon
dioxide extracts).
Mixtures of two herbal preparations included medicinal products
from Boswellia carteri (gum resin extract) and Curcuma longa
(root extract), Persea gratissma (unsaponifiables) and Glycine
max (unsaponifiables), Phellondenron amurense (bark extract)
and Citrus sinensis (peel extract), Uncaria guianensis andLepidium
meyenii (aqueous bark extracts), and a combination of root extracts
of two ginger species (Zingiber o)icinalis and Alpinia galanga (also
known as Thai ginger)).
Polyherbal preparations included two European mixtures,
Phytodolor N® and Reumalex®; a Korean mixture SKI306X®;
10 Ayurvedic formulae: RA-11®, Antarth, shunthi-guduchi (SGC),
shunthi-guduchi with guggal (SGCG), and five formulae known only
as A, B, C, D, or E; two Chinese herbal mixtures: Duhuo Jisheng
Wan and blood-nourishing, hard-soLening (BNHS); and a Japanese
herbal mixture called Boiogito.
See Table 1 for preparation details of all products.
A wide range of outcome measures were used and the reporting
of measures diDered among studies, limiting the utility of some
studies for meta-analysis. All VAS were 100 mm lines with anchor
points identified as 0 (nil symptom) and 100 (worst possible
symptom), but in four studies the VAS scores were reported on
a centimetre scale in the range 0 to 10 cm (Chopra 2013; Gupta
2011; Kuptniratsaikul 2011; Piscoya 2001). For ease of comparison
between trials we converted all VAS data to the 0 to 100 mm scale.
Several studies used the WOMAC, but this index may be used with
two possible scoring methods: a battery of 0 to 4 Likert scales,
or a battery of 100 mm VAS. Typically the Likert scale scores
are presented as aggregate scores (sums) for each of the three
subscales (pain subscore range 0 to 20, stiDness subscore range
0 to 8, physical function subscore range 0 to 68), whereas the
VAS may be aggregated (pain subscore range 0 to 500, stiDness
subscore range 0 to 200, physical function subscore range 0 to
1700) or converted to normalised units (means) for each subscale
(all subscales scored 0 to 100). Although both scoring systems
are acceptable for clinical and research use, there is no agreed
conversion ratio between them so studies using the diDering
systems are not comparable. Also, in a few studies although
standardised measures such as the WOMAC were used the data
were reported in atypical forms that required some conversion or
estimation before they could be included in these analyses. Specific
details of all data conversions are included in the Characteristics of
included studies.
Excluded studies
See: Characteristics of excluded studies.
Reasons for excluding studies were: (a) not a randomised controlled
trial (Grahame 1981; Guyader 1984; Kagore 2011; Linsheng 1997;
Loew 1996; Mishra and Singh 2003; Myers 2010; Saley 1987;
Srivastava 1989; Wang 1985; Wegener 2003; Xu 2005; Yuelong 2011;
Zell 1993), (b) review or discussion paper (Anonymous 1993; Brien
2006; Chrubasik 1998; Dharmananda 1985; Falch 1997; Gendo
1997; Kielczynski 1997; Long 2001; Reuss 1981), (c) not a herbal
intervention (Belcaro 2010; Levy 2009; Park 2009), (d) unable
to identify the herbal components of the intervention (Jacquet
2009; Kulkarni 1991), (e) individualised treatments thus not a
standardised herbal intervention (Fang 2008; Hamblin 2008), (f)
mixed sample and unable to extract data for participants with OA
only (Biswas 1998; Du 2006; Lechner 2011; SchaDner 1997), (g)
duplicate publication or part thereof (Chantre 2000; Lung 2004;
Rein 2004b; Schmid 2001; Winther 2004), (h) abstract publication
only (Biswas 1997; Schmid 1998a), or (i) did not include functional
or clinical outcomes (Zeng 2008). Subanalyses of two studies (Jung
2004; Rein 2004a) were identified in other publications (Lung 2004;
Rein 2004b; Winther 2004) and were excluded from this review
to avoid repetition of data. In the original review, one study was
classified as pending assessment subject to full translation of the
texts (Loew 1996), but in this update language was no barrier to
inclusion and this study was excluded on other grounds.
Risk of bias in included studies
See: Characteristics of included studies, 'Risk of bias' tables.
The risk of bias of each study was assessed independently by two
review authors according to the criteria described in the methods
(Higgins 2011; Schunemann 2011a). Quality of the included studies
was variable and should be taken into account when interpreting
results. See Figure 2 for a summary of the risk of bias assessment.
Only three studies adequately met all six validity criteria and thus
were at minimal risk of bias (Altman 2001; Lequesne 2002; Pavelka
2010).
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 2.   (Continued)
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Figure 2.   (Continued)
 
Although not directly measures of bias, we considered if authors
reported that they had obtained ethics committee approval,
clinical trials registration, or complied with the Declaration
of Helsinki and International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals in
Human Use Good Clinical Practice (ICH GCP) guidelines. Further,
we considered that risk of bias could be assumed to be low
if these oversights implied that a risk of bias was reduced.
For example, the ICH GCP guidelines were recommended in
Germany, France, Great Britain, and Scandanavia from 1986
onwards, therefore we have assumed that Human Research
Ethics committee approvals granted for studies aLer this time,
in these countries, necessitated compliance with the guidelines
regarding randomisation, allocation concealment, and blinding
of participants and assessors. In 1989, these guidelines were
recommended across the European Community (EC) as it was then
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constituted. Again, we have assumed that from this date studies
with ethics committee approval, conducted in EC countries, have
complied with these guidelines. In 1996, compliance with the ICH
CGP guidelines was required under German law governing clinical
trials.
The ICH GCP guidelines are now adopted by the WHO and most
countries, including many developing countries, are listed as
following these guidelines. Formally constituted human research
ethics committees are charged with ensuring that clinical trials
are conducted in compliance with these guidelines and associated
regional legislation. Six studies reported some form of board
approval or review but did not specify that the board was
a formally constituted human research ethics committee nor
reported compliance with relevant guidelines or legislation (Maheu
1998; Majima 2012; Oben 2009; Sengupta 2008; Sengupta 2010;
Vishal 2011). Nine studies did not report any form of ethical
oversight or compliance with research design guidelines (ICH GCP
guidelines or Declaration of Helsinki) (Badria 2002; Bernhardt 1991;
Chopra 2004; Ferraz 1991; Huber 1991; Kimmatkar 2003; Schadler
1988; Schmelz 1997; Warholm 2003).
Allocation
We attributed low risk of bias to 28 studies that fully described
an appropriate process of generating a randomisation schedule
(Adegbehingbe 2008; Altman 2001; Belcaro 2008; Bernhardt 1991;
Biegert 2004; Bliddal 2000; Blotman 1997; Cheras 2010; Chopra
2004; Chopra 2013; Jung 2004; Kimmatkar 2003; Kuptniratsaikul
2011; Lequesne 2002; Maheu 1998; Maheu 2013; Mehta 2007; Oben
2009; Pavelka 2010; Rein 2004a; Schmid 2000; Sengupta 2008;
Sengupta 2010; Sontakke 2007; Vishal 2011; Warholm 2003; Wigler
2003; Winther 2005). We also attributed low risk of bias to two
studies that reported compliance with the ICH GCP guidelines but
did not fully describe the randomisation processes because in these
studies adequate randomisation processes could be inferred (see
Other potential sources of bias) (Biller 2002; Frerick 2001).
A further 13 studies were described as randomised but the method
of randomisation was not reported (Appelboom 2001; Badria
2002; Cao 2005; Cisar 2008; Farid 2007; Ferraz 1991; Gupta 2011;
Jung 2001; Majima 2012; Medhi 2009; Piscoya 2001; Schadler
1988; Schmelz 1997; Teekachunhatean 2004). In another two
studies randomisation was reported in insuDicient detail to allow
replication of the method (Kuptniratsaikul 2009; Leblan 2000), and
in a further two studies the methods could be more accurately
described as quasi-randomisation (Chopra 2011; Mills 1996). We
classified each of these studies as having unclear risk of bias due to
randomisation procedures. One study was not randomised (Huber
1991) and has been classified as having high risk of bias.
Allocation concealment was poorly described in most studies.
Allocation concealment was assessed according to the Cochrane
format, as described in the methods (Higgins 2011). We attributed
low risk of bias to three studies (Adegbehingbe 2008; Maheu
1998; Maheu 2013) in which allocation concealment was explicitly
reported, and the 20 studies in which it could reasonably be
inferred from the description of methods (Altman 2001; Belcaro
2008; Bernhardt 1991; Biegert 2004; Biller 2002; Bliddal 2000;
Cao 2005; Cheras 2010; Chopra 2004; Chopra 2013; Frerick 2001;
Kimmatkar 2003; Lequesne 2002; Pavelka 2010; Rein 2004a; Schmid
2000; Sengupta 2010; Vishal 2011; Wigler 2003; Winther 2005). One
study reported that allocation was not concealed, neither from
participants nor the research assistant (Kuptniratsaikul 2011). This
study has been classified as having a high risk of bias.
Allocation concealment could not be determined in any other
study; neither could failure to conceal allocation be determined.
These studies have been classified as having unclear risk of bias for
this domain.
Blinding
Low risk of bias has been attributed to 33 studies in which the herbal
products and placebo or active controls could not be distinguished
by colour, size, smell, shape, packaging, or treatment regimen
(Adegbehingbe 2008; Altman 2001; Belcaro 2008; Biegert 2004;
Biller 2002; Bliddal 2000; Blotman 1997; Cisar 2008; Chopra 2004;
Chopra 2011; Chopra 2013; Farid 2007; Frerick 2001; Gupta 2011;
Jung 2004; Kimmatkar 2003; Leblan 2000; Lequesne 2002; Maheu
1998; Maheu 2013; Mehta 2007; Mills 1996; Pavelka 2010; Oben
2009; Rein 2004a; Schmid 2000; Sengupta 2008; Sengupta 2010;
Teekachunhatean 2004; Vishal 2011; Warholm 2003; Wigler 2003;
Winther 2005).
In a small number of studies (n = 9), the method of blinding was
inadequately described and no reference to governing guidelines
made (see Other potential sources of bias). Although we considered
it highly likely that these studies were suDiciently blinded, we
downgraded the risk of blinding to unclear (Appelboom 2001;
Badria 2002; Bernhardt 1991; Cao 2005; Ferraz 1991; Huber 1991;
Jung 2001; Medhi 2009; Schadler 1988). Risk of bias has been
downgraded to high in studies that were open label, single
blinded, or where interventions could be clearly distinguished
(Kuptniratsaikul 2009; Kuptniratsaikul 2011; Majima 2012; Sontakke
2007).
In some studies where allocation concealment was inadequately
described (see Allocation (selection bias)) it was unclear whether
clinical examiners were blinded to treatment (detection bias). We
have classified these studies as having unclear risk of bias in the
blinding domain.
Incomplete outcome data
Low risk of bias has been assigned to 28 studies in which participant
withdrawals were fully reported and analyses conducted according
to an ITT model. in these studies methods for replacing missing
data were fully reported (Altman 2001; Appelboom 2001; Bernhardt
1991; Biegert 2004; Cao 2005; Chopra 2011; Chopra 2013; Cisar
2008; Farid 2007; Frerick 2001; Jung 2001; Jung 2004; Kimmatkar
2003; Leblan 2000; Lequesne 2002; Maheu 1998; Maheu 2013;
Mehta 2007; Mills 1996; Pavelka 2010; Rein 2004a; Schadler 1988;
Schmelz 1997; Schmid 2000; Teekachunhatean 2004; Warholm
2003; Wigler 2003; Winther 2005). Unclear risk of attrition bias
has been attributed to 17 studies in which withdrawals were
reported but not considered in the analyses (per protocol analysis
only) (Adegbehingbe 2008; Belcaro 2008; Bliddal 2000; Blotman
1997; Chopra 2004; Huber 1991; Gupta 2011; Kuptniratsaikul 2009;
Kuptniratsaikul 2011; Majima 2012; Medhi 2009; Oben 2009; Piscoya
2001; Sengupta 2008; Sontakke 2007; Sengupta 2010; Vishal 2011).
Studies that neither reported participant withdrawals nor applied
any method for replacement of missing data were ascribed a high
risk of attrition bias.
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Selective reporting
Some studies adopted validated measures but outcome data were
reported as non-standardised scores (VAS 0 to 10 instead of 0 to 100,
paracetamol in tablets rather than milligrams). We converted these
data to standardised forms prior to re-analysis and have noted
these data conversions in this section of the risk of bias tables but
not attributed any increased risk.
In three studies we identified errors in data during conversion
and have downgraded these studies to unclear risk (Huber 1991;
Kuptniratsaikul 2011; Piscoya 2001).
We have downgraded to unclear risk of bias 12 studies in which
data were insuDiciently reported to allow extraction for re-analysis
(Adegbehingbe 2008; Belcaro 2008; Biegert 2004; Cheras 2010;
Chopra 2011; Frerick 2001; Huber 1991; Kuptniratsaikul 2011; Medhi
2009; Mehta 2007; Piscoya 2001; Schmelz 1997).
Examples of selective reporting included providing mean scores
only (omission of SDs) at some or all time points, or reporting
data spread as standard errors of measure (SEM) rather than SDs.
Similarly, data reported only as group change scores, percentages,
or raw scores without measures of data spread, and data presented
in graphical form only, were inadequate for re-analysis. In some
cases we were able to calculate the unreported data (for example
convert SEM to SD), however we considered that the classification
of unclear risk of bias should still be applied to this selective
reporting (Huber 1991; Maheu 2013; Piscoya 2001).
A few studies were particularly poorly reported and have been
classified as having high risk of bias for this criterion. Examples
of very poor reporting included omission of key demographic
data (for example age, gender, concomitant disease) and failure
to report reasons for withdrawals or adverse events (that is a
safety concern). In one study that was described as a crossover
design with three arms (intervention, placebo control, and non-
intervention control) data were reported from the intervention and
placebo control groups only, and no data were reported aLer the
apparent crossover (Badria 2002). We cannot be certain whether
the reporting bias in this study occurred in the description of the
research design or reporting of the results. We have treated this
study as a two group parallel design and classified it as having a
high risk of reporting bias.
In some studies reporting bias was diDicult to identify. Omission of
details may not be apparent if consistent throughout the report. For
example, in one study of pine bark extract the outcome data were
reported at 90 days only (Belcaro 2008) whereas in the other two
studies of this product the outcome data were reported at more
frequent intervals (Cisar 2008; Farid 2007). We considered it unlikely
that the former study was planned as a simple pre-post analysis
over such a wide treatment period and questioned whether mid-
point data may have been omitted from the report.
Other potential sources of bias
Selection bias due to diagnostic criteria (see Allocation (selection
bias)) is reported under the heading of 'other bias' in the risk of bias
tables.
We attributed low risk of bias to studies that recruited and
assessed participants consistently with the ACR and EULAR criteria,
obtained ethics committee approval, had clinical trials registration,
used validated outcome measures, and reported compliance with
the Declaration of Helsinki and ICH GCP guidelines. Further,
we considered that risk of bias could be assumed to be low
if satisfying one of these conditions implied the satisfaction of
another. For example, the ICH GCP guidelines were recommended
in Germany, France, Great Britain, and Scandanavia from 1986
onwards, therefore we have assumed that Human Research
Ethics committee approvals granted aLer this time for studies in
these countries necessitated compliance with the guidelines. In
1989, these guidelines were recommended across the European
Community (EC) as it was then constituted. Again, we have
assumed that from this date studies with ethics committee
approval and conducted in EC countries have complied with these
guidelines regarding randomisation, allocation concealment, and
blinding of participants and assessors.
In 1996, compliance with the ICH CGP guidelines was required
under German law governing clinical trials. The ICH GCP
guidelines are now adopted by the WHO and most countries,
including many developing countries, are listed as following
these guidelines. Formally constituted human research ethics
committees are charged with ensuring that clinical trials are
conducted in compliance with these guidelines and associated
regional legislation. We have classified as low risk all studies that
reported either compliance with ICH GCP guidelines or ethics
committee approval, or both.
Unclear risk of bias has been attributed to six studies that reported
some form of board approval or review but did not specify that the
board was a formally constituted human research ethics committee
nor reported compliance with relevant guidelines or legislation
(Maheu 1998; Majima 2012; Oben 2009; Sengupta 2008; Sengupta
2010; Vishal 2011). High risk of bias has been attributed to the
nine studies that did not report any form of ethical oversight or
compliance with research design guidelines (ICH GCP guidelines or
Declaration of Helsinki) (Badria 2002; Bernhardt 1991; Chopra 2004;
Ferraz 1991; Huber 1991; Kimmatkar 2003; Schadler 1988; Schmelz
1997; Warholm 2003).
E?ects of interventions
See: Summary of findings for the main comparison Boswellia
serrata for treating osteoarthritis; Summary of findings 2
Boswellia serrata (enriched) 100 mg for treating osteoarthritis;
Summary of findings 3 Boswellia serrata (enriched) 250 mg
for treating osteoarthritis; Summary of findings 4 Boswellia
serrata (enriched) plus non-volatile oil for treating osteoarthritis;
Summary of findings 5 Boswellia serrata compared to valdecoxib
for treating osteoarthritis; Summary of findings 6 Persea
gratissma + Glycine max (ASU 300 mg) for treating osteoarthritis;
Summary of findings 7 Persea gratissma + Glycine max (ASU 600
mg) for treating osteoarthritis; Summary of findings 8 Persea
gratissma + Glycine max (ASU 300 mg) compared to chondroitin
sulphate for treating osteoarthritis
See: 'Additional tables', Table 1: Herbal medicinal products used for
the treatment of OA.
Results are listed below, grouped by the intervention in
alphabetical order. Medicinal products from single plants are listed
first, by botanical name, followed by products formed from two
plants, followed by herbal mixtures from three or more plants. For
consistency and ease of reading this same order of presentation
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was used in Table 1: Herbal medicinal products used for the
treatment of OA.
Medicinal products from single plants
Boswellia serrata versus placebo
Boswellia serrata extracts have been subgrouped by proprietary
products because we cannot be certain that the active principle in
each product is identical.
One study investigated the proprietary Boswellia product
CapWokvel®. The extract of Boswellia serrata was compared with
placebo in 30 participants with OA in a crossover trial of two
periods of eight weeks intervention separated by a three week
washout period (Kimmatkar 2003). In this review, data have been
extracted for the first arm of the trial only and may be considered
as from an eight week parallel group trial. Pain and function (loss of
movement) were rated using a 0 to 3 scale (0 = absent, 1 = mild, 2 =
moderate, 3 = severe), and statistically significant improvements in
favour of the Boswellia serrata group were reported over the eight
weeks of intervention (pain: MD -2.45, 95% CI -2.85 to -2.23, P <
0.01; Analysis 1.1; function: MD -2.16, 95% CI -2.56 to -1.76, P < 0.01;
Analysis 1.2).
Two studies investigated the proprietary Boswellia serrata product
5-Loxin®. Both studies were undertaken by the same author team
and were of similar design, suitable for pooling. Both studies
involved three parallel groups, two intervention groups and one
placebo control, over 12 weeks. The earlier study by Sengupta
2008 was a dose-finding study comparing high (250 mg/day) and
low (100 mg/day) doses. Participants who took 250 mg of 5-Loxin
reported less pain (Analysis 3.1) and better function (Analysis 3.2)
than participants who took the placebo. The risk of adverse events
did not meaningfully diDer between groups (5-Loxin 27/57 events,
placebo 30/57 events; RR 0.90, 95% CI 0.62 to 1.30). The higher dose
of 5-Loxin did not produce significantly greater clinical outcomes
than the 100 mg dose.
In the subsequent study (Sengupta 2010), 100 mg of 5-Loxin® was
compared with 100 mg/day of an alternative Boswellia serrata
product. Meta-analysis of the data from the two 100 mg 5-Loxin®
groups in both studies showed that 90 days treatment with this
product produced improvements over placebo in pain (MD -16.94,
95% CI -22.39 to -11.50; Analysis 2.1) and function (MD -9.62, 95%
CI -11.35 to -7.89; Analysis 2.2). Also, the risk of adverse events
appeared lower in the 5-Loxin group than in the placebo group (5-
Loxin 18/48 events, placebo 30/48 events; RR 0.60, 95% CI 0.39 to
0.92; Analysis 2.3).
Two studies investigated the proprietary Boswellia serrata product
Aflapin® (Sengupta 2010; Vishal 2011). In the three way comparison
of Aflapin® and 5-Loxin® against placebo in 60 patients over
90 days, both treatment groups reported significantly greater
improvements in pain (Analysis 4.1) and function (Analysis 4.2) than
did the placebo group, and Aflapin® consistently outperformed 5-
Loxin® (Sengupta 2010). This study was conducted using an ANOVA
model and results of the three groups were presented as a series
of student's t-tests; multivariate analysis would be required to
confidently account for any chance eDect from multiple two group
comparisons. Data were extracted from the Aflapin® group in this
study and subgrouped but not meta-analysed with data from an
additional study (Vishal 2011), a two parallel group test against
placebo in patients with OA over 30 days, because of the substantial
diDerence in length of intervention between these studies (30
days, Vishal 2011; 90 days, Sengupta 2010). Viewing these studies
together, trends of eDectiveness of Aflapin® to reduce pain (30 days:
MD -14.80, 95% CI -20.29 to -9.31; 90 days: MD -18.10, CI -24.95 to
-11.25; Analysis 4.1) and increase function (30 days: MD -14.30, 95%
CI -20.70 to -8.53; 90 days: MD -15.80, 95% CI -21.92 to -9.68; Analysis
4.2). The risk of participants reporting adverse events did not diDer
between Aflapin® and the placebo groups aLer 30 or 90 days of
intervention (30 days: Aflapin® 1/30, placebo 1/29; RR 0.97, 95% CI
0.06 to 14.74; 90 days: Aflapin® 1/19, placebo 1/19; RR 1.00, 95% CI
0.07 to 14.85; Analysis 4.3).
Boswellia serrata versus cyclo-oxygenase-II (COX-II) inhibitor
anti-inflammatory drugs
A single study compared theBoswellia serrata extract Cap Wovkel
against the COX-II inhibitor anti-inflammatory drug valdecoxib in
66 participants over six months. Although follow-up was continued
for an additional month, we extracted all data at the end of the
intervention period. Although the authors reported that results
favoured the intervention, re-analysis of the data indicated that
results slightly favoured the intervention for WOMAC pain subscale
scores only (Analysis 5.1). Results favoured control on all other
outcomes, including function (Analysis 5.2). Fewer participants in
the valdecoxib group reported adverse events, thus the risk of
adverse events appeared greater in the Boswellia serrata group
(Cap Wovkel 4/33, valdecoxib 2/33; RR 2.00, 95% CI 0.39 to 10.18;
Analysis 5.3).
Curcuma domestica versus NSAIDs
A single study (107 participants recruited) compared six weeks
intervention with an ethanolic root extract from Curcuma
domestica against ibuprofen in a randomised, active control,
parallel trial. Particpants within both groups showed statistically
significant mean improvements in all outcomes over time at all
time points (two, four, and six weeks). Between-group diDerences
were not significant (Analysis 6.1; Analysis 6.2) suggesting that
Curcuma domestica has comparable eDicacy to ibuprofen in
the treatment of osteoarthritic pain and pain-related functional
impairments.
Derris scandens versus NSAIDs
An ethanolic extract from the stem of Derris scandens was tested in
a head-to-head comparison with naproxen in a two group parallel
trial over four weeks in people with OA of the knee (Kuptniratsaikul
2011). Outcomes were reported using the WOMAC-VAS, but on
a 10 cm scale. We extracted these data and converted them to
normalised scores (range 0 to 100), and in so doing identified an
error in one of the CIs. We contacted the authors who confirmed our
correction. Our re-analysis supported the authors' conclusions that
the eDectiveness of Derris scandens was not significantly diDerent
from naproxen in improving OA pain (MD 5.00, 95% CI -1.84 to
11.84; Analysis 7.1) and physical function (MD 5.11, 95% CI -0.13
to 10.33; Analysis 7.2), but that the mean diDerences and CIs may
be larger than originally reported. Also, of particular importance
in comparisons against non-steroidal anti-inflammatory drugs
(NSAIDs) Derris scandens showed a favourable adverse events
profile: fewer participants in the Derris scandens group reported
adverse events (Derris scandens 22/63, naproxen 29/62) and the risk
of an adverse event occurring in that group was markedly lower
than in the naproxen group (RR 0.75, 95% CI 0.49 to 1.15; Analysis
7.3).
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Garcinia kola
The crude seed of Garcinia kola was compared over six weeks to
two NSAIDs, naproxen and celecoxib, as well as a placebo control
in a four group parallel trial of 143 patients with OA of the knee
(Adegbehingbe 2008). Results favoured all active interventions
over placebo for reductions in pain and function. These outcomes
appeared to have been measured using two independent WOMAC
subscales with diDering reporting and scoring formats: pain was
measured using the WOMAC-VAS, and function using the WOMAC 0
to 4. Data were reported as change scores, percentages, CIs, and P
values, insuDicient for extraction in this review. Comparing eDicacy
of the active agents, pain relief appeared to have been most rapid
and persistent in the celecoxib group, and most delayed and least
persistent in the Garcinia kola group.
Harpagophytum procumbens (Devil's claw)
Four studies investigated three diDerent products from the
roots of Harpagophytum procumbens. Three studies compared
two diDerent extracts to placebo in trials completed by 174
participants (Biller 2002; Frerick 2001; Schmelz 1997). One study (92
participants) compared cryoground root powder to the weak NSAID
diacerhein (Leblan 2000).
In the studies using the ethanolic Harpagophytum extract
Flexiloges®, no improvement in WOMAC pain scores was found
(Biller 2002; Frerick 2001). These authors provided post hoc
definitions of improvement that favoured the intervention.
'Responders' to treatment were defined as participants whose
WOMAC pain scores did not increase by more than 20%, either
with (Frerick 2001) or without (Biller 2002) additional rescue
medication (up to 4000 mg ibuprofen) in weeks 17 to 20 of the
study. These definitions of response were inconsistent with the
American College of Rheumatology (ACR) criteria for response, and
data derived from these measures have not been reproduced in this
review.
In contrast, the aqueous Harpagophytum extract Arthrotabs®
showed favourable eDects on OA pain measured using a 0 to 4
categorical rating scale, but these data were also insuDiciently
reported (Schmelz 1997).
The Harpagophytum powder Harpadol® was not inferior to
diacerhein in reducing pain, as measured using a 100 mm VAS
(Analysis 1.1) (Leblan 2000). This study constituted moderate
evidence that four months daily use of 2610 mg of Harpagophytum
procumbens powder was not significantly diDerent from 100
mg diacerhein, producing comparable improvements in pain.
In this same study participants in the Harpagophytum group
used fewer NSAIDS (diclofenac) and analgesics (acetominophen
supplemented by caDeine) at all time points (30, 60, and 120 days)
than did participants in the diacerhein group. Due to diDerences
in the protocols and outcome measures these studies were not
suitable for data pooling.
Petiveria alliacea (tipi tea)
Overall, the study of tipi tea (Ferraz 1991) was inadequately
reported, although it should be noted that the study was published
only in the form of a letter. Attempts to obtain a report of the
study in greater detail were not successful. Data reported in
this study were not adequate for re-analysis but were reported
descriptively for the sake of completeness. Participants receiving
tipi tea and participants receiving placebo tea both showed
some improvement although no significant diDerences were found
between the two groups. The study was small (n = 20, crossover
design) and provided little detail with regard to inclusion criteria.
Pain scales against which the outcomes were quantified were not
disclosed. Five participants, three during use of the placebo tea and
two during use of the tipi tea, reported mild adverse eDects. Two
participants failed to complete the trial but the reasons for their
withdrawal were not explained.
Pinus pinaster (synonymPinus maritima)
Although the pine bark extract Pycnogenol® was investigated in
three studies (293 participants) the data could not be pooled
despite all studies returning results that favoured the intervention
over placebo. The two smaller, earlier studies used identical doses
of Pycnogenol® (150 mg daily) over the same intervention period
(three months) but the content of the marker substance in the
daily dose diDered considerably. Moreover, the reported pain
and physical function data used two diDerent forms of outcome
measure, the VAS 0 to 100 mm items of the WOMAC (Farid 2007)
and the 0 to 4 grading (Cisar 2008). Unlike another Cochrane review
exclusively on this product, in which results of these two studies
were pooled (Schoonees 2012), we have reported data from these
studies independently. Data in one study were reported graphically
(Cisar 2008), which was insuDicient to allow extraction for re-
analysis without a considerable margin for error. Results from the
other study demonstrated improvements in pain (Analysis 10.1)
and physical function (Analysis 10.2) for the Pycnogenol® group
over the placebo, but the small sample size (n = 37) of this study was
noted as caution against generalisation of these results.
The more recent, larger study used a confirmatory design and
reported outcome data using the WOMAC 0 to 4 (Belcaro 2008).
Despite positive outcomes from this study the data could not be
pooled with the earlier studies because a smaller dose of pine
bark extract (100 mg daily) with an undeclared content of marker
substance in the daily dose was used in the confirmatory study.
Results from this study also favoured pine bark extract over placebo
for improvements in pain (Analysis 11.1) and physical function
(Analysis 11.2). Observed together, these three studies provided
modest evidence that pine bark extract was eDective in reducing
pain and improving physical function in people with OA even at
daily doses as low as 100 mg.
Ricinus o*icinalis (castor oil)
Castor seed oil was compared to diclofenac (NSAID) in 110 patients
with probable OA of the knee in a parallel trial over four weeks
(Medhi 2009). Pain was reported on a 100 mm VAS. Results of this
exploratory study were insuDiciently reported to allow extraction
and re-analysis. Results favoured diclofenac over Rinicus o)icinalis
for improvement in pain, although pain decreased in both the
intervention and active control groups over time. The adverse event
profile markedly favoured castor oil over placebo (Analysis 12.1),
however it was unclear whether pain (possibly due to untreated OA)
was included among the adverse events reported in the placebo
group.
Rosa canina lito (rose hip)
Three studies (306 participants) compared daily doses of 5 g of
a rose hip and seed powder (Rosae caninae pseudofructus cum
fructibus powder) to placebo. Two studies reported reductions in
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OA pain on a standardised five point scale (0 to 4: 0 = no relief,
4 = almost total relief) (Rein 2004a; Warholm 2003) and the third
used the WOMAC-VAS (Winther 2005). Although the WOMAC-VAS
included a pain subscale, these pain data were not pooled. The
data in one study were insuDiciently reported to allow extraction
for re-analysis (Warholm 2003) and the remaining two studies
used diDering outcome measures to report pain (Rein 2004a;
Winther 2005). Also, the periods of intervention diDered between
studies: three months (Rein 2004a; Winther 2005), and four months
(Warholm 2003).
Previously it has been suggested that it was likely that some
participants may have been in common between the Rein 2004a
and Winther 2005 reports such that pooling data from these studies
would double count some individuals (Vlachojannis 2009), but
correspondence with the study authors confirmed that the data
were not transferred between these studies (Winther, personal
communication, 21 September 2011). In this review we have
treated these reports as independent studies.
These studies constituted modest and somewhat conflicting
evidence that daily consumption of 5 g of Rosa canina lito powder
produced improvements in OA pain superior to placebo (Analysis
13.1).
Salix daphnoides or Salix pupurea x daphnoides (willow)
Two studies (205 participants recruited) of willow bark preparations
returned diDering results (Biegert 2004; Schmid 2000). One study
compared an ethanolic bark extract of Salix daphnoides, equivalent
to 240 mg salicin, to placebo and active (100 mg diclofenac)
controls in parallel groups over six weeks to determine that
although slightly more eDective than placebo, willow bark was less
eDective than diclofenac in reducing OA pain measured using the
WOMAC pain scale (Biegert 2004). In this study similar numbers and
severities of adverse events were reported for both the willow bark
and ibuprofen interventions.
Another study compared the same daily dose of Salix purpurea
x daphnoides ethanolic bark extract to placebo and reported
improvements in WOMAC pain scores aLer two weeks of
intervention (Schmid 2000).
Although these products have diDerent names, both are drawn
from the subspecies daphnoides (subspecies of Salix purpurea) and
may be considered together, however data from these studies were
not suitable for meta-analysis because the authors did not report
measures of variance (SD) for mean scores at the 14 day time point.
In this review mean WOMAC pain and function scores were reported
for a descriptive comparison (Analysis 14.1; Analysis 14.2; Analysis
15.1; Analysis 15.2).
The risk of participants reporting adverse events was not
significantly diDerent between Salix extract and placebo (Salix
19/43, placebo 20/41; RR 0.91, 95% CI 0.57 to 1.43; Analysis 14.3),
but when compared against diclofenac the adverse events profile
of Salix daphnoides was favourable (Salix 19/43, diclofenac 30/43;
RR 0.63, 95% CI 0.43 to 0.93; Analysis 15.3).
Uncaria guianensis (cat's claw)
In a 4 week, parallel group trial comparing aqueous bark extract of
Uncaria guianensis with placebo (Piscoya 2001) participants using
cat's claw reported a statistically significant reduction in pain with
activity within the first week of treatment (P < 0.01). The same
pattern of improvements were seen in physicians' and patients'
global assessments of disease activity. These improvements were
maintained throughout the four week trial, but data from these
measures were not reported in suDicient detail to allow re-analysis
in this review. In contrast, reduction in night pain (MD -11.10,
95% CI -26.4 to 4.24, Analysis 16.1) was not statistically significant
although changes on this measure somewhat favoured cat's claw
over placebo.
Vitellaria paradoxa (shea)
A patented seed extract of Vitellaria paradoxa, the African shea
tree, was tested against placebo in a single centre, two group
parallel trial for 89 patients with OA of the hip or knee (Cheras
2010). Clinical outcomes were measured using the WOMAC and the
Comprehensive Osteoarthritis Test (COAT). Results were equivocal
on all clinical outcomes, and none of these data were reported
in suDicient detail to allow extraction. The authors focused
their report on improvements in biomarkers, which were not of
importance in this review.
Zingiber o*icinale (ginger)
Data from three studies of ginger could not be pooled because
the ginger preparations were dissimilar, including acetone extract
(Bliddal 2000), carbon dioxide extract (Wigler 2003), and a mixture
of two ginger species (Altman 2001).
A crossover trial of Zintona EC, a standardised carbon dioxide
extract containing Zingiber o)icinale (also known as Chinese
ginger), with placebo reported results in favour of the intervention
on measures of pain on movement and function (handicap), using
the 100 mm VAS for these domains from the Hebrew version of the
WOMAC (Wigler 2003) (Analysis 17.1; Analysis 17.2). The first arm of
the crossover included 24 participants; one participant in the ginger
group reported an adverse eDect with the intervention (heartburn)
(ginger 1/12, placebo 0/12; RR 3.05, 95% CI 0.16 to 78.19; Analysis
17.3).
Another study compared a 510 mg daily dose of standardised
acetone extract of Zingiber o)icinale (EV.EXT 33) with 1200 mg
ibuprofen and both tablet and capsule placebos in a crossover
trial in 67 participants (56 completed) and reported results in
favour of ibuprofen for measures of pain (100 mm VAS), Lequesne
algofunctional index, and use of NSAIDS (Bliddal 2000). Data
reporting in this study was insuDicient to allow extraction for re-
analysis.
Medicinal products from two plants
Boswellia carteri andCurcuma longa
Although the authors described this study as a crossover trial,
their reporting of the research method was consistent with a two
group parallel trial of a Boswellia-curcuma mixture compared with
placebo over three months of intervention among people with OA
(Badria 2002). Minutes of pain free walking time, considered in this
review as a measure of function, were recorded in each group aLer
one, two, and three months of intervention. At each time point the
placebo group reported a shorter mean pain free walking time, and
at two and three months the diDerences between the placebo and
intervention groups on this measure were statistically significant
(one month: MD 2.5, 95% CI -0.07 to 5.07, P = 0.06; two months: MD
4.00, 95% CI 1.31 to 6.69, P = 0.004; 3 months: MD 3.5, 95% CI 0.65
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to 6.35, P = 0.02; Analysis 18.1), but none of these measures were
adjusted for baseline scores.
For measures of pain on passive movement and pain on active
movement, group means and mean changes from baseline were
calculated from frequency tables reported in the paper (Badria
2002). No measures of data spread were reported and SDs could not
be calculated from the data provided.
Persea gratissma and Glycine max (avocado-soyabean
unsaponifiables (ASUs)) versus placebo
The avocado-soyabean unsaponifiable (ASU) product Piascledine®
was investigated in six studies; in five studies ASU was compared
with placebo (Appelboom 2001; Blotman 1997; Lequesne 2002;
Maheu 1998; Maheu 2013) and in a sixth study ASU was tested
head-to-head against a 1200 mg daily dose of chondroitin sulphate
(Pavelka 2010). When compared against chondroitin sulphate, ASU
was not inferior on any outcome (Analysis 21.1; Analysis 21.2;
Analysis 21.3).
On the basis of two studies (Blotman 1997; Maheu 1998) the original
review concluded that the evidence for ASU in the treatment of
OA was convincing (Little 2000). A further study supported this
conclusion (Appelboom 2001). Another study of Piascledine® over
two years did not reveal any diDerences between groups, neither in
the primary outcome measure of joint space width nor in clinical
parameters including pain, function, and NSAID consumption
(Lequesne 2002). A further study over three years (36 months)
showed no diDerences between the ASU and placebo groups on any
clinical or functional outcomes, but radiological assessment of joint
space width revealed that 20% fewer participants in the ASU group
showed progressive narrowing of joint space width (Maheu 2013).
Each of the five placebo-controlled studies used a daily dose
of 300 mg Piascledine®, and one study included an additional
group that received 600 mg daily (Appelboom 2001). A total of
1008 participants with OA completed these trials. In one study a
subgroup of patients with OA of the hip and of the knee were
identified and analysed independently (Maheu 1998). Pooling of
results for NSAID consumption measured as diclofenac equivalents,
pain measured using a 100 mm VAS, and Lequesne functional
index indicated that these studies were highly hetergeneous,
returning an I2 of approximately 80% for the meta-analysis of each
of these outcome measures. Although the longer trials returned
results that conflicted with the shorter trials, they were designed
to investigate structural joint changes as the primary outcome
and clinical outcomes were of secondary importance (Lequesne
2002; Maheu 2013). Lequesne and colleagues reported that they
were surprised by the lack of symptomatic improvements among
participants in the Piascledine® group and were unable to explain
why this trial was markedly diDerent to those of other well designed
trials of Piascledine® in patients with OA (Lequesne 2002). Rather
than present a single meta-analysis, we subgrouped these studies
according to the dose of Piascledine® and the length of the
intervention period.
Pain
In two studies (326 participants) pain was measured on a 100 mm
VAS aLer three months of 300 mg Piascledine® daily (Appelboom
2001; Blotman 1997). Using a random-eDects model the pooled
results were a MD of -11.90 (95% CI -23.95 to 0.15; Analysis
19.1). Results aLer six months of treatment with 300 mg daily
also favoured Piascledine® (MD -10.40, 95% CI -17.20 to -3.60)
(Maheu 1998) but aLer 12 months the results indicated no superior
performance compared with placebo (MD 1.00, 95% CI -6.58 to 8.58)
(Lequesne 2002).
Results from the one study (156 participants) that included a 600
mg daily dose were consistent in favour of Piascledine® (MD -14.20,
95% CI -20.82 to -7.58; Analysis 20.1) (Appelboom 2001).
Results aLer 36 months of treatment were reported as changes
from baseline rather than absolute scores (Maheu 2013). Because of
the considerable diDerence in length of intervention, these results
have not been meta-analysed with the results from shorter duration
studies. In this study of 399 participants there was no significant
diDerence in pain reduction between the ASU and placebo groups
(MD -0.66, 95% CI -7.39 to 6.07; Analysis 19.2).
Results also diDered somewhat according to pain location. Maheu
1998 reported greater improvement amongst participants with OA
of the hip (MD -13.80, 95% CI -25.22 to -2.38) compared with those
with OA of the knee (MD -7.10, 95% CI -14.45 to 0.25; Analysis
19.3), but in both subgroup analyses the CIs overlapped the midline
indicating inconclusive results.
Physical function
The Lequesne algofunctional index was used as a measure of
overall physical function in all studies, but these data were
extracted from three studies only (Appelboom 2001; Blotman
1997; Lequesne 2002) because the other studies also reported
function using outcome measures prioritised over Lequesne by the
Cochrane Musculoskeletal Review Group. Again, results diDered
according to the length of intervention. Results aLer three months
of treatment with either 300 mg or 600 mg Piascledine® daily
favoured use of this intervention for improvements in function
(300 mg: MD -1.80, 95% CI -2.68 to -0.92; Analysis 19.6; 600 mg:
MD -1.30, 95% CI -2.38 to -0.22; Analysis 20.2). ALer 12 months
of treatment with the 300 mg dose the MD for function was
0.10 (95% CI -0.78 to 0.98; Analysis 19.6). In one study functional
disability was also measured with a 100 mm VAS; participants
taking 300 mg Piascledine® daily reported improvement compared
with participants taking placebo aLer six months of treatment
(MD -13.20, 95% CI -20.00 to -6.40; Analysis 19.4) (Maheu 1998).
In another study the WOMAC functional scale was used as a key
outcome aLer 36 months of treatment (Maheu 2013). Results in this
study showed a MD of -1.00 (95% CI -7.14 to 5.14; Analysis 19.5).
For the four studies that measured function at the end of treatment
ASU 300 mg improved function (SMD -0.42, 95% CI -0.73 to -0.11;
I2 = 74%; Analysis 19.7). Re-expressed, this translates to a mean
reduction in functional disability of 7 mm (-5 mm to -12 mm) on
a 0 to 100 mm VAS disability scale (0 is best score). The high
heterogeneity was accounted for by the result from Lequesne
2002, the 12 month study which showed no eDect of ASU 300 mg
compared with placebo.
Overall there was moderate evidence that three or six months
of daily use of 300 mg of Piascledine® aDorded statistically
significant improvements in pain (100 mm VAS) and physical
function (Lequesne algofunctional index) but these improvements
did not persist in longer studies. Despite multiple studies with
adequate sample sizes, the evidence was graded as moderate
because allocation concealment was unreported (unclear) in each
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of the studies showing these improvements. In all other ways, these
studies were well designed, and the consistent results across three
studies were convincing.
Joint space width
Joint space width was reported in only two of the six studies of ASU
(Lequesne 2002; Maheu 2013). In a study of 108 participants over
24 months between group diDerences were identified only when
the participants were subgrouped into those with below median
and above median joint space width (JSW) scores at baseline
(Analysis 19.11). The below median JSW subgroup who consumed
ASU showed significantly less reduction in joint space width (that
is preservation of joint space) compared with participants who
consumed placebo (MD -0.43, 95% CI -0.73 to -0.13), but changes
in JSW from baseline were not significantly diDerent between
the placebo and intervention groups in the above median JSW
subgroup (MD 0.16, 95% CI -0.31 to 0.63) (Lequesne 2002). ALer 36
months there was no significant diDerence in changes in JSW from
baseline between the ASU and placebo groups (MD -0.03, 95% CI
-0.22 to 0.16).
In the longest term study participants were identified as
'progressors' if they showed a JSW reduction of greater than or
equal to 0.5 mm over three years (Maheu 2013). In the ASU group
40.4% of participants were identified as progressors compared
with 50.3% of participants in the placebo group. These data were
insuDiciently reported for extraction and re-analysis.
Adverse events
The number of participants who reported adverse events was
reported per group in each study. In two studies more participants
in the placebo groups reported adverse events (Blotman 1997;
Lequesne 2002), and in the other two studies more participants
in the 300 mg ASU groups reported adverse events (Appelboom
2001; Maheu 1998). When these data were meta-analysed for the
300 mg dose of ASU there was a negligible diDerence in the odds of a
participant in either the placebo or intervention group reporting an
adverse event (ASU 267/521, placebo 270/529; RR 1.04, 95% CI 0.97
to 1.12; Analysis 19.8). These studies together constituted high level
evidence that participants taking 300 mg of ASU daily experienced
no greater odds of adverse events than did participants taking a
placebo preparation.
Phellondendron amurense and Citrus sinensis (NP 06-1)
The medicinal plant product NP 06-1 is a mixture of Phellondenron
amurense bark extract and Citrus sinensis peel extract. Oben
2009 and colleagues tested this product against placebo in a
four group parallel study of 80 patients with OA of the knee
over eight weeks. Two groups (one intervention and one control)
included participants of normal body weight; the other two groups
included overweight participants. Results in both the normal
weight and overweight participants favoured NP 06-1 over placebo
for improvement of knee function as measured using the Lequesne
algofunctional index (MD -3.82, 95% CI -7.05 to -0.59; Analysis 22.1).
NP 06-1 contains berberine, which may have contributed to weight
loss in the overweight participants.
Uncaria guianensis and Lepidium meyenii (Reparagen®)
Reparagen® is a mixture of aqueous bark extracts of Uncaria
guianensis and Lepidium meyenii. It was tested against glucosamine
sulphate in a two group parallel trial in 95 patients with OA
of the knee (Mehta 2007). Results from this trial suggested
that Reparagen® was not significantly diDerent from glucosamine
sulphate for the remediation of OA pain. These results were
insuDiciently reported to allow data extraction for re-analysis. The
adverse event profile of Reparagen® appeared favourable (Analysis
23.1).
Zingiber o*icinale and Alpinia galanga
A standardised extract (EV.EXT 77) of ginger (Zingiber o)icinale)
and galangal (Alpina o)icinale, also known as Thai ginger) was
compared with placebo in 261 people with OA of the knee (Altman
2001). Significant improvements in favour of ginger were reported
for pain (100 mm VAS) aLer walking 50 feet (MD -9.60, 95% CI
-16.81 to -2.39, P = 0.009; Analysis 24.1). Also, improvements in all
components of the WOMAC score were reported in favour of the
ginger group over placebo. These improvements were statistically
significant for the WOMAC stiDness score and the WOMAC total
score but not for the pain and function domains of the WOMAC that
were considered in this review.
Medicinal products from three or more plants
Korean herbal mixture: SKI306X®
Two studies compared the Korean herbal preparation SKI306X® to
placebo (Jung 2001) or diclofenac controls (Jung 2004). The earlier
study (139 participants) was undertaken to determine the dose and
safety profile of the intervention. The latter study (249 participants)
was conducted to determine clinical eDicacy. In the earlier study,
daily doses of 200 mg, 400 mg, and 600 mg were compared with
placebo and outcomes measured using a pain VAS and Lesquesne
index. Meta-analyses of these results (pooling doses) demonstrated
consistent eDects in favour of SKI306X® for reducing pain (MD
-17.36, 95% CI -22.57 to -12.15; Analysis 25.1) and improving
physical function (MD -2.73, 95% CI -3.71 to -1.74; Analysis 25.2).
EDect sizes for these outcomes did not show a consistent linear
relationship to dose. There was moderate evidence that, regardless
of dose (600 mg, 1200 mg, 1800 mg), four weeks daily use of
SKI306X® produced statistically significant improvements in the
pain VAS and Lequesne algofunctional index compared to placebo.
The number of participants who reported adverse events was
reported per group, and more participants receiving 400 mg
SKI306X® reported adverse events than did participants in
any other group. When each of the intervention subgroups
was compared with the placebo group the risk ratios (RR)
diDered between comparisons, but for each subgroup the risk of
participants reporting adverse events was not clearly greater in
the placebo or intervention groups. When these data were meta-
analysed, there was negligible diDerence in the risk of a participant
in either the placebo or SKI306X group reporting an adverse event
(overall SKI306X 14/70, placebo 15/69; RR 0.93, 95% CI 0.49 to 1.79;
Analysis 25.3).
In a follow-up study, a daily dose of 600 mg SKI306X® was compared
with 100 mg diclofenac. Results favoured diclofenac for the same
outcome measures of 100 mm VAS for pain (MD 1.31, 95% CI -2.78
to 5.40; Analysis 26.1) and Lequesne's algofunctional index (MD
0.77, 95% CI 0.10 to 1.44; Analysis 26.2). Statistically significant
changes in these measures were seen within both groups over time.
Between-group diDerences in physical function were statistically
significant (P = 0.02) but diDerences in self-reported pain were not
(P = 0.53). This study constituted moderate evidence that daily use
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of 600 mg of SKI306X over four weeks produced improvements in
pain (100 mm VAS) that were not statistically significantly diDerent
from 100 mg diclofenac. When compared against diclofenac, 600
mg SKI306X appeared to have a favourable adverse event risk
profile (SKI306X 22/125, diclofenac 36/124; RR 0.61, 95% CI 0.38 to
0.97; Analysis 26.3).
Phytodolor®N
Three studies compared Phytodolor®N (prepared from ash bark,
aspen leaf, aspen bark, golden rod herb; for details see table)
to placebo or active control (piroxicam) in 176 participants and
reported results in favour of Phytodolor®N for reduced use of
NSAIDs (diclofenac) and improvement in range of motion as
measured by finger to ground distance in lumbar flexion (Bernhardt
1991; Huber 1991; Schadler 1988). Finger to ground distance is one
of the methods used to quantify the Schober test (lumbar spine
flexion in standing) and is a measure of physical function that is
more commonly used in the assessment of people with low back
pain than with OA. It is probably a meaningful measure of physical
function in participants with OA of the lumbar spine but none of
these studies were limited to participants with spinal OA.
These studies could be viewed with some skepticism because
they were undertaken by the manufacturer (Steigerwald
Pharmaceuticals). One of these studies was a crossover design
with intervention periods of seven days duration and used a dose
of Phytodolor®N 33% greater than that used in the two other
studies (Schadler 1988). The other two studies were of parallel
design, one of three weeks intervention with measures at weekly
intervals (Huber 1991) and the other of four weeks intervention
with measures at baseline and weeks one, two, and four (Bernhardt
1991). Because doses of Phytodolor®N and some of the measures
diDered among trials, and because most of the data from these
studies were reported as composite statistics (Chi2, P values), data
could not be pooled for meta-analyses. In this review all available
mean data were reported for descriptive comparison (Analysis
27.1; Analysis 27.2; Analysis 27.3). For one study, group means and
mean changes from baseline were calculated from frequency tables
reported in the paper (Bernhardt 1991). SDs could not be calculated
from the data provided.
Reumalex®
A self-prescribed dose ("2 tablets at a time") of the herbal mixture
Reumalex® was compared with placebo over two months of
treatment. Both patients with rheumatoid arthritis and OA were
recruited for this study. Separate data for the OA subgroup were
provided for the primary outcomes of the AIMS 2 pain score and
modified Ritchie index (Mills 1996). At the end of the treatment
period the mean reduction in AIMS 2 pain score was greater in the
Reumalex® group (MD -0.89, 95% CI -1.73 to -0.05; Analysis 28.1).
Four participants withdrew from each of the placebo and
intervention groups due to side eDects, and a further five
(Reumalex® n = 2, placebo n = 3) complained of exacerbation of
symptoms, but it was unclear how many of these participants were
people with OA (RR 1.08, 95% CI 0.40 to 2.91; Analysis 28.2).
Chinese herbal mixture: Duhuo Jisheng Wan
The Chinese herbal mixture Duhuo Jisheng Wan (DJW) was tested
in a head-to-head comparison against diclofenac sodium over four
weeks intervention (following one week run-in) in patients with
unilateral or bilateral OA of the knee (Teekachunhatean 2004). Pain
and stiDness across a range of conditions were measured using
a battery of VAS. The Lequesne algofunctional index was used to
capture joint function data. DJW appeared to be as eDective as
diclofenac in reducing joint pain (Analysis 29.1) and improving
function (Analysis 29.2). Unfortunately, the risk of adverse events
associated with DJW were also comparable to diclofenac (DJW
28/100, diclofenac 27/100; RR 1.04, 95% CI 0.66 to 1.63; Analysis
29.3). This toxicity profile, combined with the fact that DJW was
administered as an 18 capsule per day dose, meant that it was
unlikely to gain credence as a viable alternative to NSAIDs.
Chinese herbal mixture: blood-nourishing, hard-so:ening
The Chinese mixture for blood-nourishing and hard-soLening
(BNHS) is an extract from the root of Paeoniae alba, Gentiana
macrophylla, and Glycyrrhiza (species not stated, possibly
uralensis). This product was tested against two active controls
(western medicine control: glucosamine sulphate, Chinese
medicine control: counter osteophyte herbal mixture) although the
activity of the controls was not demonstrated in the paper and
may be questionable. Although Cao and colleagues reported this
investigation as one study it was really two distinct clinical trials run
simultaneously over four weeks in diDerent hospitals (Cao 2005).
Sixty participants (30 at each site) were randomised to receive
BNHS capsules and 30 participants were randomised to receive
one of the two active control drugs. Data from the two trials were
presented independently.
When compared with glucosamine sulphate, BNHS capsules
produced slightly superior improvements in VAS measures of pain
on walking (MD -2.00, 95% CI -6.81 to 2.81; Analysis 31.1) but no
mean improvements in WOMAC function (MD 0.00, 95% CI -2.53 to
2.53; Analysis 31.2). No adverse events were reported in this trial.
In comparison with the alternate Chinese herbal mixture counter
osteophytes, BNHS capsules produced a slight mean increase in
pain on walking (MD 2.00, 95% CI -7.12 to 11.12; Analysis 30.1) and
slight improvement in physical function (MD -2.00, 95% CI -7.57 to
3.57; Analysis 30.2). Four participants in this trial reported adverse
events with use of BNHS. No participants reported adverse events
associated with use of the alternative Chinese mixture. Because
the sample size was small, and all adverse events occurred in one
group, the risk of adverse events associated with BNHS appeared
considerable in this trial (RNHS 4/30, Chinese control 0/30; RR 9.00,
95% CI 0.51 to 160.17; Analysis 30.3) but this result may be viewed
with some skepticism considering that no participants in the other
trial reported any adverse events with BNHS capsule use.
Ayurvedic formulae
Three studies investigated seven Ayurvedic formulae. Two studies
investigated formulae available as proprietary products: Antarth®
(Gupta 2011) and RA-II® (Chopra 2004). The third study compared
five Ayurvedic formulae formed from combinations of five plant
extracts (Chopra 2011) (for details see table). Because none of the
Ayurvedic formulae were the same these studies were not suitable
for pooling and are described independently.
Ayurvedic formulae: A, B, C, D and E
Five Ayurvedic formulae formed from five herbal ingredients in
varying combinations were tested against each other and against
placebo in a six group trial over 16 weeks in 245 patients with OA
Oral herbal therapies for treating osteoarthritis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
36
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
of the knee (Chopra 2011). Pain was measured on a 0 to 10 VAS
and physical function was measured using the Indian version of the
WOMAC 0 to 4. Results of this exploratory study were not reported
in full detail to allow extraction and re-analysis. Generally results
were equivocal on most outcomes. This study may have been
underpowered to detect changes in a six group comparison (35
participants per group). The adverse event profile was noteworthy:
participants who received formula D showed markedly greater
odds of reporting adverse events (Analysis 32.1).
Ayurvedic formula: Antarth
Antarth was compared against placebo in a two group parallel trial
over 12 weeks in 90 patients with OA of the knee (Gupta 2011). Pain
was measured on a 0 to 10 cm VAS, which we converted to a 0 to 100
mm scale during data extraction. Results slightly favoured Antarth
over placebo for the reduction of pain in OA (Analysis 33.1) but
should be interpreted with caution because this exploratory study
may have been underpowdered to detect clinical eDects of Antarth.
Ayurvedic formula: RA-11
RA-11 was tested against placebo in a two group parallel trial
over 32 weeks in 90 people with OA of the knee (Chopra 2004).
Pain, stiDness, and physical function were measured using the
Indian modification of the WOMAC 0 to 4. Because the study was
fully powered, with 45 participants in each group, and rescue
medication was not permitted this study was well designed
to capture data on the pain reducing eDects of RA-11. An ITT
model was applied to the analyses and missing data were
replaced by the last observation carried forward method. Three
participants were removed from the trial by the investigators
due to "eDicacy failure". Forcibly withdrawing participants with
worsening pain and carrying forward data from the last observation
of these participants may have somewhat exaggerated the eDects
of of RA-11 on pain. Results favoured RA-11 over placebo for
improvements in pain (Analysis 34.1) and function (Analysis 34.2).
Ayurvedic formulae: SGC and SGCG
Ayurvedic formulae SGC and SGCG were tested against
glucosamine sulphate and celecoxib in a four parallel group
trial over 24 weeks (Chopra 2013). On measures of pain (VAS
0 to 100), function (WOMAC function), and with regard to
participants reporting adverse events, both Auryvedic formulae
were comparable to both glucosamine sulphate and celecoxib.
Japanese herbal mixture: Boiogito
The Japanese herbal mixture Boiogito was compared head-to-head
with loxoprofen for the management of knee pain and eDusion in
a small (n = 50) exploratory study over 12 weeks. Participants who
took Boiogito reported slightly better Knee Society Rating System
knee scores, including less joint eDusion, than participants who
took loxoprofen, but the results did not diDer significantly between
groups (MD -1.30, 95% CI -8.90 to 6.30; Analysis 39.1). On the other
hand participants who took loxoprofen reported slightly greater
functional capacity on the stair climbing component of the Knee
Society Rating System (MD 3.60, 95% CI 0.51 to 6.69; Analysis 39.2)
and no adverse events. One participant using Boiogito reported an
adverse event (Boiogito 1/24, loxoprofen 0/23; RR 2.88, 95% CI 0.12
to 67.29; Analysis 39.3).
D I S C U S S I O N
Summary of main results
Thirty-one medicinal plant products from single plant parts
(Boswellia serrata, Curcuma domestica Derris scandens, Garcinia
kola, Harpagophytum procumbens, Petiveria alliacea, Pinus
pinaster, Rosa canina lito, Salix pupurea+daphnoides, Uncaria
guianensis, Vitellaria paradoxa and Zingiber o)icinale); five
mixtures of two herbal preparations (Boswellia carteri and
Curcuma longa, Persea gratissma and Glycine max, Phellondenron
amurense and Citrus sinensis, Uncaria guianensis andLepidium
meyenii, and Zingiber o)icinalis and Alpinia galanga) and the
polyherbal preparations Phytodolor®N, Reumalex®, SKI306X®,
Chinese herbal mixtures Duhuo Jisheng Wan and blood-nourishing,
hard-soLening, Ayurvedic formulae RA-11, A, B, C, D, E, and Antarth,
and Japanese herbal mixture Boiogito were compared in 47 studies
against placebo (n = 38), active control (n = 19), and no intervention
(n = 1). Due to the diDering study protocols (diDerent outcome
measures and times of outcome assessments) and medicinal plant
products employed, pooling of data was only possible for the
proprietary products avocado-soybean unsaponifiables (ASU) and
Boswellia serrata.
Despite the great number of clinical trials carried out, reliable
data could only be achieved for the ASU product Piascledine®.
The pooled data of three studies with a confirmatory study design
showed OA improvements, but another definitive study over two
years failed to demonstrate eDectiveness except in a subgroup of
people with less severe complaints. The most recent comparison
of Piascledine® and chondroitin sulphate showed that the ASU
product was not inferior to the slow-acting anti-arthritic substance
for which eDectiveness within six months is controversial (Lee 2010;
Reichenbach 2007; Wandel 2010). Also, the most recent placebo-
controlled study lasting three years failed to show any benefit for
ASU in clinical outcome measures including the WOMAC index. The
study was planned to confirm slower radiographic progression in
symptomatic hip OA (Maheu 2013) but only 20% fewer progressors
were identified in the post hoc analysis, with progressors defined
as patients with joint width space loss > -0.5 mm.
Of the five studies that investigated three diDerent extracts
from Boswellia serrata gum resin, pooled data from two studies
indicated OA improvement for the Boswellia product 5-Loxin®. The
remaining 38 studies showed unproven benefit in the alleviation of
OA for the herbal medicinal products investigated, which originated
from Africa, Asia, Europe, India, and the Americas. Serious adverse
events were not reported for any of the medicinal plant products.
Overall completeness and applicability of evidence
Evidence from studies that recruited patients with diagnoses
of OA confirmed according to ACR or EULAR criteria may be
directly applied to clinical practice. In some studies diagnostic
criteria applied at recruitment were not labelled as ACR or EULAR
criteria but were described in suDicient detail to be confident that
they were fully consistent with the recommendations of these
authorities. In six studies, however, ACR and EULAR criteria were
not fully considered and these studies have been downgraded to
unclear risk of selection bias (Huber 1991; Jung 2001; Majima 2012;
Medhi 2009; Schadler 1988; Warholm 2003). The applicability of
evidence from these studies to clinical practice is also unclear. In
another five studies selection was so broad as to almost certainly
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have included recruitment of participants with conditions other
than OA (Badria 2002; Bernhardt 1991; Ferraz 1991; Kimmatkar
2003; Schmelz 1997). These studies are classified as having high risk
of bias and evidence from these studies may be of questionable use
in clinical practice.
The WHO recommends that the manufacturing procedure of
medicinal plant products should be described in detail (for example
if other substances are added during manufacture in order to adjust
the plant preparation to a certain level of active or characteristic
constituents or for any other purpose). A method for identification
and, where possible, assay of the plant preparation should be
added. If identification of the active principle is not possible
it should be suDicient to identify a characteristic ingredient
or mixture of ingredients (for example the 'chromatographic
fingerprint') to ensure consistent quality of the preparation in order
to be able to re-do the study with an essentially similar product
(having a comparable active principle, see below).
The active principle of a medicinal plant product is the sum of all
ingredients that produce the medicinal action. The active principle
has not been fully been identified for any of the anti-inflammatory
acting herbal medicinal products. Co-active ingredients include
flavonoids (Acacia catechu, Citrus sinensis, Curcuma species,Derris
scandens, Garcinia kola,Harpagophytum procumbens, Petiveria
alliacea, Phytodolor®N, Rosa canina, Salix species, Scutellaria
baicalensis,Zingiber species), unsaturated fatty acids (Piascledine®,
Ricinus o)icinalis, Rosa canina, SKI306X®, Vitellaria paradoxa),
alkaloids (Acacia catechu (tryptamine derivatives), Garcinia
kola,Lepidium meyenii (lepidiline), Phellondenron amurense
(berberine), Symphytum o)icinale, Uncaria species) and in
particular polyphenols (Acacia catechu, Citrus sinensis,Pines
pinaster,Rosa canina), iridoid glycosides calculated as harpagoside
(Harpagophytum procumbens), gingerols (Zingiber species),
boswellic acids (Boswellia species), curcurminoids (Curcuma
longa), or mustard glycosides (Lepidium meyenii). Mixtures of
two or more herbal preparations form a new entity with their
characteristic active principle being diDerent from that of the single
medicinal plant products, as are the actions and adverse events.
If herbal extracts are combined the superiority of the mixture over
the individual herbal preparation has to be established in vitro,
in animal experiments, and in human pharmacological studies in
order to demonstrate the superior eDect and the safety.
The minimum information given for a medicinal plant product
in an article should include the plant part, the brand name (if
the preparation has not been solely prepared for the study), the
excipient added in the case of extracts and the drug extract ratio
if no crude plant material is used. The daily dosage of the 'native'
plant preparation should be stated otherwise the extract dose may
also contain additives (Chrubasik 1996). Although not requested
by regulatory authorities, it is desirable to know the content of at
least one characteristic marker substance (if possibly a co-active
ingredient). Only few studies provided all this information (Table
1). The results of studies with insuDicient declared characteristics
are only attributable to the particular product used in the study
and cannot be transferred to other medicinal products from this
plant material unless bioequivalence of the products has been
demonstrated (Chrubasik 2003).
Salicin, the characteristic ingredient of Salix species, is an
ineDective pro-drug. However, during absorption salicin is
metabolized into co-active salicylic acid derivatives. Surprisingly,
the amount of salicylic acid produced from a daily dose of Salix bark
extract containing 240 mg of salicin corresponds to an aspirin dose
of only 100 mg, a cardioprotective rather than an anti-inflammatory
dose (Schmid 2000). This Salix extract dose, however, cannot be
used to replace aspirin as a blood thinner because it has been
shown not to have a major impact on blood clotting (Krivoy 2001). It
is implausible that the regulatory authority EMA has restricted the
use of willow bark preparations to four weeks (Vlachojannis 2013) in
light of the fact that NSAIDs in current use, with a higher risk benefit
ratio than willow extract, are used for longer treatment durations,
for example up to 138 weeks (Reginister 2007). Acute toxicity studies
in rats could not determine a lethal dose of willow bark extract
even in doses 200 times the experimental level (Glinko 1998).
Data on chronic toxicity are still lacking (EMA 2009; ESCOP 2003;).
Possible interactions with natural or synthetic blood thinners need
to be elucidated, especially if higher doses of willow bark extract
(with 360 mg or 480 mg salicin per day) are employed. A life-
threatening anaphylactic reaction was observed in a patient with
a history of allergy to salicylates (Boullata 2003). Known salicylate
allergy is therefore a contra-indication for the use of willow bark
preparations.
The clinical studies investigating medicinal products from
Harpagophytum procumbens included a cryoground powder, an
aqueous and an ethanolic extract. The extracts contained only half
the amount of harpagoside in the daily dosage than what would
be expected aLer complete extraction and if no additives were
added. The ethanolic extracts were incompletely extracted (Sporer
1999) and the aqueous extract contained additives (Chrubasik
1996). According to the European Pharmacopoeia it is required
that the starting material for Harpagophytum products contains a
minimum of 1.2% of harpagoside. Since the daily dose of extracts
should be prepared from 4.5 to 9 g of crude plant material, the
daily dosage would provide 50 to 100 mg of harpagoside or more
(European Medicines Agency (EMA) monographs). Thus, of the four
studies investigating Harpagophytum products only one has used
an appropriate dose.
In general, the daily dosages of medicinal products are based on
information from monographs or textbooks and are not the result
of dose-finding studies. It seems likely that an increase in dose
might improve the clinical eDect. This was shown for aqueous
Harpagophytum and ethanolic Salix extracts in a patient population
suDering from acute exacerbations of chronic low back pain
(Chrubasik 1999; Chrubasik 2000). However, for some medicinal
products a ceiling eDect was demonstrated. For example, a 600 mg
dose of Piascledine® per day was not more eDective than a half dose
(Appelboom 2001), and 600 mg or 400 mg of the herbal mixture
SKI306X® was not more eDective than 200 mg per day (Jung 2001),
or 250 mg of the proprietary Boswellia serrata extract 5-Loxin® was
not more eDective than 100 mg per day (Sengupta 2010). The first
medical report on the use of dried and powdered willow bark dates
back to 1763 (Stone 1763). The empirically chosen daily dose (up to
24 g) might have contained up to 1000 mg of salicin as the crude
plant material generally contains about 4% salicin. Higher doses
than that used in the study by Biegert 2004 may reliably improve
OA complaints. Future studies are required to identify the optimum
daily doses of medicinal products.
Unsaturated fatty acids contribute to the anti-inflammatory eDect
of some medicinal plant products (Appelboom 2001; Blotman 1997;
Cameron 2011; Jäger 2007; Jäger 2008; Wenzig 2008). It seems likely
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that castor seed oil may improve OA complaints. Because a dose-
finding study has not been undertaken, and high doses of castor oil
produce unpleasant laxative eDects, we question whether higher
doses of castor oil are likely to be tolerated by people with OA.
The net benefit of an intervention may be defined as the
magnitude of benefit minus the magnitude of harm (ICH 2004).
Benefit and harm are not always measurable in standardised
eDect size units, complicating the calculation of net eDect.
However, the point remains that for each of the herbal
medicines where clinical benefit is reported, clinical harm (adverse
events, toxicity) must be considered in making an overall
judgement of the usefulness of the intervention. Among the
non-herbal medications commonly used to treat OA, NSAIDs in
particular are associated with frequent and sometimes severe side
eDects (Gabriel 1991), particularly gastrointestinal complications
including dyspepsia, perforations, ulcers, and bleeds (Ofman
2002; Ofman 2003), which add considerable cost to the usual
care of people with OA (Smalley 1996). In theory, ginger
and Curcuma products might go along with an increased risk
of stomach bleeding, however this has not been suDiciently
evaluated (www.ema.europa.eu/docs/en_GB/document_library/
Herbal_-_Community_herbal_monograph/2011/09/
WC500112680.pdf'; www.ema.europa.eu/docs/en_GB/
document_library/Herbal_-
_Community_herbal_monograph/2010/02/WC500070703.pdf). In
fact, no serious adverse events were reported with any herbal
intervention in the included studies. It appears that the benefit risk
ratio of medicinal plant products is superior to that of NSAIDs. A
recent pharmacovigilance analysis revealed 117 reported adverse
events, mostly cutaneous, hepatic and gastrointestinal disorders,
associated with the intake of Piascledine®. Although the incidence
of adverse events seems to be 'very rare', in light of the fact
that the product is widely prescribed in France there is concern
regarding possible under-reporting of adverse events (Olivier 2010)
(www.drugcite.com/?q=PIASCLEDINE&s=&a=).
A systematic review of adverse events is available for
Harpagophytum procumbens that includes 28 clinical studies
(mostly observational) reporting on 6892 patients who consumed
Harpagophytum extract for up to one year. In none of the double
blind studies was the incidence of adverse events higher during
treatment with Harpagophytum than during placebo treatment.
Minor adverse events (AE) were described across 20 studies in 138
of 4274 Harpagophytum consumers. This corresponds to an overall
adverse event rate of around 3% for Harpagophytum preparations
with a maximum of 100 mg harpagoside as the daily dosage
(Vlachojannis 2008). Some of the adverse events, particularly
minor gastrointestinal complaints and allergies, were probably
related to Harpagophytum. Three studies on preclinical toxicity
indicated very low acute toxicity (ESCOP 2003). Data on chronic
toxicity, including mutagenicity, carcinogenicity, teratogenicity,
and embryogenicity, were not found (ESCOP 2003). For most
medicinal plant products preclinical data are not available,
and only some of them report on their AE profiles (Basch
2004; Chrubasik 2005; ESCOP 2003; ESCOP 2009; Krishnaraju
2010; Schoonees 2012; Stohs 2011; Valerio 2005; www.herbal-
ahp.org, http://apps.who.int/medicinedocs/en/d/Js2200e/). It is
thus recommended to do safety pharmacological studies
according to published guidelines (www.fda.gov/cder/guidance/
index.htm, www.emea.europa.eu/pdfs/human/ich/030095en.pdf)
for the individual medicinal plant products. If a
carcinogenic eDect is assumed, carcinogenicity studies are
also mandatory (www.ich.org/LOB/media/MEDIA489.pdf). If the
guidelines of good manufacturing practice including those
for the starting material (www.api-conference.org/pa4.cgi?
src=eca_news_data.htm&nr=488&show=daten/news/
GMP_News_488.htm&id=S11510781142) are considered,
contamination of medicinal products with other herbal medicines,
pesticides, heavy metals, or drugs can be ruled out.
The adverse eDect quota and profile for Phytodolor®N appear
to be better than for NSAIDs. Gastrointestinal complaints were
most frequently reported (2.6%), and occasionally allergic skin
reactions have occurred. Some adverse eDects are partly due to the
alcohol content of Phytodolor®N (45.6% vol, 0.7 g per 40 drops),
which poses a health risk to children and to adults with liver
disease, alcoholism, epilepsy, or brain damage. Caution is advised
during pregnancy or lactation and for drivers and individuals who
operate machines, even though no impairment of consciousness or
reactivity is expected to occur with 0.7 g of alcohol per dose. Studies
on mutagenicity, teratogenicity, and toxicity in the parent animals
and their progeny gave no evidence for any toxic eDects arising from
the intake of the combination during pregnancy and the lactation
period (Gundermann 2001).
Quality of the evidence
Generally the studies included in this review are of lower quality
than desired, but we stress that these studies represent the
current best quality evidence for the eDectiveness of oral medicinal
plant interventions in the treatment of OA. Poorer quality studies
with non-randomised, uncontrolled designs were excluded (for
example Guyader 1984; Myers 2010; Rosen 2013). We excluded
clinical trials of products that are not strictly herbal so as to avoid
misinterpretation of the results of these studies in herbal medicine
practice (for example Belcaro 2010; Jacquet 2009; Kulkarni 1991;
Levy 2009). We note that more recent studies typically have higher
quality reporting than older studies, and commend researchers in
this field for the improvement of research design and reporting.
There is moderate-quality evidence that in people with OA,
Boswellia serrata slightly improved pain and function. The evidence
was downgraded to moderate as there is a potential for imprecision
due to the small number of participants contributing to these
outcomes. There is moderate-quality evidence that avocado-
soybean unsaponifiables (ASU) probably improved pain and
function slightly but may not preserve joint space. Evidence was
downgraded due to inconsistency across results, or imprecision.
Further research may change our estimates of the size of eDects,
and the precision around estimates.
We are uncertain whether other oral herbal products improve OA
pain or function, or slow progression of joint structure damage
because the evidence available is limited to single studies only,
or studies providing data that cannot be pooled. Some of these
studies are of low to very low quality, and some important outcome
measures (eg: quality of life, joint space width) were omitted.
Potential biases in the review process
Incomplete reporting in some studies may have led us to
undervalue the evidence of eDectiveness, because we made strict
judgements of methodological quality on the basis of reporting.
On the other hand, incomplete reporting may be indicative of bias
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in studies such that incompletely reported trials may overestimate
the treatment eDects, thus we stand by our strict, conservative
judgements (Higgins 2011). For example, in countries in which the
ICH guidelines are implemented in law, Human Research Ethics
Committees would approve a clinical trial protocol only if it accords
with the ICH good clinical practice consolidated guidelines (ICH
2004). Randomisation, blinding, masking of outcome assessment,
and allocation concealment will probably have been adequately
conducted even if the study was simply reported as "randomised
and double-blind". To allow full and accurate assessment of future
studies, we recommend that authors conform to the Consolidated
Standards of Reporting Trials (CONSORT) (Begg 1996; Moher
2001).       
Studies fail for a variety of reasons and, although venturing into
conjecture, we consider that groups may have diDered at baseline
according to some parameters that were not measured, but may
have influenced the primary outcome measures. For example,
baseline data in the Lequesne 2002 study did not include details of
the quantity of NSAIDs consumed or use of opioids for pain. Neither
was anything reported about the mood state of the participants,
which may also have influenced pain measures. Joint space
loss was significantly reduced in patients with mild OA possibly
indicating that early use of ASU may act preventively, but this
suggestion needs to be confirmed in a follow-up study. Concerns
regarding baseline diDerences between groups are amplified for
studies with inadequate or unclear methods of randomisation and
allocation concealment.
Many studies, although well designed, were probably
underpowered and the lack of evidence of eDect may be due
to Type II error. Trends to eDectiveness may be suggested from
underpowered studies if improvements can be calculated and
reported as eDect sizes.
Glucosamine sulphate and chondroitin sulphate were used as
active controls in some studies (Cao 2005; Chopra 2013; Mehta
2007; Pavelka 2010) but we question this assumption. Several
recent systematic reviews suggest that chondroitin sulphate has
negligible eDect on OA pain (Reichenbach 2007; Wandel 2010) and a
small but significant protective eDect against joint space narrowing
(Lee 2010). Glucosamine sulphate does not act on pain pathways
or mediators. Glucosamine is an amino acid that may enhance
cartilage repair and, due to this reparative process, pain may reduce
in people with OA but typically these changes take six to 12 weeks
to occur and eDect sizes are not large (Lee 2010; Reichenbach
2007). In a meta-analysis of 10 large randomised controlled trials of
glucosamine, chondroitin, or the two in combination on joint pain
and on radiological progression of disease in OA of the hip or knee
Wandel and colleagues determined that glucosamine use produced
a mean reduction in pain of 4 mm on a 100 mm VAS, an eDect that
did not exceed a minimum clinically important diDerence (Wandel
2010).
We attempted to minimise bias in this review through
transparent and thorough methods. We adopted a broad search
strategy without language restrictions. We attempted to include
grey literature by seeking manufacturers' reports, theses and
unpublished reports as well as searching electronic databases. We
removed duplicate publications from our analysis and reported
fully our reasons for excluding or not assessing any trials.
We conducted independent data extraction, in duplicate, of all
included studies. Despite these strategies the review may be
subject to some bias, particularly our personal biases due to
our clinical practice experiences in arthritis care (MC) and herbal
medicine (SC).
Agreements and disagreements with other studies or
reviews
This review is the update of a Cochrane review (Little 2000), which
we divided into two parts. For completeness, the updated review
of topical herbal medicines for the treatment of OA (Cameron 2013)
should be read in conjunction with this updated review.
The results of this review are largely consistent with the findings
of earlier reviews that included meta-analyses of trials of ASU
(Cameron 2007; Cameron 2009; Christensen 2008a; Little 2000),
which showed that this combination of two herbs shows benefits
for OA pain and function in the short term. The addition of larger
and longer term studies to these meta-analyses suggests that the
eDects of ASU on pain and function are not sustained over longer
periods of two to three years, and that the eDects of ASU on joint
structure are small at best (Lequesne 2002; Maheu 2013).
In people with low back pain the ethanolic Salix bark extract in two
doses demonstrated a dose-dependent eDect superior to placebo
(Chrubasik 2000), and was not inferior to the synthetic rofecoxib
(Chrubasik 2001). In one of the two studies included in this review,
a comparable dose of Salix extract failed to produce a significant
eDect in patients with OA, while the control group responded
favourably to treatment with diclofenac (Biegert 2004). It may well
be that a higher Salix extract dose might have relieved OA patients'
pain; empirically, higher willow bark extract doses have been used
for the treatment of pain since the middle ages (Vlachojannis 2009).
This review is also largely consistent with a previous systematic
review and meta-analysis of randomised controlled trials of Rosa
canina for OA (Christensen 2008b). The same three studies are
included in both reviews. Unlike Christensen and colleagues we did
not pool pain scores for meta-analysis because diDerent outcome
measures were used across two of the three trials (Rein 2004a;
Winther 2005), and in the third study pain data were reported
insuDiciently for data extraction and re-analysis (Warholm 2003).
We concur with Christensen and colleagues that Rosa canina
probably reduces pain in OA but we recommend that this purported
eDect be thoroughly tested in a suDiciently powered randomised
controlled trial using standardised outcome measures.
This review diDers somewhat from an earlier Cochrane review
exclusively on pine bark extract (Schoonees 2012). We identified
and included the studies from the Schoonees and colleagues'
review but we have reported data from these studies independently
rather than pooling them for meta-analysis because diDerent
outcome measures (WOMAC-VAS (Farid 2007) and WOMAC 0 to
4 (Cisar 2008)) were used across the studies, and data in one
study were reported graphically (Cisar 2008), insuDicient to allow
extraction for re-analysis.
This review is compromised by many poorly designed clinical
trials that were underpowered and inadequately blinded. Herbal
medicine is not a field known for the widespread adoption of
evidence-based practice, however, in light of the low quality
body of evidence in oral herbal treatment for OA, practitioners
might continue to ignore the research and do what they 'have
always done'. Even small eDect sizes may represent clinically
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meaningful improvements, particularly if these small eDects
represent improvements in a common condition with a substantial
population burden of disease (for example OA). In light of the fact
that serious adverse events related to any of the medicinal plant
products were not observed, physicians and patients should not
be discouraged in using herbal medicines at all. In this section,
therefore, we have chosen to address some of the common biases
in herbal medicine as well as in this review.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
See: 'Summary of findings' tables.
We have provided a tabulated summary of key clinical messages
to assist practitioners in transferring the findings of this updated
review into their clinical work. The current available evidence for
herbal treatment of osteoarthritis (OA) is generally sparse. For most
medicinal plant products there is insuDicient evidence to support
or discourage use.
The original review concluded that there was consistent evidence
that a proprietary product from avocado-soybean unsaponifiables
(ASU) can provide long term symptomatic relief, particularly for
patients with chronic but stable OA of the hip, and that ASU
may also help patients to reduce their consumption of non-
steroidal anti-inflammatory drugs (NSAIDs). These results need to
be reconsidered in the light of three new studies: one study over
six months that supports the previous findings (Appelboom 2001),
another longer term study that reported no improvements over
placebo among people using 300 mg ASU daily for 12 to 24 months
(Lequesne 2002), and the most recent showing ASU as not inferior
to chondroitin sulphate (Pavelka 2010). Despite symptomatic
improvements, ASU does not appear to have a major impact on
joint structure in patients with OA. Similarly, non-inferiority to
chondroitin sulphate may mean little because chondroitin sulphate
is not significantly eDective in reducing osteoarthritic pain, and
has only a small eDect on joint space narrowing that occurs only
with long term (two plus years) treatment (Wandel 2010). We
suggest that the length of intervention may be an important factor
that diDers among these studies, and recommend that clinicians
consider monitoring pain and physical function as part of routine
care for patients using ASU, particularly with prolonged use of this
intervention.
High tolerance of the medicinal plant products was demonstrated
in all studies. Caution is warranted in interpreting safety. Although
no serious drug-related adverse events occurred in the studies so
far, comprehensive safety data are still required for all medicinal
plant products except for the mixture Phytodolor®.
Implications for research
Several studies were excluded from this review on the grounds
of flawed research design, including unclear recruitment criteria
and inadequate definition of the herbal interventions. Other
studies were included but are of limited usefulness because
the selection criteria were incomplete or data were manipulated
post hoc to support the authors' preferred conclusions. High
quality, adequately powered clinical studies investigating herbal
interventions are required. We recommend that future researchers
give attention to the detail of study design, ensuring that
participant samples are well defined according to ACR criteria and
recruited without bias; that herbal preparations are reported in
detail, including dose, extraction method, and active principle;
and that study results are recorded using reliable, valid
outcome measures, in particular for the consensus criteria of
the Outcomes Measures in Rheumatology-Osteoarthritis Research
Sicuety International (OMERACT-OARSI) that combine pain and
functional impairments in the identification of treatment response
(Pham 2003; Pham 2004) be used in these studies to be able to
compare the eDicacy of diDerent medicinal plant products.
So far, longer term studies over one and two years have been
carried out only for aqueous Harpagophytum extract with 50 mg
harpagoside in a daily dosage (Chrubasik 2007) and the ASU
product Piascledine® (Lequesne 2002). Since OA is a chronic
condition, future long term studies over several years are needed to
prove the eDective and safe use of medicinal plant products.
OA of the knee, hip, and spine is a degenerative disease aDecting
the joint cartilage and the underlying subchondral cartilage.
Progressive loss of articular cartilage, appositional new bone
formation in the subchondral trabeculae, and formation of new
cartilage and bone at the joint margins result in pain, stiDness,
limitation of function, and diminished quality of life (Sangha 2000).
Although there is no clear explanation for diDerences in eDect
among body regions, some investigators have reported that pain
from hip OA responds better to treatment with a herbal medicinal
product than does OA pain in other regions (Chrubasik 2002; Maheu
1998), suggesting that the site of joint disease may influence pain
outcomes. We suggest that future researchers consider recruiting
participants with particular joint involvement or stratify results
according to site of disease.
There is also a tendency to duplicate publications in this field,
by publishing abstracts of conference presentations as well as
complete papers, or publishing the same paper in multiple
languages. Duplication of publications may be legitimate but
tends to create the appearance of a larger body of evidence than
actually exists. We advise caution in the duplication of publications
and recommend that, where possible, authors indicate that
a manuscript or part thereof has been previously published
elsewhere.
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Characteristics of included studies [ordered by study ID]
 
Methods Randomised, double-blind, placebo and active controls, 4 parallel groups, single centre study. Duration
6 weeks
Participants Randomised n=143, Completed n=84. Mean age: placebo control 53.2 yrs, active control 1 (naproxen
1000mg) 51.0 yrs, active control 2 (Celebrex 400mg) 52.5 yrs, intervention 54.1 yrs. M:F placebo control
Adegbehingbe 2008 
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7:14, active control A 6:15, active control B 6:15, intervention 5:16. Inclusion: primary or secondary OA
knee (ACR criteria), pain at rest VAS 0-100 >45mm at baseline
Interventions Tradename not provided: Garcinia kola 400mg (2 x 200mg), tablets
Active control A: naproxen 1000mg (2 x 500mg), tablets
Active control B: celecoxib (Celebrex) 400mg (2 x 200mg), tablets
Placebo control: ascorbic acid 200mg (2 x 100g), tablets
Outcomes WOMAC-VAS (Pain), WOMAC 0-4 (Function), walking distance, time to pain relief
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics com-
mittee approval. Results favour intervention and active controls over placebo. Reductions in pain were
not significantly different between Garcinia kola and the active controls, although onset of pain relief
was most rapid and most persistent in the celebrex group.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised in blocks of four within each stratum, using computer generated
random number sequences
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment: Medications prepared by nursing staD, ad-
ministered by blinded senior orthopaedic registrar
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active intervention, placebo, and active controls not distinguished by look,
taste, smell, packaging, or medication regimen. Baseline and outcome asses-
sor blinded to allocations
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals (low risk)
Per protocol analysis only (unclear risk)
Selective reporting (re-
porting bias)
Unclear risk Outcome data reported as change scores, percentages, confidence intervals,
and P values only, insufficient for extraction (unclear risk).
WOMAC subscales for pain and physical function used independently, and in
different forms (VAS and 0-4).
Reported adverse events (low risk)
Other bias Low risk Diagnosis and assessment consistent with ACR criteria
Adegbehingbe 2008  (Continued)
 
 
Methods Randomised, double-blind, placebo control, 2 parallel groups, 10 centre study. Duration 12 weeks
Participants Randomised n=261, Completed n=247. Mean age 65 yrs. M:F 37:63. Inclusion: OA knee stage II-IV (ACR
criteria), knee pain on standing 40-90mm on VAS 100mm
Interventions EV.EXT 77: mixture of Zingiber officinale (ginger) and Alpina galanga (galangal) extracts, 510mg (2 x
255mg), capsules
Placebo control: coconut oil, capsules
Altman 2001 
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Rescue medication permitted: acetominophen, up to 4000mg (4 x 2 x 500mg) daily PRN
Concurrent medication permitted: aspirin, up to 325mg daily for anticoagulation
Outcomes Pain on standing, pain walking 50L, WOMAC-VAS (normalised units), SF-12, patient global 1-5
Notes Confirmatory study design; statistical power not reported, but post-hoc calculation of power based
on sample size and design indicates adequate power to detect medium to large effects (if d=0.5, then
P=0.97). Reported compliance with ICH GCP guidelines and ethics committee approval. Results favour
intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised to one of two groups using a computer generated random num-
ber sequence
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred: "both the investigators and
the patients were blinded to treatment assignment"
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell, pack-
aging, or medication regimen
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals
Included intention-to-treat analysis
Selective reporting (re-
porting bias)
Low risk Reported adverse events
Other bias Low risk Diagnosis and assessment consistent with ACR criteria
Altman 2001  (Continued)
 
 
Methods Randomised, double-blind, placebo control, 3 parallel groups, multicentre study. Duration 90 days (˜12
weeks)
Participants Randomised n=260, Completed n=206. Age range 45-80 yrs. M:F 55:205. Inclusion: OA knee (ACR crite-
ria), VAS 0-100 pain on standing 40-90mm, baseline analgesia 90-110mg diclofenac equivalents
Interventions Piascledine 300*: Persa gratissma and Glycine max, avocado / soyabean unsaponifiables, 300mg /
600mg, OD, tablets
Placebo control: ingredients not reported
Outcomes NSAID use (diclofenac equivalents), days without NSAIDs, pain VAS 0-100, Lesquesne index, patient effi-
cacy assessment, clinician efficacy assessment, adverse events
Notes Confirmatory study; statistical power not reported, but post-hoc calculation of power based on sam-
ple size and design indicates adequate power to detect medium to large effects (if Cohen's f=0.25, then
P=0.90). Reported ethics committee approval. Results favour intervention.
Risk of bias
Appelboom 2001 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double-blind, method not reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals
Included per protocol and intention-to-treat analyses
Selective reporting (re-
porting bias)
Low risk Reported adverse events
Other bias Low risk Diagnosis and assessment consistent with ACR criteria
Appelboom 2001  (Continued)
 
 
Methods Randomised, double-blind, placebo control, 3 parallel groups (intervention, placebo control, non-inter-
vention control). Erroneously described as "cross-over trial". Duration 3 months (˜12 weeks)
Participants Randomised n=60; intervention n=30, placebo n=15, non-intervention control n=15. Age and gender da-
ta not reported. Inclusion: OA knee (criteria not specified)
Interventions Tradename not provided. Boswellia-curcuma extract mixture, 1500mg (3 x 500mg), capsules
Placebo control: ingredients not reported
Outcomes Nocturnal pain, pain with active movement 0-3, pain with passive movement 0-3, tenderness 0-3, knee
effusion 0-3, pain-free walking time minutes, antioxidant enzyme SOD, free radical damage markers
NO, nitrate, nitrite, and CD, CD4
Notes Exploratory study design; power, effect, and sample size not determined a priori. Did not report ethical
oversight or compliance with guidelines. Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method not reported. Group sizes dissimilar and
likely to have been determined a priori
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double-blind, method not reported
Incomplete outcome data
(attrition bias) 
High risk Withdrawals not reported. Age and gender data not reported
Badria 2002 
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All outcomes
Selective reporting (re-
porting bias)
High risk Described as a crossover trial, but method of crossover and data from second
arm not reported. Considered as a parallel trial for this review (high risk)
Adverse events not reported (high risk)
Conclusion not supported by data: Reported efficacy and tolerability of
boswellia-curcumin as superior to diclofenac, but this trial did not include di-
clofenac as an active control (high risk)
Other bias High risk Diagnosis of OA not established at baseline (high risk)
Unvalidated outcome measures (unclear risk)
Badria 2002  (Continued)
 
 
Methods Randomised, double-blind, placebo control, 2 parallel group study. Duration 3 months (˜12 weeks)
Participants Randomised n=156; intervention n=77, control n=79. Completed n=143. Mean age: control 47.8 yrs, in-
tervention 48.6 yrs. M:F: control 39:40, intervention 39:38. Inclusion: OA knee (radiographic criteria)
Interventions Pycnogenol®: Pinus pinaster, pine bark extract, 100mg (2 x 50mg), tablets
Placebo control: ingredients not reported, tablets
Outcomes WOMAC 0-4, mobility (treadmill walking)
Notes Confirmatory study design; statistical power 80%, alpha set at 0.05. Reported ethics committee ap-
proval and compliance with Declaration of Helsinki. Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants allocated to treatment groups using randomisation by block al-
location sequences created from a computer generated random number se-
quence
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred1
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Active intervention and placebo not distinguished
by look, taste, smell or packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals (low risk)
Unclear whether analysis is per protocol or intention-to-treat (unclear risk)
Selective reporting (re-
porting bias)
Unclear risk Adverse events reported generally, but not individually (unclear risk)
Reported WOMAC subscale scores but no standard deviations: standard devia-
tions computed from item scores for extraction and re-analysis (unclear risk)
Other bias Unclear risk Diagnosis and assessment based on radiographic criteria only (unclear risk)
Belcaro 2008 
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Methods Randomised, double-blind, placebo control, active control (unblinded), 3 parallel groups. Duration 4
weeks
Participants Randomised n=108; intervention n=36, placebo n=36, piroxicam n=36. Completed n=108. Mean age
52 yrs. M:F 22:50. Inclusion: OA (criteria not specified), acute or recurrent degenerative arthritic com-
plaints
Interventions PhytodolorRN: standardised extract mixture of ash bark, aspen leaf, aspen bark, golden rod herb, 3 x 30
drops, tincture
Active control: piroxicam (Feldene 20), 20mg, OD
Placebo control: ingredients not reported
Concurrent treatment permitted: balneology (thermal baths), and physiotherapy
Outcomes Pain with movement 0-3, enduring pain 0-3, mobility impairment 0-3, finger-ground distance, grip
strength, PGA 0-6, patient perception efficacy 0-3
Notes Exploratory study design; power, effect, and sample size not determined a priori. Did not report ethical
oversight or compliance with guidelines. Results favour intervention. Some outcome measures (eg: fin-
ger-ground distance) are non-specific and may be of limited use in rheumatological assessment.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised to one of three groups using a table of random numbers
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double-blind. In PhytodolorRN and placebo groups, active inter-
vention and placebo not distinguished by look, taste, smell or packaging (low
risk)
Piroxicam group not blinded (unclear risk)
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported no withdrawals (low risk)
Intention-to-treat analysis can be assumed
Selective reporting (re-
porting bias)
Unclear risk Most outcome data reported as change scores, percentages, graphs and p val-
ues only, insufficient for extraction (unclear risk)
Reported adverse events (low risk)
Other bias High risk Diagnosis not based on ACR criteria. Non-homogenous sample (any degenera-
tive arthropathy, any site) (high risk)
Unvalidated outcome measures (unclear risk)
Bernhardt 1991 
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Methods Randomised, double-blind, placebo control, active control, 3 parallel groups. Duration 6 weeks
Participants Randomised n=127, Completed n=106. Mean age 62 yrs. M:F 53:74. Inclusion: OA knee or hip (ACR crite-
ria), WOMAC >30mm, aspirin 100mg/d
Interventions Assalix*: Salix daphnoides cortex (willow bark), ethanolic extract, 1572.96mg (2 x 2 x 393.24mg, equiva-
lent to 240mg salicin), tablets
Active control: diclofenac, 100mg (2 x 2 x 25mg), tablets
Placebo control: ingredients not reported, tablets
Outcomes WOMAC-VAS (normalised units), SF-36, patient efficacy assessment VAS 0-100, physician efficacy as-
sessment VAS 0-100, HAQ-DI (German)
Notes Confirmatory study; statistical power 80%, alpha set at 0.05 (2 tailed). Reported compliance with ICH
GCP guidelines and the Declaration of Helsinki. Results equivocal.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised to one of three groups using a computer generated random num-
ber sequence
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred1. Authors contacted for con-
firmation, but details of allocation concealment not provided
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Active interventions and placebo not distinguished
by look, taste, smell, packaging, or medication regimen
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals. Included intention-to-treat and per protocol analyses
Selective reporting (re-
porting bias)
Unclear risk Mid-point data reported as mean scores only (no standard deviations), there-
fore not adequate for extraction and re-analysis (unclear risk)
Reported adverse events (low risk)
Other bias Low risk Diagnosis and assessment consistent with ACR criteria
Biegert 2004 
 
 
Methods Randomised, double-blind, placebo control, 2 parallel groups. Duration 20 weeks
Participants Randomised n=78, Completed n=77. Age and gender data not reported. Inclusion: OA knee (ACR crite-
ria)
Interventions LoHar 45 flexi-loges®*: Harpagophytum procumbens (devil's claw), ethanolic extract, 960mg, tablets
Placebo control: ingredients not reported
Biller 2002 
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Outcomes WOMAC-VAS (German version). Post hoc "responders” to treatment were defined as participants whose
WOMAC pain scores increased by not more than 20% without additional rescue medication in weeks
17-20
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported compliance
with ICH GCP guidelines. Results equivocal: no improvement on primary outcome measure (WOMAC).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Described as randomised, method not reported1. Authors contacted: provided
full details of computer generated randomisation sequence
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred1. Authors contacted for con-
firmation, but details of allocation concealment not provided
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Active intervention and placebo not distinguished
by look, taste, smell or packaging
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Brief report. Full report not available (high risk)
Reported withdrawals (low risk)
Unclear whether analysis is per protocol or intention-to-treat analysis (unclear
risk)
Selective reporting (re-
porting bias)
High risk Age and gender data not reported (high risk)
Reasons for withdrawal (ie: adverse events) not reported (unclear risk)
Outcome data reported as percentages only, insufficient for extraction (un-
clear risk)
Results showed no improvement on planned primary outcome measure
(WOMAC). Alternate outcome measure and definition of improvement con-
structed post hoc
Other bias Unclear risk Diagnosis consistent with ACR criteria (low risk)
Post-hoc created outcome measure is unvalidated (unclear risk)
Biller 2002  (Continued)
 
 
Methods Randomised, double-blind, placebo control, active control, 3 group crossover. Duration 12 weeks (1
week washout followed by 3 weeks intervention)
Participants Randomised n=67, Completed n=56. Mean age 66 yrs, range 24-87 yrs. M:F 15:41. Inclusion: OA hip or
knee, radiologically verified Kellgren grade I-IV, VAS 0-100 pain on mvt >30mm
Interventions Eurovita.EXT 33: Zingiber officinale (Chinese ginger) extract, 510mg (3 x 170mg), capsules
Active control: ibuprofen, 400mg, tablets
Placebo control: ingredients not reported, capsules and tablets
Bliddal 2000 
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Rescue medicine permitted: paracetamol (acetominophen), 3000mg daily, PRN
Outcomes Pain VAS 0-100, Lequesne index, range of motion (hip or knee), acetominophen use, investigator treat-
ment preference, daily pain diary (4 point Likert scale)
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics com-
mittee approval and compliance with ICH GCP guidelines. Results favour ibuprofen over ginger, ginger
over placebo.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Described as randomised, method of randomisation incompletely reported1.
Reported as randomised in blocks of six to one of three groups, with further
randomisation of treatment sequence within blocks. Authors contacted for
confirmation, but further details not provided
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred1. Authors contacted for con-
firmation, but details of allocation concealment not provided
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Double-dummy method, placebo controls for both
intervention and active controls. Active interventions and placebos not distin-
guished by look, taste, smell or packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals (low risk)
Included per-protocol analysis only (unclear risk)
Selective reporting (re-
porting bias)
Low risk Reported adverse events. Discussed intervention safety (low risk)
Other bias Low risk Diagnosis and assessment consistent with ACR criteria
Bliddal 2000  (Continued)
 
 
Methods Randomised, double-blind, placebo control, 2 parallel groups, multicentre (n not specified). Duration
90 days (˜12 weeks)
Participants Completed n=163. Mean age 63 yrs. M:F 55:108. Inclusion: OA knee (n=101) or hip (n=62) (ACR criteria),
Kellgren grade IB-III, pain requiring NSAIDs for 3 months
Interventions Piascledine 300*: Persa gratissma and Glycine max, avocado / soyabean unsaponifiables, 300mg /
600mg, OD, tablets
Placebo control: ingredients not reported
Rescue medication permitted: one of 7 predefined NSAIDs taken by all participants for first 45 days. Re-
sumption of same NSAID allowed during second 45 days
Outcomes Resumption of NSAIDS, time oD NSAIDS, NSAID use (diclofenac equivalents), Lequesne index, pain VAS
0-100, patient global 0-4, physician global 0-4
Notes Confirmatory study design, power 80%, alpha 0.05. Reported compliance with Helsinki Declaration and
ethics committee approval. Results favour intervention for reduced use of NSAIDs, but pain scores are
similar in the two groups.
Blotman 1997 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Described as randomised, in blocks of four, stratified according to site of
arthritis (hip or knee), to one of two groups, using a table of random numbers
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Active intervention and placebo not distinguished
by look, taste, smell or packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals (low risk)
Included per protocol analysis only (unclear risk)
Selective reporting (re-
porting bias)
Low risk Reported adverse events
Other bias Low risk Diagnosis and assessment consistent with ACR criteria
Blotman 1997  (Continued)
 
 
Methods Randomised, unblinded, active control, 2 parallel groups, two centres. Duration 4 weeks
Participants Randomised n=120, intervention (n=60; n=30 at x centres), Chinese control n=30, Western control n=30.
Completed n=116. Inclusion: OA knee (ACR criteria), at least 5 days on NSAIDs, adverse events with
NSAIDs, pain with walking at least 20mm (VAS 0-100) in the previous 48h
Interventions Tradename not provided. Chinese herbal mixture (blood-nourishing, hard-softening; BNHS), 3150mg
Active control (Chinese): Chinese mixture to counter osteophytes, 5250mg, capsules
Active control (Western): Viatril-s 2250mg (crystalline glucosamine sulphate 1884mg equivalent to glu-
cosamine sulphate 1500mg, sodium chloride 384mg)
Rescue medication permitted: paracetamol (acetominophen), up to 4000mg daily, PRN; and aspirin, up
to 100mg daily in a stable dose
Outcomes WOMAC-VAS (normalised scores), pain during walking 0-100 VAS, patient global 0-4, physician global
0-4
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics com-
mittee approval and compliance with ICH GCP guidelines. Improvements occured in all groups over
time. Results indicate that BNHS is not inferior to counter osteophyte Chinese mixture or Viatril-s.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method inadequately reported: "sealed envelope
method"
Cao 2005 
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Allocation concealment
(selection bias)
Low risk Allocation concealment can be inferred: "sealed envelope method"
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as blinded, method inadequately reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals
Included intention-to-treat analysis
Selective reporting (re-
porting bias)
Low risk Reported adverse events (low risk)
Other bias Low risk Diagnosis and assessment consistent with ACR criteria
Cao 2005  (Continued)
 
 
Methods Ramdonised, double-blind, placebo control, 2 parallel groups, single centre. Duration 18 weeks (3
weeks washout, 15 weeks trial)
Participants Completed n=89, intervention n=39, control n=50. OA hip or OA knee (ACR criteria), overall WOMAC
score=30 at baseline
Interventions SheaFlex70: Vitellaria paradoxia, 100% sheabutter extract with 75% triterpene esters, 2250mg (3 x
750mg), capsules
Placebo control: 100% canola oil, 2250mg (3 x 750mg), capsules
Outcomes WOMAC, Comprehensive Osteoarthritis Test (COAT)
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics com-
mittee approval and clinical trials registration (ACTRN12606000162516). Results equivocal on clinical
outcomes. Changes in WOMAC scores were not significant either within or between groups. Significant
decrease in COAT pain subscale score within the shea group over time was not significantly different
from this outcome in the control group at the end of the trial. Significant differences in some inflamma-
tory markers were reported, but are not of relevance to this review.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised to one of two groups using a computer generated random num-
ber sequence
Allocation concealment
(selection bias)
Low risk Allocation "held by a third party to the investigator and trial sponsor"
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active intervention, placebo, and active controls not distinguished by look,
taste, smell, packaging, or medication regimen
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Withdrawals not reported (high risk)
Per-protocol analysis only (unclear risk)
Cheras 2010 
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Selective reporting (re-
porting bias)
High risk Clinical outcome data reported as percentages and P values (non-significant)
only, insufficient for extraction (unclear risk)
Adverse events not reported (high risk)
Other bias Low risk Diagnosis and assessment consistent with ACR criteria
Cheras 2010  (Continued)
 
 
Methods Randomised, double-blind, placebo control, 2 parallel groups. Duration 32 weeks
Participants Randomised n=90, intervention n=45, control n=45. Midpoint (16 weeks) n=78. Completed n=62, inter-
vention n=31, control n=31. Age 35+ years. OA knee (ACR criteria). Stable NSAIDs for 1 month at base-
line. Not pregnant
Interventions RA-11: Ayurvedic medication, 2 capsules
Placebo control: ingredients not reported
Rescue medication not permitted
Concurrent medication permitted: stable medication for concomitant diseases
Outcomes WOMAC 0-4 (Asian - Indian modification), VAS 0-100, 50 feet walk time (seconds), physician global as-
sessment 0-4, patient global assessment 0-4, early morning stiffness (minutes), knee swelling 0-3
Notes Confirmatory study design, power 80%, alpha 0.05 (2 tailed). Did not report ethical oversight or compli-
ance with guidelines. Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Described as randomised: "...assigned to the active or placebo groups as per a
predetermined computer generated randomisation schedule..."
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred: "A sealed copy of the ran-
domization code was kept with the sponsor and the chief investigator but was
not revealed to the subjects or the clinical staD until completion of the study."
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell, pack-
aging, or medication regimen
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals. Included intention-to-treat analysis. Last observation
carried forward to replace missing data (low risk)
Three participants were withdrawn by the investigators due to "efficacy fail-
ure", which may confound results (unclear risk)
Selective reporting (re-
porting bias)
Low risk Pre-determined levels of improvement (MCID) (low risk)
Reported adverse events. Two participants in intervention group died, but
these deaths were attributed to concomitant cardiovascular disease
Other bias Low risk Diagnosis consistent with ACR criteria (low risk)
Chopra 2004 
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Methods Randomised, double-blind, placebo and active control, 7 parallel groups, multicentre (n not specified).
Duration 16 weeks
Participants Randomised n=245, all groups n=35. Completed n=202. Data available for analysis n=236. Mean age:
placebo control 54 yrs, active control 54.2 yrs, intervention A 57.5 yrs, intervention B 56.6 yrs, inter-
vention C 56.8 yrs, intervention D 56.2 yrs, intervention E 56.2 yrs. M:F not reported. Inclusion: OA knee
(ACR criteria with lower age limit reduced to 40 years)
Interventions Tradenames not provided. five Ayurvedic formulations containing Zingiber officinale and Tinospora
cordifolia and combinations ofEmblica officinale, Withania somnifera, or Tribulus terrestris, variable dos-
es (4 x approx 500mg), capsules
Active control: glucosamine sulphate, 1000mg (4 x 250mg). Capsule mass approx 500mg
Placebo control: charcoal and synthetic ginger essence, 2000mg (4 x 500mg), capsules
Rescue medication permitted: paracetamol (acetominophen), 2000mg (4 x 500mg) PRN
Outcomes Pain on weightbearing VAS 0-10, WOMAC 0-4 (Indian version), paracetamol use
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics com-
mittee approval. Results equivocal for primary outcomes. Trend to favour intervention C for pain relief,
paracetamol use, and knee function
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, but participants allocated directly to groups on or-
der of enrolment into the trial (quasi-randomised)
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Active interventions, active control, and placebo
not distinguished by look, taste, smell or packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals. Included intention-to-treat analysis
Selective reporting (re-
porting bias)
Unclear risk Outcome data reported as change scores and percentages only, insufficient for
extraction (unclear risk)
Reported adverse events (low risk)
Other bias Low risk Diagnosis / assessment consistent with ACR criteria
Synthetic ginger extract in placebo may not be inert
Chopra 2011 
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Methods Randomised, double-blind, active control, multicentre (n=3), 4 parallel groups. Duration 24 weeks (+2
to 5 days washout for participants using NSAIDs)
Participants Randomised n=440, intervention SGC n=110, intervention SGCG n=110, active control celecoxib n=110,
active control glucosamine n=110. Completed n=314, SGC n=75, SGCG n=75, celecoxib n=78, glu-
cosamine n=86. Age range 40-70 years. Inclusion: OA knee (ACR criteria with modified age range), uni-
lateral or bilateral knee OA, baseline VAS 0-100 (pain on weightbearing) >54mm. Not pregnant or lactat-
ing, not taking medications likely to influence pain / functional outcomes, no known GIT bleeding
Interventions Tradename not provided. Standardised Ayurvedic formulation (shunthi-guduchi, SGCG), 2400mg (2 x
400mg, TID), capsules
Tradename not provided. Standardised Ayurvedic formulation (shunthi-guduchi with guggal, SGCG),
2400mg (2 x 400mg, TID), capsules
Active control A: celecoxib, 200mg (2 x 33.3mg, TID), capsules
Active control B: glucosamine sulphate, 2000mg (2 x 333mg, TID), capsules
Rescue medication permitted: 500mg acetominophen (paracetamol), PRN
Outcomes Pain on weightbearing VAS 0-10, WOMAC 0-4 (Indian version for hip and knee; pain and function sub-
scales only), patient global 1-5, physical global 1-5, HAQ
Notes Confirmatory study; statistical power 80%, alpha set at 0.05 (2 tailed). Reported compliance with ICH
GCP guidelines, and Declaration of Helsinki. Reported clinical trial registration (CTRI/2008/091/000063).
Results for Ayurvedic interventions show equivalent outcomes in pain and function to glucosamine sul-
phate and celecoxib, but the more participants in the Ayurvedic group reported (unexpected) adverse
events.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised in order of enrolment in the trial. "The study biostatistician (S.S.)
used a standard software program to generate a randomized schedule of per-
muted block randomization with block size 4 for blinded (coded) drug allot-
ment."
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Active interventions, active control, and placebo
not distinguished by look, taste, smell or packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals
Included both intention-to-treat and per protocol analyses
Selective reporting (re-
porting bias)
Low risk Outcome data reported as means and confidence intervals only, standard de-
viations computed for extraction and re-analysis
Pain VAS 0-10 converted to 100mm scale for data extraction and re-analysis
Reported adverse events
Other bias Low risk Diagnosis/assessment consistent with ACR criteria
Chopra 2013 
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Active control B, glucosamine sulphate, is not an analgesic, and may be a poor
choice of control in a trial using pain as a primary outcome measure
Chopra 2013  (Continued)
 
 
Methods Randomised, double-blind, placebo control, 2 parallel groups. Duration 12 weeks intervention, plus 2
weeks washout/follow-up
Participants Randomised n=100, Completed intervention n=90, Completed washout n=81. Mean age 54 yrs. M:F con-
trol 18:32, intervention 14:36. Inclusion: OA knee (ACR criteria), Kellgren grade I or II, mild-moderate
pain in target knee for at least 3 months, morning stiffness, knee crepitus, age > 25 years. Female par-
ticipants not pregnant, nor planning pregnancy for > 12 months post study
Interventions Pycnogenol®: Pinus pinaster, pine bark extract with 90% proanthocyanines, 150mg (3 x 50mg), in 50mg
doses TID with meals, tablets
Placebo control: ingredients not reported, tablets
Concurrent medication permitted: stable NSAIDs and analgesics
Outcomes WOMAC 0-4 (Slovak version), Pain VAS 0-100
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics com-
mittee approval. Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Active intervention and placebo not distinguished
by look, taste, smell, packaging, or medication regimen
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals
Included intention-to-treat analysis
Selective reporting (re-
porting bias)
Low risk Reported adverse events (low risk)
Other bias Low risk Diagnosis and assessment consistent with ACR criteria
Cisar 2008 
 
 
Methods Randomised, double-blind, placebo control, 2 parallel groups. Duration 3 months (˜12 weeks)
Participants Randomised n=37; intervention n=19, control n=18. Completed n=35. Mean age: control 48.9 yrs, inter-
vention 47.5yrs. M:F: control 1:17, intervention 2:18. Inclusion: OA knee (ACR criteria)
Farid 2007 
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Interventions Pycnogenol®: Pinus pinaster, pine bark extract with 70% proanthocyanines, 150mg (3 x 50mg), tablets
Placebo control: "inactive ingredient", ingredients not report, tablets
Outcomes WOMAC-VAS (aggregated scores), NSAID/COX-2 inhibitor use
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics com-
mittee approval. Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method not reported
Allocation concealment
(selection bias)
Unclear risk Adequate concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Active intervention and placebo not distinguished
by look, taste, smell or packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals. Reported identical per-protocol and intention-to-treat
analyses
Selective reporting (re-
porting bias)
Unclear risk Reported no adverse events (low risk)
Other bias Low risk Diagnosis / assessment based on ACR criteria
Farid 2007  (Continued)
 
 
Methods Randomised, double-blind, placebo control, 2 group crossover. Duration 3 weeks (2 x 1 week crossover,
1 week washout)
Participants Randomised n=22, Completed n=20. Mean age 62 yrs, range 47-78 yrs. Inclusion: OA hip or knee, clinical
and radiographic verification (criteria not specified)
Interventions Tipi tea: Petiveria alliacea, aqueous extract, 3 x 200ml tea (equivalent to 9gm tipi)
Placebo control: Sape, Imperata exaltata (dose not specified)
Outcomes Pain (scale not reported) at rest, pain with mvt, pain at night, 15 metre walking time, MACTAR patient
preference questionnaire
Notes Exploratory study design; power, effect, and sample size not determined a priori. Did not report ethical
oversight or compliance with guidelines. Results equivocal.
Risk of bias
Bias Authors' judgement Support for judgement
Ferraz 1991 
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Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double-blind, method not reported
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Brief report. Full report not available (high risk)
Reported withdrawals (low risk)
Selective reporting (re-
porting bias)
Low risk Reported adverse events (low risk)
Other bias High risk Criteria for diagnosis of OA not specified (high risk)
Financial and in kind support not reported
Ferraz 1991  (Continued)
 
 
Methods Randomised, double-blind, placebo control, 2 parallel groups. Duration 20 weeks
Participants Randomised n=46; intervention n=24, control n=22. Completed n=41, intevention n=21, control n=20.
Mean age: intervention 58 yrs, control 61 yrs. Gender data not reported. Inclusion: OA hip (ACR criteria)
Interventions LoHar-45 flexi-loges®: Harpagophytum procumbens (devil's claw), 960mg, ethanolic extract, tablets
Placebo control: ingredients not reported
Outcomes WOMAC-VAS (German version). Post hoc "responders” to treatment were defined as participants whose
WOMAC pain scores did not increase by more than 20% in weeks 17 to 20 of the study
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported compliance
with ICH GCP guidelines. Results equivocal: no improvement on primary outcome measure (WOMAC).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Described as randomised, method not reported1. Authors contacted: provided
full details of computer generated randomisation sequence
Allocation concealment
(selection bias)
Low risk Allocation concealment not reported1. Authors contacted for confirmation,
but details of allocation concealment not provided
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Active intervention and placebo not distinguished
by look, taste, smell or packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals. Reported intention-to-treat analysis
Frerick 2001 
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Selective reporting (re-
porting bias)
High risk Reasons for withdrawals and adverse events not reported (high risk)
Outcome data reported as change scores, percentages, and bar charts only, in-
sufficient for extraction (unclear risk)
Results show no improvement on planned primary outcome measure (WOM-
AC). Alternate outcome measure and definition of improvement constructed
post hoc (high risk)
Other bias Unclear risk Diagnosis consistent with ACR criteria (low risk)
Post-hoc created outcome measure not validated (unclear risk)
Frerick 2001  (Continued)
 
 
Methods Randomised, double-blind, placebo control, 2 parallel groups, multicentre (n=3). Duration 3 months
(˜12 weeks)
Participants Randomised n=90. Completed n=88; intervention n=44, control n=44. Inclusion: OA knee (knee pain,
swelling, stiffness, tenderness, age 45+ years, one or more radiological signs)
Interventions Antarth, Ayurvedic phytomedicine (mixture), dose not stated, 2 x BID, capsules
Placebo control: ingredients not reports, capsules
Rescue medication permitted: diclofenac sodium, up to 50mg BID; ranitidine up to 150mg OD
Outcomes Pain VAS 0-10, pain walking 0-4, pain squatting 0-4, pain crossing legs 0-4, pain climbing stairs 0-4,
physician global (descriptive), patient global (descriptive), rescue medication use
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics com-
mittee approval. Results slightly favour intervention. Participants receiving Antarth used less rescue
medication and may be more satisfied than participants receiving placebo.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Active intervention and placebo control not distin-
guished by look, taste, smell, packaging, or medication regimen
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals (low risk)
Per-protocol analysis only (unclear risk)
Selective reporting (re-
porting bias)
Low risk Outcome data reported as VAS 0-10, converted to 100mm scale for data extrac-
tion (low risk)
Reported no adverse events (low risk)
Gupta 2011 
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Other bias Unclear risk Diagnosis not consistent with ACR criteria, but likely to be OA (unclear risk)
Gupta 2011  (Continued)
 
 
Methods Double-blind, placebo control, 2 parallel groups. Duration 3 weeks
Participants Recruited n=40, Completed n=38. Age range 50-80 yrs. M:F 4:24. Inclusion: OA (criteria not specified), at
least one indication for treatment with antirheumatics
Interventions PhytodolorRN: standardised extract mixture of ash bark, aspen leaf, aspen bark, golden rod herb, 3 x 30
drops, tincture
Placebo control: ingredients not reported
Outcomes Rescue medication use, joint size, maximum ROM, pain at rest, pain with mvt, pressure pain, fin-
ger-ground distance (spine only), Schober index, percussion pain, serum biochemistry
Notes Exploratory study design; power, effect, and sample size not determined a priori. Did not report ethi-
cal oversight or compliance with guidelines. Results favour intervention. Some outcome measures (eg:
Schober index) are non-specific and may be of limited use in rheumatological assessment.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Not randomised
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double-blind, method not reported. In other studies of Phytodo-
lorRN, active intervention and placebo not distinguished by look, taste, smell
or packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals (low risk)
Per-protocol analysis only (unclear risk)
Selective reporting (re-
porting bias)
High risk Outcome data variances reported as standard error of measurement (SEM).
When converted to standard deviation (SD), data are skewed, violating an as-
sumption of the inferential analyses (unclear risk)
Adverse events not reported (high risk)
Other bias Unclear risk Criteria for diagnosis of OA not specified (unclear risk)
Unvalidated outcome measures (unclear risk)
Huber 1991 
 
 
Methods Randomised, double-blind, placebo control, 4 parallel groups, multicentre (n=2). Duration 4 weeks
Jung 2001 
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Participants Randomised n=96, Completed n=93. Mean age 58 yrs. M:F 9:84. Inclusion: OA knee, clinical and radi-
ographic verification (criteria not specified), pain VAS 0-100 >35mm
Interventions SKI306X: standardised extract mixture of Clematis mandshurica, Prunella vulgaris, Trichosanthes kir-
ilowii, 600mg (3 x 200mg), 1200mg (3 x 400mg), 1800mg (3 x 600mg), tablets
Placebo control: ingredients not reported, tablets
Outcomes Pain VAS 0-100, Lequesne index, patient opinion of efficacy 1-5, investigator opinion of efficacy 1-5, tol-
erability, serum biochemistry, heamatology, urinanalysis
Notes Confirmatory study design, but statistical power not reported. Reported compliance with Helsinki Dec-
laration and ethics committee approval. Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double-blind, method incompletely reported. Assume active in-
tervention and placebo not distinguished by look, taste, smell or packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals
Selective reporting (re-
porting bias)
Low risk Reported adverse events. Discussed intervention safety
Other bias Unclear risk Criteria for diagnosis of OA not specified, clinical and radiographic verification
(unclear risk)
Jung 2001  (Continued)
 
 
Methods Randomised, double-blind, active control, 2 parallel groups. Duration 4 weeks
Participants Randomised n=249, Completed n=214. Mean age 60 yrs. M:F 18:231. Inclusion: OA knee (ACR criteria),
pain VAS 0-100 >35mm
Interventions SKI306X: standardised extract mixture of Clematis mandshurica, Prunella vulgaris, Trichosanthes kir-
ilowii, 600mg (3 x 200mg), tablets
Active control: diclofenac SR, 100mg OD, tablets
Placebo controls: ingredients not reported, tablets (double dummy)
Concurrent medication permitted: medications for conditions unrelated to OA, if known not to interact
with either study medications
Jung 2004 
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Outcomes Pain VAS 0-100, Lequesne, patient global 1-5, physician global 1-5, tolerability, serum biochemistry,
haematology, urinanalysis
Notes Confirmatory study design, statistical power 80%, alpha 0.05.Reported compliance with the Declara-
tion of Helsinki and institutional review board oversight. Results equivocal: SKI306X equally effective as
diclofenac on pain, Lequesne index, patient and physician global scores. Participants using SKI306X re-
ported fewer adverse events.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised in blocks of four or six to one of two groups using a computer
generated random number sequence
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Double-dummy method, placebo controls for both
intervention and active controls. Active interventions and placebo not distin-
guished by look, taste, smell or packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals
Included per-protocol and intention-to-treat analyses
Selective reporting (re-
porting bias)
Low risk Reported adverse events. Discussed intervention safety
Other bias Low risk Diagnosis / assessment consistent with ACR criteria (low)
Jung 2004  (Continued)
 
 
Methods Randomised, double-blind, placebo control, crossover. Duration 19 weeks (2 x 8 weeks intervention + 3
week washout)
Participants Randomised n=30, Completed n=30. No withdrawals. Mean age 59 yrs, range 45-72 yrs. M:F 12:18. Inclu-
sion: OA knee, clinical and radiographic verification (criteria not specified), currently using physiothera-
py and NSAIDs
Interventions Cap Wokvel™: Boswellia serrata (Gajabhakshya) extract with 40% boswellic acid, 1000mg (3 x 333mg),
capsules
Placebo control: starch powder, capsules
Outcomes Joint pain 0-3, loss of function 0-3, swelling 0-3
Notes Exploratory study design; power, effect, and sample size not determined a priori. Did not report ethical
oversight or compliance with guidelines. Reported that study formed part of an academic coursework
requirement. Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Kimmatkar 2003 
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Random sequence genera-
tion (selection bias)
Low risk Randomised to one of two groups using a computer generated random num-
ber sequence
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred: "The clinical orthopedic in-
vestigator and the patients were blind for the interventions"
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Active intervention and placebo not distinguished
by look, taste, smell or packaging or medication regimen
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported 100% compliance, no withdrawals
Selective reporting (re-
porting bias)
Low risk Reported adverse events (low risk)
Other bias Unclear risk Criteria for diagnosis of OA not specified: "clinoradiographic verification" (un-
clear risk)
Kimmatkar 2003  (Continued)
 
 
Methods Randomised, single blind, active control, 2 parallel groups. Duration 6 weeks
Participants Randomised n=107, Completed n=91. Mean age intervention 61.4 yrs, active control 60.0 yrs. Primary
OA knee (ACR criteria)
Interventions Tradename not provided.Curcuma domestica extract, 2000mg (4 x 500mg) with 1000mg curcuminoids,
capsules
Active control: ibuprofen, 800mg (2 x 400mg), method of administration not reported
Outcomes Pain on level walking NRS 0-10, pain on stair climbing NRS 0-10, 100m walk (seconds), stair climb and
descent (seconds)
Notes Confirmatory study design, power 80%, alpha 0.05. Reported ethics committee approval. Efficacy of
Curcuma domestica is not significantly different from active control (ibuprofen).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method of randomisation incompletely reported.
Reported as "a computer randomisation code kept by a research assistant"
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Blinding incomplete: research assistant not blind to allocation, and medica-
tion regimens differ between active control and intervention
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals (low risk)
Per-protocol analysis only (unclear risk)
Kuptniratsaikul 2009 
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Selective reporting (re-
porting bias)
Low risk Reported adverse events (low risk)
Other bias Unclear risk Diagnosis consistent with ACR criteria (low risk)
Outcome assessments not validated measures (unclear risk)
Kuptniratsaikul 2009  (Continued)
 
 
Methods Randomised, single blind, active control, 2 parallel groups. Duration 4 weeks
Participants Randomised n=125; intervention n=63, control n=62. Completed n=107; intervention n=55, control
n=52. Inclusion: primary OA knee (ACR criteria)
Interventions Tradename not provided. Derris scandens extract, 800mg (400mg BID)
Active control: naproxen, 500mg (250mg BID)
Outcomes WOMAC-VAS (10cm normalised scores), 6 minute walk, patient global (categorical 1-6), patient satisfac-
tion (categorical 1-6)
Notes Confirmatory study design; power 80%, alpha 0.05. Reported ethics committee approval. Efficacy of
Derris scandens is not significantly different from active control (naproxen).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation according to computer generated randomisation code
Allocation concealment
(selection bias)
High risk Allocation not concealed from participants or research assistant
Blinding (performance
bias and detection bias) 
All outcomes
High risk Blinding incomplete: research assistant not blind to allocation, and interven-
tions may be distinguishable between active control and intervention. inter-
ventions distinguishable
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals (low risk)
Per-protocol analysis only (unclear risk)
Selective reporting (re-
porting bias)
Unclear risk Outcome data WOMAC-VAS converted to 100mm scale for data extraction. Er-
ror identified during data extraction (unclear risk).
Reported adverse events (low risk)
Other bias Low risk Diagnosis / assessment consistent with ACR criteria
Reported financial and in kind support, declared no competing financial inter-
ests
Kuptniratsaikul 2011 
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Methods Randomised, double blind, active control, 2 parallel groups, multicentre (n=30 rheumatology prac-
tices). Duration 4 months (˜20 weeks)
Participants Randomised n=122, Completed n=92. Mean age 61 yrs. M:F 45:77. Inclusion: primary OA knee or hip
(ACR criteria), Kellgren stage I-III
Interventions Harpadol®: Harpagophytum procumbens (devil's claw), freeze-ground powder, 2610 mg (6 x 435mg),
equivalent to 60mg harpagoside, capsules.
Active control: diacerhein, 100mg (2 x 50mg), capsules
Placebo controls: ingredients not reports, capsules (double dummy)
Rescue medication permitted: acetaminophen-caffeine OD PRN, followed by diclofenac 150mg (3 x
50mg) PRN
Outcomes Pain VAS 0-100, disability VAS 0-100, Lequesne index, rescue medication use, patient global, investiga-
tor treatment preference
Notes Confirmatory study; statistical power 90%, alpha 0.05 (1 tailed). Reported compliance with Declara-
tion of Helsinki and ethics committee approval. Results indicate Harpagophytum equally effective as
diacerhein on pain, function, and Lequesne index. Participants using Harpagophytum used less rescue
medication (acetaminophen-caffeine or diclofenac) and reported significantly fewer adverse effects.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method of randomisation incompletely reported.
Reported as randomised in blocks of four patients at each study centre
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Double-dummy method, placebo controls for both
intervention and active controls. Active interventions and placebos not distin-
guished by look, taste, smell, packaging, or medication regimen
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals. Included per-protocol and intention-to-treat analyses.
Missing data replaced using the last observation carried forward method
Selective reporting (re-
porting bias)
Low risk Reported adverse events. Discussed intervention safety
Other bias Low risk Diagnosis/assessment consistent with ACR criteria
Leblan 2000 
 
 
Methods Randomised, placebo control, 2 parallel groups, multicentre (50 rheumatology practices). Duration 2
years (˜104 weeks)
Participants Randomised n=163, Completed n=96, Returned 2 radiographs n=108. Mean age 63 years. M:F 102:61. In-
clusion: OA hip (ACR criteria), Kellgren stage I-III, joint space narrowing >1mm, Lequesne index >4
Lequesne 2002 
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Interventions Piascledine 300: Persa gratissma and Glycine max (avocado-soyabean unsaponifiables), 300mg, cap-
sules
Placebo control: ingredients not reported, capsules
Rescue medication permitted: NSAIDs measured in diclofenac equivalents, and analgesics (not speci-
fied), PRN
Concurrent medication permitted: all concomitant medications for medical diseases
Outcomes Joint space width, Lequesne index, global pain VAS 0-100, NSAID use (diclofenac equivalents), patient
global (verbal 7 point scale), investigator global (verbal 4 point scale), days of sick leave, n participants
requiring hip replacements
Notes Confirmatory study; statistical power 80%, alpha 0.05. Reported ethics committee approval. Results
equivocal; results favour intervention in subgroup of participants with advanced joint space narrowing.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised in blocks of four, to one of two groups, by an independent statisti-
cal unit
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred1
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell or
packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals. Included per-protocol and intention-to-treat analyses
Selective reporting (re-
porting bias)
Low risk Reported adverse events. Discussed intervention safety
Other bias Low risk Diagnosis / assessment consistent with ACR criteria (ie: EULAR criteria)
Lequesne 2002  (Continued)
 
 
Methods Randomised, double-blind, placebo control, 2 parallel groups, multicentre (n not specified). Duration
8.5 months (˜34 weeks); 15 day washout, 6 month intervention (˜24 weeks), 2 month follow-up
Participants Randomised n=164, Completed n=144. Mean age 64 yrs. M:F 46:118. Inclusion: OA knee or hip (ACR cri-
teria), Kellgren stage IB-III, active OA for 6 months, regular pain for 3 months
Interventions Piascledine 300: Persa gratissma and Glycine max (avocado-soyabean unsaponifiables), 300mg, cap-
sules
Placebo control: ingredients not reported, capsules
Rescue medication permitted: analgesics PRN, up to 1 intra-articular injection of corticosteroid "if ab-
solutely necessary"
Maheu 1998 
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Outcomes Lequesne index, pain VAS 0-100, disability VAS 0-100, number of participants using NSAIDs
Notes Confirmatory study design; statistical power 90%, alpha 0.05. Reported review board approval, but un-
clear whether a formally constituted HREC approved the study protocol. Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised in blocks of four, to one of two groups, using a table of random
numbers
Allocation concealment
(selection bias)
Low risk Adequate. Allocation completed by an independent statistician
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell, or
packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals. Included per-protocol and intention-to-treat analyses
Selective reporting (re-
porting bias)
Low risk Reported adverse events. Discussed intervention safety
Other bias Low risk Diagnosis / assessment consistent with ACR criteria (low risk)
Maheu 1998  (Continued)
 
 
Methods Randomised, double-blind, placebo control, 2 parallel groups, multicentre (n=122; 52 rheumatology
clinics, 70 general practices). Duration 3 years
Participants Randomised n=399, Completed n=345. Mean age 62 yrs. M:F 46:54. Inclusion: OA hip (ACR criteria), joint
space width (JSW) 1-4mm, Lequesne index 3-10 (scale 0-24), pain for at least 1 year. Most symptomatic
hip selected as target joint
Interventions Piascledine 300: Persa gratissma and Glycine max (avocado/soyabean unsaponifiables), 300mg, cap-
sules
Placebo control: ingredients not reported, capsules
Rescue medication permitted: analgesics or NSAIDs PRN recorded in self-report diary
Outcomes Change in joint space width (JSW; narrowest point on pelvis / hip AP view), WOMAC-VAS, Lequesne in-
dex (normalised 0-100)
Notes Confirmatory study design; planned recruitment n=380 for statistical power 90%, alpha 0.05; actual
power exceeded 75%. Reported ethics committee approval. Results equivocal for clinical outcomes.
Fewer participants (20%) in the intervention group showed progression of joint space narrowing.
Risk of bias
Bias Authors' judgement Support for judgement
Maheu 2013 
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Random sequence genera-
tion (selection bias)
Low risk Described as randomised: "Randomisation...by blocks of two for each stratum
defined by baseline JSW"
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred: "Randomisation list estab-
lished by an independent company"
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell, pack-
aging, or medication regimen
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals. Included per-protocol and intention-to-treat analyses
Selective reporting (re-
porting bias)
Unclear risk Variances reported as standard error of measurement (SEM). When converted
to standard deviation (SD), data are not normally distributed, violating an as-
sumption of the inferential analyses (unclear risk)
Change in JSW reported as joint loss in mm. Negative scores converted to posi-
tive for reanalysis so that higher scores mean worse (low risk).
Reported adverse events. Discussed intervention safety (low risk)
Other bias Low risk Diagnosis / assessment consistent with ACR criteria
Maheu 2013  (Continued)
 
 
Methods Randomised, unblinded, adjunct to active treatment, 2 parallel groups. Duration 12 weeks
Participants Randomised n=50; intervention n=25, control n=25. Inclusion: primary knee OA (criteria not specified)
with joint effusion
Interventions Boiogito: Japanese herbal mixture containing extract of Sinomenium acutum, Astragalus, Atractylodes
Lancea, Jujube, Glycyrrhiza, ginger, 7.5g (2.5g TID); and loxoprofen 60mg (20mg TID)
Control: loxoprofen 60mg (20mg TID)
Boiogito provided as adjunct therapy to loxoprofen
Outcomes Knee Society Rating System, SF-36, joint effusion (joint puncture)
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported institutional
review board oversight, but unclear whether a formally consistuted Human Research Ethics Committee
approved the research design. Improvement in pain and function occured in both groups over time. In-
terventiong roup showed reduction in joint effusion as well as other measures.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Majima 2012 
Oral herbal therapies for treating osteoarthritis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
77
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open trial. Medication regimens differ between active control and intervention
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals (low risk)
Per-protocol analysis only (unclear risk)
Selective reporting (re-
porting bias)
Low risk Reported adverse events
Other bias Unclear risk Criteria for diagnosis of OA not specified (unclear risk)
Majima 2012  (Continued)
 
 
Methods Randomised, double-blind, active control, 2 parallel groups. Duration 4 weeks
Participants Randomised n=110; intervention n=55, control n=55. Completed n=100; intervention n=50, control
n=50. Age 40+ years. OA knee (not ACR criteria), knee pain, knee swelling
Interventions Tradename not provided. Ricinus officinalis. Castor oil, 2.7ml (3 x 0.9ml), capsule
Active control: diclofenac sodium, 150mg (3 x 50mg), capsule
Concurrent intervention permitted: all participants encouraged to have physiotherapy
Outcomes Pain VAS 0-100
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics com-
mittee approval. Results favour diclofenac over castor oil for improvement in osteoarthritic knee pain.
Pain improved in both intervention and active control groups, but improvement was greater in the di-
clofenac group.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported. Participants "selected from outpatients"
may imply that allocation was unconcealed, or that participation in the study
was not voluntary (unclear risk)
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double-blind, method incompletely reported. Assume active in-
tervention and placebo not distinguished by look, taste, smell or packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals (low risk)
Per-protocol analysis only (unclear risk)
Five participants withdrew due to "efficacy failure", which may confound re-
sults
Selective reporting (re-
porting bias)
Unclear risk Clinical outcome data reported as percentages and P values only, insufficient
for extraction (unclear risk)
Medhi 2009 
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Reported adverse events (low risk)
Other bias Unclear risk Diagnosis / assessment not consistent with ACR criteria (unclear risk)
Medhi 2009  (Continued)
 
 
Methods Randomised, double blind, active control (glucosamine sulfate), 2 parallel groups. Duration 8 weeks
Participants Randomised n=95; intervention n=48, control n=47. Completed n=79; intervention n=41, control n=38.
Mean age: control 55.1 yrs, intevention 51.9 yrs. OA knee (ACR criteria), Kellgren II or III, function VAS
0-100 between 40mm and 80mm at baseline
Interventions Reparagen®: combination of Uncaria guianensis (cat's claw; 300mg) and Lepidium meyenii (1500mg),
1800mg (2 x 2 x 450mg)
Active control: glucosamine sulfate, 1500mg (2 x 2 x 375mg), capsules
Rescue medication permitted: paracetamol (acetaminophen), up to 1500mg (3 x 500mg) per day in
weeks 1-4, 1000mg (2 x 500mg) per day in weeks 5-8
Outcomes WOMAC 0-4, pain VAS 0-100, rescue medication use
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported compli-
ance with Helsinki Declaration and ethics committee approval. Reported clinical trials registration
(ISRCTN25438351). Efficacy of Reparagen® is not significantly different from glucosamine sulfate.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Used a fixed allocation randomisation procedure
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Intervention and active control not distinguished by look, taste, smell, packag-
ing, or medication regimen
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals. Included intention-to-treat analysis
Selective reporting (re-
porting bias)
Unclear risk Outcome data reported as change scores, percentages, graphs, and p values
only, insufficient for extraction (unclear risk)
Reported adverse events (low risk)
Other bias Low risk Diagnosis/assessment consistent with ACR criteria
Mehta 2007 
 
 
Methods Randomised, double-blind, placebo control, 2 parallel groups. Duration 2 months (˜8 weeks)
Mills 1996 
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Participants Randomised n=82 (all participants, OA and RA), Completed n=52 (plus RA n=20). Mean age (all partic-
ipants, OA and RA) 62 yrs. Gender data not reported. Inclusion: Self-identified arthritis pain, subse-
quently assessed by rheumatologist (ACR criteria), AIMS2 pain score of at least 3, not using prescribed
salicylates, NSAIDs, or analgesics
Interventions Reumalex: polyherbal mixture including extracts of willow bark, guaiacum resin, black cohosh, sarspar-
illa, and poplar bark, 2 "at a time", tablets.
Placebo control: calcium phosphate, tablets
Concurrent medication permitted: stable self-prescribed analgesics
Outcomes Pain AIMS 2, modified Ritchie index, analgesic use (diary)
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics com-
mittee approval. Results equivocal; medium effect size improvements in pain, but no reduction in anal-
gesic use.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, but participants allocated directly to groups on or-
der of enrolment into the trial (quasi-randomised): "Assigned by accession to
pre-set lists of allocations randomised for equalisation in every ten, and after
stratification by clinical condition, to one of two groups"
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Active interventions, active control, and placebo
not distinguished by look, taste, smell or packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals (low risk)
Per-protocol analysis only (unclear risk)
Selective reporting (re-
porting bias)
Low risk Reported adverse events (low risk)
Other bias Low risk Diagnosis/assessment consistent with ACR criteria
Mills 1996  (Continued)
 
 
Methods Randomised, double blind, placebo control, 4 parallel groups (2 x normal weight patients, 2 x over-
weight patients). Duration 8 weeks
Participants Randomised n=80, Completed n=45. Age range 25-60 yrs (mean age not reported). Gender data not re-
ported. OA knee (ACR criteria) in adults of normal weight and overweight
Interventions NP 06-1: mixture of Phellodendron amurense tree bark extract with 50% berberine and Citrus sinensis
peel extract a minimum of 30% polymethoxylated flavones, 1480mg (2 x 2 x 370mg), capsules
Placebo control: ingredients not reported, capsules
Oben 2009 
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Outcomes Lequesne index, BMI, CRP, ESR
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported university
oversight, but unclear whether a formally consistuted human research ethics committee approved the
research design. Results favour intervention. In the overweight intervention group, weight loss during
the intervention period may have contributed to improvement.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number sequence
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell, pack-
aging, or medication regimen
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals (low risk)
Per protocol analysis only (unclear risk)
Selective reporting (re-
porting bias)
Unclear risk Incompletely reported adverse events
Other bias Unclear risk Diagnosis / assessment consistent with ACR criteria (low risk)
Possible confounder: the berberine component of the intervention may have
contributed to weight loss
Oben 2009  (Continued)
 
 
Methods Randomised, double blind, active control, 2 parallel groups, multicentre (26 centres in 5 countries). Du-
ration 8 months (6 months intervention, 2 months follow up)
Participants Randomised n=361; intervention n=183, control n=178. Completed n=263; intervention n=142, control
n=121. Included in ITT analyses n=357, intervention n=181, control n=176. Age 45+ years (range not re-
ported). M:F 62:299. OA knee (ACR criteria)
Interventions Piascledine 300: Persa gratissma and Glycine max (avocado-soyabean unsaponifiables), 300mg, cap-
sules
Active control: chondroitin sulphate, 1200mg (3 x 400mg), capsules
Placebo control: ingredients not reported, capsules
Rescue medication permitted: paracetamol (acetominophen), dose not reported
Outcomes WOMAC-VAS (aggregated scores), pain with active movement VAS 0-100, pain at rest VAS 0-100,
Lequesne index (0-24), use of rescue medication
Notes Confirmatory study; statistical power 80%, alpha 0.05. Reported ethics committee application (ap-
proval not specified), and compliance with ICH GCP guidelines. WOMAC aggregated scores converted
Pavelka 2010 
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to normalised scores for data extraction and re-analysis. Results show that ASU is not inferior to chon-
droitin sulphate on any outcome.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Described as randomised, method of randomisation incompletely reported1.
"Randomisation to the two treatment groups was performed using the com-
puter program Rancode 1.0". Author contacted: provided full details of com-
puter generated randomisation
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred1. Author contacted: con-
firmed allocation concealment using single sealed opaque envelopes
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Double-dummy method, placebo controls for both
intervention and active controls. Active interventions and placebos not distin-
guished by look, taste, smell or packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals. Included intention-to-treat analysis
Selective reporting (re-
porting bias)
Low risk Reported adverse events. Discussed intervention safety
Other bias Low risk Diagnosis/assessment consistent with ACR criteria
Pavelka 2010  (Continued)
 
 
Methods Randomised, placebo control, 2 parallel groups, multicentre study. Duration 4 weeks
Participants Randomised n=45, Completed n=45. Reported no withdrawals. Assume that group sizes were allocated
a priori; intervention n=30, control n=15. Mean age 60 yrs, range 45-75 yrs. All male. Inclusion: OA knee
(ACR criteria), Kellgren stage II-III, pain most days of the month, NSAIDs for 3 months
Interventions Tradename not provided. Uncaria guianensis (cat's claw), aqueous extract, freeze-dried, 100mg, tablets
Placebo control: ingredient not reported, "same excipient but without cat's claw", tablets
Outcomes Pain at rest VAS 0-10, pain at night VAS 0-10, tenderness 0-3, global tolerance 0-4, blood variables
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported compliance
with Declaration of Helsinki. Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method not reported. Assume that group sizes were
allocated a priori
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Piscoya 2001 
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Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell or
packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported 100% compliance, no withdrawals (intervention over 4 weeks) (low
risk)
Per-protocol analysis (unclear risk)
Selective reporting (re-
porting bias)
Unclear risk Outcome measure VAS 0-10 converted to 100mm scale for data extraction (low
risk)
Variances reported as standard error of measurement (SEM). When converted
to standard deviation (SD), data are skewed, violating an assumption of the in-
ferential analyses (unclear risk)
Reported adverse events (low risk)
Other bias Low risk Diagnosis / assessment consistent with ACR criteria
Piscoya 2001  (Continued)
 
 
Methods Randomised, placebo control, 2 group crossover. Duration 6.5 months; 14 days run-in, 2 x 3 months
(˜12 weeks) intervention, no washout period)
Participants Randomised n=112, Completed stage 1 n=97, Completed stage 2 n=85. Mean age 67 yrs. M:F 41:71. In-
clusion: primary OA hip, knee, hand, shoulder, or neck, radiographic verification (criteria not specified),
mild to moderate pain
Interventions Hyben Vital: Rosa canina lito (rosehip and seed), 5000mg (2 x 5 x 500mg) equivalent to 1.5mg galac-
tolipid, capsules
Placebo control: ingredients not reported, capsules
Rescue medication permitted: self-prescribed analgesics, measured in paracetamol equivalents
Concurrent medication permitted: stable prescribed NSAIDs
Outcomes Pain change 0-4, rescue medication use (paracetamol equivalents), joint stiffness change 0-4, point in
time severity of pain, joint stiffness, wellbeing diary (mood, energy, sleep), patient treatment prefer-
ence
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics com-
mittee approval. Results moderately favour intervention. Evidence of carry-over effect in the group re-
ceiving the intervention prior to the placebo.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised in blocks of four, to one of two groups, using a computer generat-
ed allocation schedule
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred1
Rein 2004a 
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Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell, or
packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals
Included per-protocol and intention-to-treat analyses
Selective reporting (re-
porting bias)
Unclear risk Reported adverse events (low risk)
Subgroup analyses published separately (unclear risk)
Other bias High risk Criteria for diagnosis of OA not specified (high risk)
Rein 2004a  (Continued)
 
 
Methods Randomised, double blind, placebo control, 2 group crossover. Duration 14 days (˜2 weeks); 2 x 7 days
(˜1 week) intervention, no washout period
Participants Randomised n=30, Completed n=30. Mean age 66 yrs, range 45-81 yrs. M:F 7:23. Inclusion: OA knee, hip,
thumb, shoulder (criteria not specified)
Interventions PhytodolorRN: standardised extract mixture of ash bark, aspen leaf, aspen bark, golden rod herb, 3 x 40
drops, tincture
Placebo control: ingredients not reported
Outcomes Diclofenac use, pain at rest 0-3, pressure pain 0-3, pain with mvt 0-3, mobility impairment (scale not re-
ported)
Notes Exploratory study design; power, effect, and sample size not determined a priori. Did not report ethical
oversight or compliance with guidelines. Results favour intervention (reduced used of diclofenac only,
results equivocal for other outcomes).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double blind, method not reported. In other studies of Phytodo-
lorRN, active intervention and placebo not distinguished by look, taste, smell
or packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported 100% compliance, no withdrawals: likely in intervention over 7 days
Intention-to-treat analysis can be assumed
Selective reporting (re-
porting bias)
Unclear risk Reported adverse events (low risk)
Schadler 1988 
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Other bias Unclear risk Criteria for diagnosis of OA not specified (unclear risk)
Schadler 1988  (Continued)
 
 
Methods Randomised, placebo control, 2 parallel groups. Duration 30 days (˜4 weeks)
Participants Randomised n=56, Completed n=56. Age and gender data not reported. Inclusion: OA spine (criteria not
specified), acute exacerbations
Interventions Arthrotabs®: Harpagophytum procumbens (devil's claw), aqueous extract, 4290mg (2 x 3 x 715mg),
tablets
Placebo control: ingredients not reported
Outcomes Pain 0-4
Notes Exploratory study design; power, effect, and sample size not determined a priori. Did not report ethical
oversight or compliance with guidelines. Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method not reported
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double blind, method not reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported 100% compliance, no withdrawals
Selective reporting (re-
porting bias)
Unclear risk Outcome data reported as percentages and bar charts only, insufficient for ex-
traction (unclear risk)
Reported adverse events (low risk)
Other bias High risk Criteria for diagnosis of OA not specified (high risk)
Unvalidated outcome measure (unclear risk)
Schmelz 1997 
 
 
Methods Randomised, placebo control, 2 parallel, stratified groups. Duration 2 weeks
Participants Randomised n=78, Completed n=68. Mean age 53 yrs. M:F 59:19. Inclusion: OA hip or knee (ACR criteria),
clinical, radiographic and laboratory verification
Schmid 2000 
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Interventions Tradename not provided. Salix purpurea x daphnoides cortex (willow bark) extract, 1360mg (2 x 2 x
340mg, equivalent to 240mg salicin), tablets
Placebo control: cellulose and lactose, tablets
Outcomes WOMAC, patient global, physician global, haematology, urinanalysis
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics com-
mittee approval and compliance with ICH GCP guidelines. Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised in blocks of four, using a computer generated random number se-
quence
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred1. Authors contacted for con-
firmation, but details of allocation concealment not provided
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell, or
packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals. Included per-protocol and intention-to-treat analyses
Selective reporting (re-
porting bias)
Low risk Reported adverse events. Discussed intervention safety (low risk)
Other bias Low risk Diagnosis/assessment consistent with ACR criteria
Schmid 2000  (Continued)
 
 
Methods Randomised, double blind, placebo control, 3 parallel groups (2 x intervention). Duration 90 days (˜12
weeks)
Participants Randomised n=75, Completed n=70, intervention low dose (100mg/day 5-Loxin) n=24, intervention
high dose (250mg/day 5-Loxin) n=23, control n=23 Mean age: control 52.4 yrs, intervention low dose
52.3 yrs, intervention high dose 53.2 yrs. M:F intervention low dose 7:17, intervention high dose 8:15,
control 5:18. OA knee (ACR criteria), must report pain with movement VAS 0-100 between 40mm and
70mm and Lequesne index > 7 points at baseline
Interventions 5-Loxin®: extract of Boswellia serrata with 30% 3-O-acetyl-11-keto-beta-boswellic acid, low dose 100mg
(2 x 50mg), high dose 250mg (5 x 50mg), capsules
Placebo control: rice bran, capsules
Rescue medication permitted: ibuprofen, up to 1200mg (3 x 400mg) PRN
Outcomes VAS, Lequesne index, WOMAC
Notes Confirmatory study design: statistical power 80%, alpha set at 0.05 ( 2 tailed). Reported institutional re-
view board oversight, but unclear whether a formally constituted HREC approved the research design.
Reported clinical trails registration (ISRCTN05212803). Results favour intervention.
Sengupta 2008 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated randomisation table
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell, pack-
aging, or medication regimen
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals (low risk)
Per protocol analysis only (unclear risk)
Selective reporting (re-
porting bias)
Unclear risk Reported adverse events
Standard errors of measure erroneously labelled as standard deviations for
some outcome data (WOMAC function subscale). Errors corrected during data
extraction for re-analysis (Analysis 2.2, Analysis 3.2)
Other bias Unclear risk Diagnosis/assessment consistent with ACR crtieria (low risk)
Non-comparable groups: Intervention low-dose group reported markedly
greater pain (WOMAC subscale) than the other groups at baseline (unclear risk)
Sengupta 2008  (Continued)
 
 
Methods Randomised, placebo control, 3 parallel groups (2 active products derived from the same herb), single
centre trial. Duration 90 days (˜12 weeks)
Participants Randomised n=60, Completed n=57, intervention A (100mg/day 5-Loxin) n=19, intervention B (100mg/
day Aflapin) n=19, control n=19. Mean age: intervention A 51.6 yrs, intervention B 53.2 yrs, control 52.4
yrs. M:F intervention A 3:16, intervention B 7:12, control 9:10. OA knee (ACR criteria), regular NSAID or
acetominophen use for pain, must report pain VAS 0-100 between 40mm and 70mm and Lequesne in-
dex > 7 points at baseline after regular medication washout
Interventions 5-Loxin®: extract of Boswellia serrata with 30% 3-O-acetyl-11-keto-beta-boswellic acid 100mg (2 x
50mg), capsules
Aflapin®: extract ofBoswellia serrata, enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid, and
non-volatile Boswellia serrata oil, 100mg (2 x 50mg), capsules
Placebo control: ingredients not reported, "filled with a suitable excipient", capsules
Rescue medication permitted: ibuprofen, up to 1200mg (3 x 400mg) PRN
Outcomes Pain VAS 0-100, Lequesne index, WOMAC-VAS (normalised units) pain, stiffness, physical function sub-
scales
Notes Confirmatory study design; statistical power 80%, alpha set at 0.05 (2 tailed). Reported institutional re-
view board oversight, but unclear whether a formally constituted human research ethics committee
approved the research design. Reported clinical trials registration (ISRCTN80793440). Results favour
Aflapin over 5-Loxin, and both products over placebo.
Sengupta 2010 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated randomisation table
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred: "The clinical trial pharma-
cist and statistician ensured that treatment codes remained confidential"
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell, pack-
aging, or medication regimen
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals (low risk)
Per-protocol analysis only (unclear risk)
Selective reporting (re-
porting bias)
Low risk Reported adverse events
Other bias Low risk Diagnosis/assessment consistent with ACR criteria (low risk)
Sengupta 2010  (Continued)
 
 
Methods Randomised, unblinded, active control (valdecoxib), 2 parallel groups. Duration 7 months; 6 months
(˜24 weeks) intervention, plus 1 month follow-up
Participants Randomised n=66; intervention n=33, control n=33. Completed n=57; intervention n=31, control n=27.
Age 40-70 years. OA knee (ACR criteria). Not pregnant or lactating
Interventions Cap Wovkel™: containing Boswellia serrata extract with 65% organic acids, 999mg (3 x 333mg), cap-
sules
Active control: valdecoxib, 10mg OD, tablets
Rescue medication permitted: ibuprofen, up to 1200mg (400mg TID), PRN
Outcomes WOMAC-VAS (aggregated scores)
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported university
oversight, but unclear whether a formally constituted HREC approved the research design. WOMAC ag-
gregated scores converted to normalised VAS 0-100 scale during data extraction for re-analysis. Results
reported to favour intervention, but re-analysis of data indicates that results slightly favour interven-
tion for WOMAC pain subscale scores only. Results favour control on all other outcomes.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised using an independent computerised system: "The patients were
randomly allocated by SAS for Windows..."
Allocation concealment
(selection bias)
High risk Open trial. Allocation not concealed
Sontakke 2007 
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Blinding (performance
bias and detection bias) 
All outcomes
High risk Open trial. Medication regimens differ between active control and intervention
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals (low risk)
Per-protocol analysis only (unclear risk)
Selective reporting (re-
porting bias)
Low risk Reported adverse events and rescue medication use
Other bias Low risk Diagnosis / assessment consistent with ACR criteria
Sontakke 2007  (Continued)
 
 
Methods Randomised, double blind, active control, 2 parallel groups. Duration 5 weeks; 1 week run-in, 4 weeks
intervention
Participants Randomised n=200, Completed n=188. Mean age 62 yrs. M:F 41:159. Inclusion: OA knee unilateral or bi-
lateral (ACR criteria), Kellgren stage II-IV
Interventions Duhuo Jisheng Wan (DJW): herbal mixture containing angelica root and mulberry mistletoe, 9000mg (6
x 3 x 500mg), capsules
Active control: diclofenac sodium (Voltaren), 75mg (3 x 25mg), tablets packed in capsules
Placebo controls: cane sugar, tablets packed in capsules, and capsules
Outcomes Battery of pain VAS 0-100 (night pain, pain with standing, pain with movement, pain with stair climb-
ing, resting pain, total pain), battery of stiffness VAS 0-100 (morning stiffness, stiffness at rest, total stiff-
ness), Lequesne index, time to climb 10 stairs, patient opinion of improvement VAS 0-100, investigator
opinion of improvement VAS 0-100
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics
committee approval and compliance with Declaration of Helsinki. Reported clinical trials registration
(ISRCTN70292892). DJW equally effective as diclofenac on pain, stiffness, and Lequesne index. Partic-
ipants using DJW reported improvements after a longer period of intervention that participants using
diclofenac. Toxicity profiles of interventions are approximately equal. DJW is a large dose (9g, adminis-
tered as 18 capsules per day) which may be a barrier to long-term clinical compliance.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method not reported. Baseline parameters com-
pared for significant differences
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Double-dummy method, placebo controls for both
intervention and active controls. Active interventions and placebos not distin-
guished by look, taste, smell or packaging
Incomplete outcome data
(attrition bias) 
Low risk Reported withdrawals. Included intention-to-treat analysis
Teekachunhatean 2004 
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All outcomes
Selective reporting (re-
porting bias)
Low risk Reported adverse events. Discussed intervention safety
Other bias Low risk Diagnosis / assessment consistent with ACR criteria
Teekachunhatean 2004  (Continued)
 
 
Methods Randomised, double blind, placebo control, 2 parallel groups. Duration 30 days (˜5 weeks)
Participants Randomised n=60; intervention n=30, control n=30. Completed n=59; intervention n=30, control n=29.
Age 40-80 years. OA knee (ACR criteria), most painful knee VAS >40mm, Lequesne index >7
Interventions Aflapin®: extract ofBoswellia serrata with 30% 3-O-acetyl-11-keto-beta-boswellic acid and non-volatile
Boswellia serrata oil, 100mg (2 x 50mg), capsules.
Placebo control: ingredients not reported, "similar organoleptic properties", capsules
Rescue medication permitted: ibuprofen, up to 1200mg (3 x 400mg) PRN
Outcomes VAS, Lequesne index, WOMAC-VAS (normalised units), pain, stiffness, physical function subscales
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported institution-
al review board oversight, but unclear whether a formally constituted HREC approved the research de-
sign. Reported clinical trials registration (ISRCTN69643551). Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated randomisation schedule
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred: "Randomization codes were
secured confidentially by the clinical trial pharmacist and statistician"
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Active intervention and placebo not distinguished
by look, taste, smell, packaging, or medication regimen
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals (low risk)
Per-protocol analysis only (unclear risk)
Selective reporting (re-
porting bias)
Low risk Reported adverse events
Other bias Low risk Diagnosis / assessment consistent with ACR criteria
Vishal 2011 
 
 
Methods Randomised, placebo control, 2 parallel groups. Duration 4 months (˜20 weeks)
Warholm 2003 
Oral herbal therapies for treating osteoarthritis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
90
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Participants Randomised n=100; intervention n=50, control n=50. Completed n=96; intervention n= 48, control n=48.
Mean age 65 yrs. M:F 35:65. Inclusion: OA hip or knee, radiographic verification (criteria not specified)
Interventions Hyben Vital: Rosa canina lito (rosehip and seed), 5000mg (2 x 5 x 500mg), equivalent to 1.5mg galac-
tolipid, capsules
Placebo control: ingredients not reported, capsules
Outcomes Active and passive range of motion (goniometer), activities of daily living VAS 0-10, pain relief 0-4,
NSAID use
Notes Exploratory study design; power, effect, and sample size not determined a priori. Did not report ethi-
cal oversight or compliance with guidelines. Results favour intervention for some ranges of motion and
pain, but are less convincing for activities of daily living.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised using an independent computerised system
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell, pack-
aging, or medication regimen
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals. Included intention-to-treat and per protocol analyses
Selective reporting (re-
porting bias)
Unclear risk Pain data reported as percentages and graphs only, insufficient for data ex-
traction (unclear risk)
Reported adverse events (low risk)
Other bias Unclear risk Criteria for diagnosis of OA not specified, radiographic verification only (un-
clear risk)
Warholm 2003  (Continued)
 
 
Methods Randomised, double blind, placebo control, 2 group crossover. Duration 48.5 weeks; 4 days run-in, 2 x
12 weeks crossover, 24 weeks open follow-up
Participants Randomised n=29, Completed stage 1 n=24, Completed stage 2 n=20, Completed stage 3 (open trial)
n=17. Mean age 62 yrs, range 42-85 yrs Inclusion: OA knee (ACR criteria), Kellgren II-IV, pain VAS 0-100
>35mm. Not pregnant or lactating
Interventions Zintona EC: Zingiber officinale (ginger) extract, 1000mg (4 x 250mg), equivalent to 40mg gingerol, cap-
sules. Capsule contains 10mg gingerol absorbed on maltodextrin
Placebo control: maltodextrin only
Outcomes WOMAC (Hebrew), knee circumference
Wigler 2003 
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Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics com-
mittee approval. Results equivocal in stage 1. Results in stage 2 and stage 3 favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised to one of two groups using a computer generated random num-
ber sequence
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred: "Both patients and investi-
gators were blinded to treatment assignment"
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell, pack-
aging, or medication regimen
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals. Included intention-to-treat analysis (success versus
failure)
Selective reporting (re-
porting bias)
Unclear risk Outcome data reported as means and confidence intervals. Standard devia-
tions calculated for data extraction (unclear risk)
Reported adverse events
Other bias Low risk Diagnosis / assessment consistent with ACR criteria
Wigler 2003  (Continued)
 
 
Methods Randomised, placebo control, 2 group crossover. Duration 6.5 months; 14 days run-in, 2 x 3 months
(˜12 weeks) intervention, no washout period
Participants Randomised n=94, Completed stage 1 n=94, Completed stage 2 n=80. Mean age 66 yrs. M:F 40:54. Inclu-
sion: aged 35+ years, primary OA hip or knee, radiographic verification (ACR criteria), mild to moderate
pain
Interventions LitoZin: Rosa canina lito (rosehip and seed), 5000mg (2 x 5 x 500mg), equivalent to 1.5mg galactolipid,
capsules
Placebo control: ingredients not reported, "inactive powder of similar taste, smell, and colour", cap-
sules
Outcomes WOMAC-VAS
Notes Exploratory study design; power, effect, and sample size not determined a priori. Reported ethics com-
mittee approval. Results moderately favour intervention. Evidence of carryover effect in the group re-
ceiving the intervention prior to the placebo.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised in blocks of four, to one of two groups, using a computer generat-
ed allocation schedule
Winther 2005 
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Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred1
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active intervention and placebo not distinguished by look, taste, smell, or
packaging
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals. Included intention-to-treat analysis
Selective reporting (re-
porting bias)
Unclear risk Reported adverse events (low risk)
Subgroup analyses published separately (unclear risk)
Other bias Low risk Diagnosis / assessment consistent with ACR criteria
Winther 2005  (Continued)
Unless otherwise stated, all oral medications are reported as total daily doses, which may have been administered in single or divided
doses.
Unless subscales are named, outcome measures (eg: WOMAC, HAQ, COAT) were used in entirety. Unless specified, all outcome measures
were administered, scored, and scaled according to Osteoarthritis Research Society International (OARSI) standards.
1. Reported compliance with ICH GCP guidelines (ICH 2004) anchored in European law, or ethics committee oversight that would require
the same, so adequate randomisation, allocation concealment, and blinding can be assumed.
2. Indicates that the tradename was not provided in the manuscript, but has been determined through communication with the
manufacturing company noted in the acknowledgements.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Anonymous 1993 Discussion paper
Belcaro 2010 Intervention included extracted or synthetic curcumin and another synthetic compound from soy
lecithin (isolated compounds), therefore not herbal as per WHO definition
Biswas 1997 Abstract only. Unable to identify individual herbal interventions. Ingredients not listed in sufficient
detail to allow replication of the study
Biswas 1998 Mixed sample, including people with rheumatoid arthritis and non-specific arthritis. Unable to ex-
tract data on OA only
Brien 2006 Review paper
Chantre 2000 Repeat publication of Leblan 2000
Chrubasik 1998 Review paper
Dharmananda 1985 Discussion paper
Du 2006 Mixed sample, including people with "rheumatism due to blockage of cold and damp". Unable to
extract data on OA only
Falch 1997 Discussion paper
Fang 2008 Individualised treatments, not a standardised dose, therefore, considered as a case series rather
than RCT. Metabolic outcomes only. No functional or clinical outcomes
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Study Reason for exclusion
Gendo 1997 Discussion paper
Grahame 1981 Not RCT
Guyader 1984 Case series, not RCT. Used inappropriate statistical analyses
Hamblin 2008 Individualised treatments, not a standardised plant product or dose, therefore, a case series rather
than RCT. Abstract only available from CENTRAL. Cannot locate full manuscript
Jacquet 2009 Intervention not purely herbal. Unable to identify effects of herbal intervention alone
Kagore 2011 Case study
Kielczynski 1997 Discussion paper
Kulkarni 1991 Intervention not purely herbal. Unable to identify effects of herbal interventions alone. Ingredients
not listed in sufficient detail to allow replication of the study
Lechner 2011 Individualised treatments, not a standardised plant product or dose, therefore, considered as a
case series rather than RCT
Levy 2009 Intervention (Limbrel) included extracted biacalin and catechin (flavanoids, isolated compounds),
therefore not herbal as per WHO definition. According to the manufacturer, "each capsule of Lim-
brel also contains 50 mg of citrated zinc bisglycinate, which provides 10 mg of elemental zinc", a
potentially active substance (http://www.limbrel.com/limbrel.php). Study is only repeatable using
the proprietary product
Linsheng 1997 Not RCT
Loew 1996 Not RCT. Primary measures not consistent with the topic of this review
Long 2001 Review paper
Lung 2004 Repeat analysis (safety data only) of Jung 2004
Mishra and Singh 2003 Not RCT (single group trial). Author list in indexed citation differs from actual publication
Myers 2010 Not RCT (open label, uncontrolled study)
Park 2009 Intervention included magnesium (mineral), therefore not herbal as per WHO definition. Magne-
sium is a potentially active substance that may alter the active principle of the herbal extracts, un-
less it has been demonstrated that they are essentially similar
Rein 2004b Abstract only. Subgroup analysis of Rein 2004a
Reuss 1981 Discussion paper
Rosen 2013 Not RCT. Open-label, uncontrolled, cohort (single group) study
Sagar 1988 Not RCT
Saley 1987 Not RCT
Schaffner 1997 Mixed sample, including people with back pain not due to osteoarthritis. Unable to extract data on
OA only
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Study Reason for exclusion
Schmid 1998a Abstract only. Abstract to Schmid 2000 and Schmid 2001
Schmid 2001 Repeat publication of Schmid 2000
Srivastava 1989 Not RCT
Wang 1985 Not RCT
Wegener 2003 Not RCT
Winther 2004 Abstract only. Subgroup analysis of Rein 2004a
Xu 2005 Not RCT (case series)
Yuelong 2011 Not RCT (protocol for RCT)
Zell 1993 Not RCT
Zeng 2008 Metabolic outcomes only. No functional or clinical outcomes
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods RCT, 2 parallel groups. Duration: 4 weeks
Participants n=96 (intervention n=48, active control n=48)
Interventions Intervention: Bushen Huoxue Qubi decoction (ingredients unknown), one bag/day
Active control: diacerein (50 mg Bid, Po) and celecoxib (0.2 Qd, Po)
Outcomes VAS (outcome and scale unknown), WOMAC, relative viscosity, aggregation index and IL-1beta, NO,
iNOS, LPO, SOD in serum, adverse events
Notes Abstract only available. China Journal of Chinese materia medica indexed, but not held in known
collections. Full manuscript sought in hard copy via inter-library loan.
Gao 2012 
 
 
Methods RCT, multicentre (n=2; USA and Hong Kong), 2 parallel groups. Duration: 8 weeks
Participants n=92 (USA n=53, Hong Kong n=39)
Interventions Intervention: Hou-Lou-Xiao-Ling Dan 5,180 mg/day (15 capsules in 3 divided doses)
Control: placebo (ingredients unknown), dose matched to intervention
Outcomes WOMAC, patient global, patient global assessment of response to therapy
Notes Abstract only available. Abstracts from the annual ACR meeting are published in Arthritis and
Rheumatism. This study will be classified if a full manuscript published.
Hochberg 2012 
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Methods RCT, 3 parallel groups
Participants n=160 (A: intervention n=76, B: active control n=42, C: intervention plus active control n=46)
Interventions Intervention: wangbi (ingredients and dose unknown)
Active control: voltaren (dose unknown)
Outcomes Morning stiffness, joint tenderness, swelling, pain, functional activities, adverse reactions (out-
come measures unknown). Results favour combination therapy
Notes Abstract only available. Chinese Journal of Intergrated Traditional and Western medicine indexed,
but not held in known collections. Full manuscript sought in hard copy via inter-library loan.
Kang 2011 
 
 
Methods RCT
Participants n=86. 4 groups: manipulation plus pyrola (n=22), manipulation (n=22), pyrola compound tradition-
al Chinese medicine (n=22), and self-exercise (n=20)
Interventions The manipulation group: Prone position, rolling manipulation to the affected thigh for 5 minutes,
mainly the Weizhong and Weiyang of the fossa poplitea and the posterolateral part of the leg;
Supine position, rolling manipulation for 5 minutes to affected side of quadriceps femoris and su-
perior part of the whirbone; Alternately manipulation of pressing-kneading, flicking-poking and
digital-pressing to Dubi, xiyan, Yanglingquan, Heding, Xiyangguan and Liangqiu; Rotating of the
knee joint cooperated by the passive stretch, flexion, inward and lateral rotation; At last, spreading
some ointment of Chinese holly leaf on the affected knee joint and scrubbing until give the patient
a warm sensation. The treatment was done three times weekly for 4 weeks.
Pyrola group: The patients were treated with Chinese herbs orally (modified pyrola compound tra-
ditional Chinese medicine) twice a day with water for weeks.
Manipulation plus pyrola group: Patients were treated by Chinese herb orally besides the manipu-
lation with the same processes as the manipulation group for 4 weeks.
Self-exercise group: Patients were told to do exercise themselves such as stretching exercises, ac-
tive and passive range-of-motion exercises, strengthening exercises and so on for 4 weeks. 
Outcomes WOMAC 0-100, 20m walk time
Notes Abstract only available. Chinese Journal of Clinical Rehabilitation not indexed. Full manuscript
sought in hard copy via inter-library loan.
Liu 2006 
 
 
Methods RCT
Participants n=88 (intervention n=44, control n=44)
Interventions Intervention: diclofenac 75mg/day with 1000mg/day curcumin (Curcuma longa extract)
Pinsornsak 2012 
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Active control: diclofenac 75mg/day with placebo (unknown)
Outcomes Pain VAS, KOOS. Results equivocal
Notes Abstract only available. Journal of the Medical Association of Thailand indexed, but not held in
known collections. Full manuscript sought in hard copy via inter-library loan.
Pinsornsak 2012  (Continued)
 
 
Methods RCT
Participants n=90 (intervention n=45, control n=45)
Interventions Intervention: gubitong decoction (dose and ingredients unknown)
Control: glucosamine sulfate 1500mg/day (3 x 500mg)
Outcomes WOMAC, symptom VAS. Results equivocal: statistically significant improvement in treatment and
control groups
Notes Abstract only available. Chinese Journal of Integrative Medicine not indexed. Full manuscript sought
in hard copy via inter-library loan.
Tao 2009 
 
 
Methods RCT
Participants n=88 (intervention n=44, control n=44)
Interventions Intervention: Bushen Quhan Tongluo herbs by orally or externally washing
Bushen Quhan. Tongluo: Hutaorou (12 g), Buguzhi (12 g), Chaoduzhong (12 g), Shudi (15 g), Dahuix-
iang (9 g), Luoshiteng (15 g), Zhichuanwu (9 g), Sanqi (6 g), Wugong (3 g), Jixieteng (15 g). The pre-
scription for external washing: Tuogucao (40 g), Danggui (15 g), Sumu (15 g), Shengdahuang (15 g),
Shengnanxing (10 g), Ruxiang (10 g), Meyao (10 g), Bingpian (3 g). Oral administration: The medi-
cine shall be taken with water of 37 degrees C one dose a day.
Patients in the control group were given sulfated glucosamine (Weiguli Capsule. Each capsule con-
tains 314 mg of sulfated glucosamine crystal, which is equal to 250 mg of sulfated glucosamine)
two capsules a time and 3 times a day as well as piroxicam (Yantong Xikang Pill) once a day and 20
mg each time. Patients in both groups were administrated for 12 weeks
Outcomes WOMAC
Notes Abstract only available. Chinese Journal of Clinical Rehabilitation not indexed. Full manuscript
sought in hard copy via inter-library loan.
Unable to distinguish oral administration internvention group from topical administration inter-
vention group results from abstract alone.
Zhong 2006 
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Comparison 1.   Boswellia serrata 999 mg versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain (0 to 3) 1   Mean Difference (IV, Random, 95% CI) Totals not selected
2 Function: loss of function (0 to 3) 1   Mean Difference (IV, Random, 95% CI) Totals not selected
3 Participants (n) reported adverse
effects
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 1.1.   Comparison 1 Boswellia serrata 999 mg versus placebo, Outcome 1 Pain (0 to 3).
Study or subgroup Boswellia serrata Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Kimmatkar 2003 15 0.3 (0.5) 15 2.5 (0.7) -2.24[-2.64,-1.84]
Favours Boswellia serrata 42-4 -2 0 Favours placebo
 
 
Analysis 1.2.   Comparison 1 Boswellia serrata 999 mg versus placebo, Outcome 2 Function: loss of function (0 to 3).
Study or subgroup Boswellia serrata Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Kimmatkar 2003 15 0.3 (0.5) 15 2.5 (0.6) -2.16[-2.56,-1.76]
Favours Boswellia serrata 21-2 -1 0 Favours placebo
 
 
Analysis 1.3.   Comparison 1 Boswellia serrata 999 mg versus
placebo, Outcome 3 Participants (n) reported adverse e?ects.
Study or subgroup Boswellia serrata Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Kimmatkar 2003 2/15 0/15 5[0.26,96.13]
Favours Boswellia serrata 1000.01 100.1 1 Favours placebo
 
 
Comparison 2.   Boswellia serrata (enriched) 100 mg versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 at 90 days 2 85 Mean Difference (IV, Random,
95% CI)
-16.57 [-24.67, -8.47]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2 WOMAC-VAS (Function) 2 85 Mean Difference (IV, Random,
95% CI)
-8.21 [-14.21, -2.22]
3 Adverse event episodes (n) reported 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 2.1.   Comparison 2 Boswellia serrata (enriched) 100
mg versus placebo, Outcome 1 Pain VAS 0-100 at 90 days.
Study or subgroup Boswellia serrata Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Sengupta 2008 24 21.4 (7.1) 23 41.8 (16) 53.91% -20.39[-27.52,-13.26]
Sengupta 2010 19 26.2 (16.5) 19 38.3 (9) 46.09% -12.1[-20.55,-3.65]
   
Total *** 43   42   100% -16.57[-24.67,-8.47]
Heterogeneity: Tau2=18.46; Chi2=2.16, df=1(P=0.14); I2=53.71%  
Test for overall effect: Z=4.01(P<0.0001)  
Favours Boswellia serrata 5025-50 -25 0 Favours placebo
 
 
Analysis 2.2.   Comparison 2 Boswellia serrata (enriched) 100 mg versus placebo, Outcome 2 WOMAC-VAS (Function).
Study or subgroup Boswellia serrata Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Sengupta 2008 24 24.3 (21) 23 34.1 (5.2) 47.97% -9.75[-18.41,-1.09]
Sengupta 2010 19 25.2 (15) 19 32 (10.8) 52.03% -6.8[-15.11,1.51]
   
Total *** 43   42   100% -8.21[-14.21,-2.22]
Heterogeneity: Tau2=0; Chi2=0.23, df=1(P=0.63); I2=0%  
Test for overall effect: Z=2.69(P=0.01)  
Favours Boswellia serrata 2010-20 -10 0 Favours placebo
 
 
Analysis 2.3.   Comparison 2 Boswellia serrata (enriched) 100 mg
versus placebo, Outcome 3 Adverse event episodes (n) reported.
Study or subgroup Boswellia serrata (e100) Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Sengupta 2008 18/48 30/48 0.6[0.39,0.92]
Favours Boswellia serrata 1000.01 100.1 1 Favours placebo
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Comparison 3.   Boswellia serrata (enriched) 250 mg versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 at 90 days 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
2 WOMAC-VAS (Function) 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
3 Adverse event episodes (n) reported 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 3.1.   Comparison 3 Boswellia serrata (enriched) 250
mg versus placebo, Outcome 1 Pain VAS 0-100 at 90 days.
Study or subgroup Favours Boswellia serrata Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Sengupta 2008 23 14.2 (6.8) 23 41.8 (16) -27.54[-34.64,-20.44]
Favours Boswellia serrata 10050-100 -50 0 Favours placebo
 
 
Analysis 3.2.   Comparison 3 Boswellia serrata (enriched) 250 mg versus placebo, Outcome 2 WOMAC-VAS (Function).
Study or subgroup Boswellia serrata (e250) Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Sengupta 2008 24 17.3 (9.7) 23 34.1 (5.2) -16.8[-21.23,-12.37]
Favours Boswellia serrata 2010-20 -10 0 Favours placebo
 
 
Analysis 3.3.   Comparison 3 Boswellia serrata (enriched) 250 mg
versus placebo, Outcome 3 Adverse event episodes (n) reported.
Study or subgroup Boswellia serrata (e250) Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Sengupta 2008 27/57 30/57 0.9[0.62,1.3]
Favours Boswellia serrata 1000.01 100.1 1 Favours placebo
 
 
Comparison 4.   Boswellia serrata (enriched) 100 mg plus non-volatile oil versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 2 97 Mean Difference (IV, Random, 95% CI) -16.09 [-20.37, -11.81]
1.1 At 90 days 1 38 Mean Difference (IV, Random, 95% CI) -18.10 [-24.95, -11.25]
Oral herbal therapies for treating osteoarthritis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
100
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.2 At 30 days 1 59 Mean Difference (IV, Random, 95% CI) -14.80 [-20.29, -9.31]
2 WOMAC-VAS (Function) 2 97 Mean Difference (IV, Random, 95% CI) -15.01 [-19.21, -10.81]
2.1 At 30 days 1 59 Mean Difference (IV, Random, 95% CI) -14.30 [-20.07, -8.53]
2.2 At 90 days 1 38 Mean Difference (IV, Random, 95% CI) -15.8 [-21.92, -9.68]
3 Participants (n) reported
adverse events
2 97 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.13, 7.29]
3.1 At 30 days 1 59 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.06, 16.20]
3.2 At 90 days 1 38 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.06, 17.25]
 
 
Analysis 4.1.   Comparison 4 Boswellia serrata (enriched) 100 mg
plus non-volatile oil versus placebo, Outcome 1 Pain VAS 0-100.
Study or subgroup Boswellia ser-
rata (e+NV)
Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
4.1.1 At 90 days  
Sengupta 2010 19 20.2 (12.3) 19 38.3 (9) 39.05% -18.1[-24.95,-11.25]
Subtotal *** 19   19   39.05% -18.1[-24.95,-11.25]
Heterogeneity: Not applicable  
Test for overall effect: Z=5.18(P<0.0001)  
   
4.1.2 At 30 days  
Vishal 2011 30 24.5 (11.9) 29 39.3 (9.5) 60.95% -14.8[-20.29,-9.31]
Subtotal *** 30   29   60.95% -14.8[-20.29,-9.31]
Heterogeneity: Not applicable  
Test for overall effect: Z=5.29(P<0.0001)  
   
Total *** 49   48   100% -16.09[-20.37,-11.81]
Heterogeneity: Tau2=0; Chi2=0.54, df=1(P=0.46); I2=0%  
Test for overall effect: Z=7.36(P<0.0001)  
Test for subgroup differences: Chi2=0.54, df=1 (P=0.46), I2=0%  
Favours Boswellia serrata 2010-20 -10 0 Favours placebo
 
 
Analysis 4.2.   Comparison 4 Boswellia serrata (enriched) 100 mg plus
non-volatile oil versus placebo, Outcome 2 WOMAC-VAS (Function).
Study or subgroup Boswellia ser-
rata (e+NV)
Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
4.2.1 At 30 days  
Favours Boswellia serrata 2010-20 -10 0 Favours placebo
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Study or subgroup Boswellia ser-
rata (e+NV)
Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Vishal 2011 30 22.5 (11.1) 29 36.8 (11.5) 52.98% -14.3[-20.07,-8.53]
Subtotal *** 30   29   52.98% -14.3[-20.07,-8.53]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.86(P<0.0001)  
   
4.2.2 At 90 days  
Sengupta 2010 19 16.2 (8.3) 19 32 (10.8) 47.02% -15.8[-21.92,-9.68]
Subtotal *** 19   19   47.02% -15.8[-21.92,-9.68]
Heterogeneity: Not applicable  
Test for overall effect: Z=5.06(P<0.0001)  
   
Total *** 49   48   100% -15.01[-19.21,-10.81]
Heterogeneity: Tau2=0; Chi2=0.12, df=1(P=0.73); I2=0%  
Test for overall effect: Z=7(P<0.0001)  
Test for subgroup differences: Chi2=0.12, df=1 (P=0.73), I2=0%  
Favours Boswellia serrata 2010-20 -10 0 Favours placebo
 
 
Analysis 4.3.   Comparison 4 Boswellia serrata (enriched) 100 mg plus non-
volatile oil versus placebo, Outcome 3 Participants (n) reported adverse events.
Study or subgroup Boswellia
serrata (e+NV)
Placebo Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.3.1 At 30 days  
Vishal 2011 1/30 1/29 50.49% 0.97[0.06,16.2]
Subtotal (95% CI) 30 29 50.49% 0.97[0.06,16.2]
Total events: 1 ( Boswellia serrata (e+NV)), 1 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.02(P=0.98)  
   
4.3.2 At 90 days  
Sengupta 2010 1/19 1/19 49.51% 1[0.06,17.25]
Subtotal (95% CI) 19 19 49.51% 1[0.06,17.25]
Total events: 1 ( Boswellia serrata (e+NV)), 1 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 49 48 100% 0.98[0.13,7.29]
Total events: 2 ( Boswellia serrata (e+NV)), 2 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.99); I2=0%  
Test for overall effect: Z=0.02(P=0.99)  
Test for subgroup differences: Chi2=0, df=1 (P=0.99), I2=0%  
Favours Boswellia serrata 1000.01 100.1 1 Favours placebo
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Comparison 5.   Boswellia serrata 999 mg versus valdecoxib
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 WOMAC-VAS (Pain) 1 58 Mean Difference (IV, Random, 95% CI) -0.51 [-7.26, 6.24]
2 WOMAC-VAS (Function) 1 58 Mean Difference (IV, Random, 95% CI) 2.49 [-4.07, 9.05]
3 Participants (n) reported ad-
verse events
1 66 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.39, 10.18]
4 Participants (n) withdrew due
to adverse events
1 66 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.13, 71.07]
 
 
Analysis 5.1.   Comparison 5 Boswellia serrata 999 mg versus valdecoxib, Outcome 1 WOMAC-VAS (Pain).
Study or subgroup Boswellia serrata Valdecoxib Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Sontakke 2007 27 16.6 (12.5) 31 17.1 (13.8) 100% -0.51[-7.26,6.24]
   
Total *** 27   31   100% -0.51[-7.26,6.24]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.15(P=0.88)  
Favours Boswellia serrata 2010-20 -10 0 Favours valdecoxib
 
 
Analysis 5.2.   Comparison 5 Boswellia serrata 999 mg versus valdecoxib, Outcome 2 WOMAC-VAS (Function).
Study or subgroup Boswellia serrata Valdecoxib Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Sontakke 2007 27 19.1 (12.2) 31 16.6 (13.3) 100% 2.49[-4.07,9.05]
   
Total *** 27   31   100% 2.49[-4.07,9.05]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.74(P=0.46)  
Favours Boswellia serrata 5025-50 -25 0 Favours valdecoxib
 
 
Analysis 5.3.   Comparison 5 Boswellia serrata 999 mg versus
valdecoxib, Outcome 3 Participants (n) reported adverse events.
Study or subgroup Boswellia
serrata
Valdecoxib Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Sontakke 2007 4/33 2/33 100% 2[0.39,10.18]
   
Total (95% CI) 33 33 100% 2[0.39,10.18]
Total events: 4 ( Boswellia serrata), 2 (Valdecoxib)  
Favours Boswellia serrata 1000.01 100.1 1 Favours valdecoxib
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Study or subgroup Boswellia
serrata
Valdecoxib Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.83(P=0.4)  
Favours Boswellia serrata 1000.01 100.1 1 Favours valdecoxib
 
 
Analysis 5.4.   Comparison 5 Boswellia serrata 999 mg versus
valdecoxib, Outcome 4 Participants (n) withdrew due to adverse events.
Study or subgroup Boswellia
serrata
Valdecoxib Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Sontakke 2007 1/33 0/33 100% 3[0.13,71.07]
   
Total (95% CI) 33 33 100% 3[0.13,71.07]
Total events: 1 ( Boswellia serrata), 0 (Valdecoxib)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.68(P=0.5)  
Favours Boswellia 1000.01 100.1 1 Favours valdecoxib
 
 
Comparison 6.   Curcuma domestica versus ibuprofen
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain on walking NRS 0-10 1   Mean Difference (IV, Random, 95% CI) Subtotals only
2 Function: 100m walk time (sec-
onds)
1   Mean Difference (IV, Random, 95% CI) Subtotals only
3 Participants (n) reported adverse
events
1 100 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.46, 1.25]
 
 
Analysis 6.1.   Comparison 6 Curcuma domestica versus ibuprofen, Outcome 1 Pain on walking NRS 0-10.
Study or subgroup Curcuma domestica Ibuprofen Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Kuptniratsaikul 2009 45 2.7 (2.5) 46 3.1 (2.3) 0% -0.4[-1.39,0.59]
Favours Curcuma 2010-20 -10 0 Favours ibuprofen
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Analysis 6.2.   Comparison 6 Curcuma domestica versus ibuprofen, Outcome 2 Function: 100m walk time (seconds).
Study or subgroup Curcuma domestica Ibuprofen Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Kuptniratsaikul 2009 45 96.7 (17) 46 97 (25.7) 0% -0.3[-9.23,8.63]
Favours Curcuma 10050-100 -50 0 Favours ibuprofen
 
 
Analysis 6.3.   Comparison 6 Curcuma domestica versus
ibuprofen, Outcome 3 Participants (n) reported adverse events.
Study or subgroup Curcuma
domestica
Ibuprofen Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kuptniratsaikul 2009 16/48 23/52 100% 0.75[0.46,1.25]
   
Total (95% CI) 48 52 100% 0.75[0.46,1.25]
Total events: 16 ( Curcuma domestica), 23 (Ibuprofen)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.1(P=0.27)  
Favours Curcuma 1000.01 100.1 1 Favours ibuprofen
 
 
Comparison 7.   Derris scandens versus naproxen
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 WOMAC-VAS (Pain) change from
baseline
1 107 Mean Difference (IV, Random, 95% CI) 5.0 [-1.84, 11.84]
2 WOMAC-VAS (Function) change from
baseline
1 107 Mean Difference (IV, Random, 95% CI) 5.10 [-0.13, 10.33]
3 Participants (n) reported adverse
events.
1 125 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.49, 1.15]
 
 
Analysis 7.1.   Comparison 7 Derris scandens versus naproxen, Outcome 1 WOMAC-VAS (Pain) change from baseline.
Study or subgroup Derris scandens Naproxen Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Kuptniratsaikul 2011 55 -17.5 (17) 52 -22.5 (19) 100% 5[-1.84,11.84]
   
Total *** 55   52   100% 5[-1.84,11.84]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.43(P=0.15)  
Favours Derris 10050-100 -50 0 Favours naproxen
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Analysis 7.2.   Comparison 7 Derris scandens versus naproxen,
Outcome 2 WOMAC-VAS (Function) change from baseline.
Study or subgroup Derris scandens Naproxen Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Kuptniratsaikul 2011 55 -8.7 (13.6) 52 -13.8 (14) 100% 5.1[-0.13,10.33]
   
Total *** 55   52   100% 5.1[-0.13,10.33]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.91(P=0.06)  
Favours Derris 10050-100 -50 0 Favours naproxen
 
 
Analysis 7.3.   Comparison 7 Derris scandens versus naproxen, Outcome 3 Participants (n) reported adverse events..
Study or subgroup Derris scandens Naproxen Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kuptniratsaikul 2011 22/63 29/62 100% 0.75[0.49,1.15]
   
Total (95% CI) 63 62 100% 0.75[0.49,1.15]
Total events: 22 ( Derris scandens), 29 (Naproxen)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.33(P=0.18)  
Favours Derris 1000.01 100.1 1 Favours naproxen
 
 
Comparison 8.   Harpagophytum procumbens versus diacerhein
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 change from baseline at
120 days
1 92 Mean Difference (IV, Random, 95% CI) -5.10 [-6.52, -3.68]
2 Participants (n) reported adverse events 1 92 Risk Ratio (M-H, Random, 95% CI) 0.4 [0.21, 0.75]
 
 
Analysis 8.1.   Comparison 8 Harpagophytum procumbens versus
diacerhein, Outcome 1 Pain VAS 0-100 change from baseline at 120 days.
Study or subgroup Harpagophytum
procumbens
Diacerhein Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Leblan 2000 50 -30.6 (3.3) 42 -25.5 (3.6) 100% -5.1[-6.52,-3.68]
   
Total *** 50   42   100% -5.1[-6.52,-3.68]
Heterogeneity: Not applicable  
Test for overall effect: Z=7.03(P<0.0001)  
Favours Harpagophytum 105-10 -5 0 Favours diacerhein
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Analysis 8.2.   Comparison 8 Harpagophytum procumbens versus
diacerhein, Outcome 2 Participants (n) reported adverse events.
Study or subgroup Harpago-
phytum
procumbens
Diacerhein Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Leblan 2000 10/50 21/42 100% 0.4[0.21,0.75]
   
Total (95% CI) 50 42 100% 0.4[0.21,0.75]
Total events: 10 ( Harpagophytum procumbens), 21 (Diacerhein)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.84(P=0)  
Favours Harpagophytum 1000.01 100.1 1 Favours diacerhein
 
 
Comparison 9.   Petiveria alliacea versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain (scale unknown) with mvt change
from baseline
1 40 Mean Difference (IV, Random, 95% CI) -0.10 [-1.31, 1.11]
2 Participants (n) reported adverse events 1 40 Risk Ratio (M-H, Random, 95% CI) 1.5 [0.28, 8.04]
 
 
Analysis 9.1.   Comparison 9 Petiveria alliacea versus placebo,
Outcome 1 Pain (scale unknown) with mvt change from baseline.
Study or subgroup Petiveria alliacea Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Ferraz 1991 20 -2 (1.9) 20 -1.9 (2) 100% -0.1[-1.31,1.11]
   
Total *** 20   20   100% -0.1[-1.31,1.11]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.16(P=0.87)  
Favours Petiveria 105-10 -5 0 Favours placebo
 
 
Analysis 9.2.   Comparison 9 Petiveria alliacea versus placebo, Outcome 2 Participants (n) reported adverse events.
Study or subgroup Petiveria
alliacea
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Ferraz 1991 3/20 2/20 100% 1.5[0.28,8.04]
   
Total (95% CI) 20 20 100% 1.5[0.28,8.04]
Favours Petiveria 1000.01 100.1 1 Favours placebo
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Study or subgroup Petiveria
alliacea
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 3 ( Petiveria alliacea), 2 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.47(P=0.64)  
Favours Petiveria 1000.01 100.1 1 Favours placebo
 
 
Comparison 10.   Pinus pinaster (Pycnogenol® 150 mg) versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 WOMAC-VAS (Pain) 1 37 Mean Difference (IV, Random,
95% CI)
-142.0 [-199.55, -84.45]
2 WOMAC-VAS (Function) 1 37 Mean Difference (IV, Random,
95% CI)
-529.0 [-741.59, -316.41]
3 Participants (n) reported adverse
events
2 137 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.08, 1.97]
 
 
Analysis 10.1.   Comparison 10 Pinus pinaster (Pycnogenol® 150 mg) versus placebo, Outcome 1 WOMAC-VAS (Pain).
Study or subgroup Pycnogenol 150mg Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Farid 2007 19 164 (72) 18 306 (103) 100% -142[-199.55,-84.45]
   
Total *** 19   18   100% -142[-199.55,-84.45]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.84(P<0.0001)  
Favours Pycnogenol 500250-500 -250 0 Favours placebo
 
 
Analysis 10.2.   Comparison 10 Pinus pinaster (Pycnogenol®
150 mg) versus placebo, Outcome 2 WOMAC-VAS (Function).
Study or subgroup Pycnogenol 150mg Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Farid 2007 19 485 (259) 18 1014 (385) 100% -529[-741.59,-316.41]
   
Total *** 19   18   100% -529[-741.59,-316.41]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.88(P<0.0001)  
Favours Pycnogenol 1000500-1000-500 0 Favours placebo
 
 
Oral herbal therapies for treating osteoarthritis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
108
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Analysis 10.3.   Comparison 10 Pinus pinaster (Pycnogenol® 150 mg)
versus placebo, Outcome 3 Participants (n) reported adverse events.
Study or subgroup Pycnogenol
150mg
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Cisar 2008 2/50 5/50 100% 0.4[0.08,1.97]
Farid 2007 0/19 0/18   Not estimable
   
Total (95% CI) 69 68 100% 0.4[0.08,1.97]
Total events: 2 (Pycnogenol 150mg), 5 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.13(P=0.26)  
Favours Pycnogenol 2000.005 100.1 1 Favours placebo
 
 
Comparison 11.   Pinus pinaster (Pycnogenol® 100 mg) versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 WOMAC 0-4 (Pain) 1 156 Mean Difference (IV, Random, 95% CI) -7.50 [-8.43, -6.57]
2 WOMAC 0-4 (Function) 1 156 Mean Difference (IV, Random, 95% CI) -29.3 [-30.99, -27.61]
 
 
Analysis 11.1.   Comparison 11 Pinus pinaster (Pycnogenol® 100 mg) versus placebo, Outcome 1 WOMAC 0-4 (Pain).
Study or subgroup Pycnogenol 100mg Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Belcaro 2008 77 7.7 (2.2) 79 15.2 (3.6) 100% -7.5[-8.43,-6.57]
   
Total *** 77   79   100% -7.5[-8.43,-6.57]
Heterogeneity: Not applicable  
Test for overall effect: Z=15.76(P<0.0001)  
Favours Pycnogenol 5025-50 -25 0 Favours placebo
 
 
Analysis 11.2.   Comparison 11 Pinus pinaster (Pycnogenol®
100 mg) versus placebo, Outcome 2 WOMAC 0-4 (Function).
Study or subgroup Pycnogenol 100mg Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Belcaro 2008 77 23.8 (3.3) 79 53.1 (6.9) 100% -29.3[-30.99,-27.61]
   
Total *** 77   79   100% -29.3[-30.99,-27.61]
Heterogeneity: Not applicable  
Test for overall effect: Z=33.95(P<0.0001)  
Favours Pycnogenol 10050-100 -50 0 Favours placebo
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Comparison 12.   Ricinus o*icinale versus placebo
Outcome or subgroup title No. of
studies
No. of par-
ticipants
Statistical method Effect size
1 Participants (n) reported adverse events 1 100 Risk Ratio (M-H, Random, 95% CI) 0.04 [0.00, 0.66]
 
 
Analysis 12.1.   Comparison 12 Ricinus o*icinale versus placebo, Outcome 1 Participants (n) reported adverse events.
Study or subgroup Favours Ricinus Favours
placebo
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Medhi 2009 0/50 12/50 100% 0.04[0,0.66]
   
Total (95% CI) 50 50 100% 0.04[0,0.66]
Total events: 0 ( Favours Ricinus), 12 (Favours placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.25(P=0.02)  
Favours Ricinus 1000.01 100.1 1 Favours placebo
 
 
Comparison 13.   Rosa canina versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Relief of pain (0 to 4) at 3 months 1 97 Mean Difference (IV, Random, 95%
CI)
0.43 [-0.12, 0.98]
2 WOMAC-VAS (Pain) 1 94 Mean Difference (IV, Random, 95%
CI)
-2.5 [-10.20, 5.20]
3 WOMAC-VAS (Function) 1 94 Mean Difference (IV, Random, 95%
CI)
-1.20 [-8.98, 6.58]
4 Participants (n) reported adverse events 2 194 Risk Ratio (M-H, Random, 95% CI) 1.67 [0.63, 4.43]
 
 
Analysis 13.1.   Comparison 13 Rosa canina versus placebo, Outcome 1 Relief of pain (0 to 4) at 3 months.
Study or subgroup Rosa canina Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Rein 2004a 50 1.5 (1.3) 47 1 (1.5) 100% 0.43[-0.12,0.98]
   
Total *** 50   47   100% 0.43[-0.12,0.98]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.54(P=0.12)  
Favours Rosa canina 105-10 -5 0 Favours placebo
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Analysis 13.2.   Comparison 13 Rosa canina versus placebo, Outcome 2 WOMAC-VAS (Pain).
Study or subgroup Rosa canina Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Winther 2005 47 33.8 (17.6) 47 36.3 (20.4) 100% -2.5[-10.2,5.2]
   
Total *** 47   47   100% -2.5[-10.2,5.2]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.64(P=0.52)  
Favours Rosa canina 10050-100 -50 0 Favours placebo
 
 
Analysis 13.3.   Comparison 13 Rosa canina versus placebo, Outcome 3 WOMAC-VAS (Function).
Study or subgroup Rosa canina Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Winther 2005 47 37 (18.1) 47 38.2 (20.3) 100% -1.2[-8.98,6.58]
   
Total *** 47   47   100% -1.2[-8.98,6.58]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.3(P=0.76)  
Favours Rosa canina 10050-100 -50 0 Favours placebo
 
 
Analysis 13.4.   Comparison 13 Rosa canina versus placebo, Outcome 4 Participants (n) reported adverse events.
Study or subgroup Rosa canina Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Warholm 2003 2/50 2/50 25.72% 1[0.15,6.82]
Winther 2005 8/47 4/47 74.28% 2[0.65,6.19]
   
Total (95% CI) 97 97 100% 1.67[0.63,4.43]
Total events: 10 ( Rosa canina), 6 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.37, df=1(P=0.54); I2=0%  
Test for overall effect: Z=1.04(P=0.3)  
Favours Rosa canina 100.1 50.2 20.5 1 Favours placebo
 
 
Comparison 14.   Salix purpurea x daphnoides versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 at 14 days 1 68 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 Function VAS 0-100 at 14 days 1 68 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3 Participants (n) reported adverse
events
1 84 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.57, 1.43]
 
 
Analysis 14.1.   Comparison 14 Salix purpurea x daphnoides versus placebo, Outcome 1 Pain VAS 0-100 at 14 days.
Study or subgroup Salix purpura Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Schmid 2000 33 33.2 (0) 35 48.2 (0)   Not estimable
   
Total *** 33   35   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours Salix 10050-100 -50 0 Favours placebo
 
 
Analysis 14.2.   Comparison 14 Salix purpurea x daphnoides
versus placebo, Outcome 2 Function VAS 0-100 at 14 days.
Study or subgroup Salix purpura Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Schmid 2000 33 34.2 (0) 35 41.3 (0)   Not estimable
   
Total *** 33   35   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours Salix 10050-100 -50 0 Favours placebo
 
 
Analysis 14.3.   Comparison 14 Salix purpurea x daphnoides versus
placebo, Outcome 3 Participants (n) reported adverse events.
Study or subgroup Salix purpura Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Biegert 2004 19/43 20/41 100% 0.91[0.57,1.43]
   
Total (95% CI) 43 41 100% 0.91[0.57,1.43]
Total events: 19 ( Salix purpura), 20 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.42(P=0.67)  
Favours Salix 1000.01 100.1 1 Favours placebo
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Comparison 15.   Salix purpurea x daphnoides versus diclofenac
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 WOMAC-VAS (Pain) 1   Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 At 14 days 1 86 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 At 42 days 1 86 Mean Difference (IV, Random, 95% CI) 15.0 [5.91, 24.09]
2 WOMAC-VAS (Function) 1   Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 At 14 days 1 86 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 At 42 days 1 86 Mean Difference (IV, Random, 95% CI) 12.0 [2.70, 21.30]
3 Participants (n) reported ad-
verse events
1 86 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.43, 0.93]
 
 
Analysis 15.1.   Comparison 15 Salix purpurea x daphnoides versus diclofenac, Outcome 1 WOMAC-VAS (Pain).
Study or subgroup Salix purpura Diclofenac Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
15.1.1 At 14 days  
Biegert 2004 43 42 (0) 43 26 (0)   Not estimable
Subtotal *** 43   43   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
15.1.2 At 42 days  
Biegert 2004 43 41 (22) 43 26 (21) 100% 15[5.91,24.09]
Subtotal *** 43   43   100% 15[5.91,24.09]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.23(P=0)  
Test for subgroup differences: Not applicable  
Favours Salix 10050-100 -50 0 Favours diclofenac
 
 
Analysis 15.2.   Comparison 15 Salix purpurea x daphnoides versus diclofenac, Outcome 2 WOMAC-VAS (Function).
Study or subgroup Salix purpura Diclofenac Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
15.2.1 At 14 days  
Biegert 2004 43 43 (0) 43 28 (0)   Not estimable
Subtotal *** 43   43   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
15.2.2 At 42 days  
Favours Salix 10050-100 -50 0 Favours diclofenac
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Study or subgroup Salix purpura Diclofenac Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Biegert 2004 43 40 (22) 43 28 (22) 100% 12[2.7,21.3]
Subtotal *** 43   43   100% 12[2.7,21.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.53(P=0.01)  
Test for subgroup differences: Not applicable  
Favours Salix 10050-100 -50 0 Favours diclofenac
 
 
Analysis 15.3.   Comparison 15 Salix purpurea x daphnoides versus
diclofenac, Outcome 3 Participants (n) reported adverse events.
Study or subgroup Salix purpura Diclofenac Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Biegert 2004 19/43 30/43 100% 0.63[0.43,0.93]
   
Total (95% CI) 43 43 100% 0.63[0.43,0.93]
Total events: 19 ( Salix purpura), 30 (Diclofenac)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.3(P=0.02)  
Favours Salix 500.02 100.1 1 Favours diclofenac
 
 
Comparison 16.   Uncaria guianensis versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 (night) 1 45 Mean Difference (IV, Random, 95% CI) -11.10 [-26.44, 4.24]
2 Participants (n) reported adverse
events
1 45 Risk Ratio (M-H, Random, 95% CI) 1.67 [0.54, 5.17]
 
 
Analysis 16.1.   Comparison 16 Uncaria guianensis versus placebo, Outcome 1 Pain VAS 0-100 (night).
Study or subgroup Uncaria guianensis Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Piscoya 2001 30 30.6 (20.3) 15 41.7 (26.7) 100% -11.1[-26.44,4.24]
   
Total *** 30   15   100% -11.1[-26.44,4.24]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.42(P=0.16)  
Favours Uncaria 10050-100 -50 0 Favours placebo
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Analysis 16.2.   Comparison 16 Uncaria guianensis versus
placebo, Outcome 2 Participants (n) reported adverse events.
Study or subgroup Uncaria
guianensis
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Piscoya 2001 10/30 3/15 100% 1.67[0.54,5.17]
   
Total (95% CI) 30 15 100% 1.67[0.54,5.17]
Total events: 10 ( Uncaria guianensis), 3 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.88(P=0.38)  
Favours Uncaria 100.1 50.2 20.5 1 Favours placebo
 
 
Comparison 17.   Zingiber o*icinale (Zintona EC) versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 (movement) 1 24 Mean Difference (IV, Random, 95% CI) -9.0 [-31.12, 13.12]
2 Function (handicap) VAS 0-100 1 24 Mean Difference (IV, Random, 95% CI) -6.0 [-27.25, 15.25]
3 Participants (n) reported ad-
verse events
1 24 Risk Ratio (M-H, Random, 95% CI) 3.5 [0.16, 78.19]
 
 
Analysis 17.1.   Comparison 17 Zingiber o*icinale (Zintona
EC) versus placebo, Outcome 1 Pain VAS 0-100 (movement).
Study or subgroup Zingiber officinale Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Wigler 2003 11 41 (28) 13 50 (27) 100% -9[-31.12,13.12]
   
Total *** 11   13   100% -9[-31.12,13.12]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.8(P=0.43)  
Favours Zingiber 10050-100 -50 0 Favours placebo
 
 
Analysis 17.2.   Comparison 17 Zingiber o*icinale (Zintona EC)
versus placebo, Outcome 2 Function (handicap) VAS 0-100.
Study or subgroup Zingiber officinale Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Wigler 2003 11 40 (26) 13 46 (27) 100% -6[-27.25,15.25]
   
Total *** 11   13   100% -6[-27.25,15.25]
Favours Zingiber 10050-100 -50 0 Favours placebo
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Study or subgroup Zingiber officinale Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.55(P=0.58)  
Favours Zingiber 10050-100 -50 0 Favours placebo
 
 
Analysis 17.3.   Comparison 17 Zingiber o*icinale (Zintona EC) versus
placebo, Outcome 3 Participants (n) reported adverse events.
Study or subgroup Zingiber
officinale
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Wigler 2003 1/11 0/13 100% 3.5[0.16,78.19]
   
Total (95% CI) 11 13 100% 3.5[0.16,78.19]
Total events: 1 ( Zingiber officinale), 0 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.79(P=0.43)  
Favours Zingiber 1000.01 100.1 1 Favours placebo
 
 
Comparison 18.   Boswellia carteri + Curcuma longa versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Function: pain free walking time
(minutes)
1   Mean Difference (IV, Random, 95% CI) Totals not selected
1.1 At 1 month 1   Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 At 2 months 1   Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 At 3 months 1   Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 18.1.   Comparison 18 Boswellia carteri + Curcuma longa
versus placebo, Outcome 1 Function: pain free walking time (minutes).
Study or subgroup Boswellia+Curcuma Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
18.1.1 At 1 month  
Badria 2002 30 11.2 (5.8) 15 8.7 (3) 2.5[-0.07,5.07]
   
18.1.2 At 2 months  
Badria 2002 30 12.7 (6.3) 15 8.7 (3) 4[1.31,6.69]
   
18.1.3 At 3 months  
Favours Boswellia+Curcuma 105-10 -5 0 Favours placebo
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Study or subgroup Boswellia+Curcuma Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Badria 2002 30 13.5 (5.9) 15 10 (3.8) 3.5[0.65,6.35]
Favours Boswellia+Curcuma 105-10 -5 0 Favours placebo
 
 
Comparison 19.   Persea gratissma + Glycine max (ASU 300 mg) versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 4 651 Mean Difference (IV, Random,
95% CI)
-8.47 [-15.90, -1.04]
1.1 At 3 months 2 326 Mean Difference (IV, Random,
95% CI)
-11.90 [-23.95, 0.15]
1.2 At 6 months 1 162 Mean Difference (IV, Random,
95% CI)
-10.40 [-17.20, -3.60]
1.3 At 12 months 1 163 Mean Difference (IV, Random,
95% CI)
1.0 [-6.58, 8.58]
2 Pain VAS 0-100 change from baseline at
36 months
1 345 Mean Difference (IV, Random,
95% CI)
-0.66 [-7.39, 6.07]
3 Pain VAS 0-100 grouped by joint 1 324 Mean Difference (IV, Random,
95% CI)
-9.06 [-15.24, -2.88]
3.1 VAS (hip OA) 1 162 Mean Difference (IV, Random,
95% CI)
-13.80 [-25.22, -2.38]
3.2 VAS (knee OA) 1 162 Mean Difference (IV, Random,
95% CI)
-7.10 [-14.45, 0.25]
4 Function: disability VAS 0-100 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
5 WOMAC-VAS (Function) change from
baseline at 36 months
1 345 Mean Difference (IV, Random,
95% CI)
-1.0 [-7.14, 5.14]
6 Lequesne algofunctional index 3 480 Mean Difference (IV, Random,
95% CI)
-1.17 [-2.54, 0.20]
6.1 At 3 months 2 317 Mean Difference (IV, Random,
95% CI)
-1.80 [-2.68, -0.92]
6.2 At 12 months 1 163 Mean Difference (IV, Random,
95% CI)
0.10 [-0.78, 0.98]
7 Function (various tools) 4 642 Std. Mean Difference (IV, Ran-
dom, 95% CI)
-0.42 [-0.73, -0.11]
8 Participants (n) reported adverse events 5 1050 Risk Ratio (M-H, Random, 95%
CI)
1.04 [0.97, 1.12]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
9 Participants (n) withdrew due to ad-
verse events
1 398 Risk Ratio (M-H, Random, 95%
CI)
1.14 [0.73, 1.80]
10 Particpants (n) reported serious ad-
verse events
1 398 Risk Ratio (M-H, Random, 95%
CI)
1.22 [0.94, 1.59]
11 JSW change from baseline 2 453 Mean Difference (IV, Random,
95% CI)
-0.12 [-0.43, 0.19]
11.1 < median group, at 24 months 1 55 Mean Difference (IV, Random,
95% CI)
-0.43 [-0.73, -0.13]
11.2 > median group, at 24 months 1 53 Mean Difference (IV, Random,
95% CI)
0.16 [-0.31, 0.63]
11.3 At 36 months 1 345 Mean Difference (IV, Random,
95% CI)
-0.03 [-0.22, 0.16]
 
 
Analysis 19.1.   Comparison 19 Persea gratissma + Glycine
max (ASU 300 mg) versus placebo, Outcome 1 Pain VAS 0-100.
Study or subgroup ASU 300mg Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
19.1.1 At 3 months  
Appelboom 2001 85 24.2 (21.2) 78 42.4 (21.4) 25.04% -18.2[-24.75,-11.65]
Blotman 1997 80 37.3 (17.6) 83 43.2 (17) 26.82% -5.9[-11.22,-0.58]
Subtotal *** 165   161   51.85% -11.9[-23.95,0.15]
Heterogeneity: Tau2=66.39; Chi2=8.17, df=1(P=0); I2=87.76%  
Test for overall effect: Z=1.93(P=0.05)  
   
19.1.2 At 6 months  
Maheu 1998 84 35.3 (21.1) 78 45.7 (23) 24.66% -10.4[-17.2,-3.6]
Subtotal *** 84   78   24.66% -10.4[-17.2,-3.6]
Heterogeneity: Not applicable  
Test for overall effect: Z=3(P=0)  
   
19.1.3 At 12 months  
Lequesne 2002 85 31.8 (22.2) 78 30.8 (26.7) 23.49% 1[-6.58,8.58]
Subtotal *** 85   78   23.49% 1[-6.58,8.58]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.26(P=0.8)  
   
Total *** 334   317   100% -8.47[-15.9,-1.04]
Heterogeneity: Tau2=46.2; Chi2=15.69, df=3(P=0); I2=80.88%  
Test for overall effect: Z=2.23(P=0.03)  
Test for subgroup differences: Chi2=5.79, df=1 (P=0.06), I2=65.47%  
Favours ASU 300mg 2010-20 -10 0 Favours placebo
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Analysis 19.2.   Comparison 19 Persea gratissma + Glycine max (ASU 300 mg)
versus placebo, Outcome 2 Pain VAS 0-100 change from baseline at 36 months.
Study or subgroup ASU 300mg Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Maheu 2013 166 -4.3 (32.3) 179 -3.6 (31.4) 100% -0.66[-7.39,6.07]
   
Total *** 166   179   100% -0.66[-7.39,6.07]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.19(P=0.85)  
Favours ASU 300mg 10050-100 -50 0 Favours placebo
 
 
Analysis 19.3.   Comparison 19 Persea gratissma + Glycine max (ASU
300 mg) versus placebo, Outcome 3 Pain VAS 0-100 grouped by joint.
Study or subgroup ASU 300mg Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
19.3.1 VAS (hip OA)  
Maheu 1998 84 37.5 (33.9) 78 51.3 (39.7) 29.28% -13.8[-25.22,-2.38]
Subtotal *** 84   78   29.28% -13.8[-25.22,-2.38]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.37(P=0.02)  
   
19.3.2 VAS (knee OA)  
Maheu 1998 84 33 (24.8) 78 40.1 (23) 70.72% -7.1[-14.45,0.25]
Subtotal *** 84   78   70.72% -7.1[-14.45,0.25]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.89(P=0.06)  
   
Total *** 168   156   100% -9.06[-15.24,-2.88]
Heterogeneity: Tau2=0; Chi2=0.94, df=1(P=0.33); I2=0%  
Test for overall effect: Z=2.87(P=0)  
Test for subgroup differences: Chi2=0.94, df=1 (P=0.33), I2=0%  
Favours ASU 300mg 2010-20 -10 0 Favours placebo
 
 
Analysis 19.4.   Comparison 19 Persea gratissma + Glycine max (ASU
300 mg) versus placebo, Outcome 4 Function: disability VAS 0-100.
Study or subgroup ASU 300mg Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Maheu 1998 84 33.9 (21.1) 78 47.1 (23) -13.2[-20,-6.4]
Favours ASU 300mg 2010-20 -10 0 Favours placebo
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Analysis 19.5.   Comparison 19 Persea gratissma + Glycine max (ASU 300 mg) versus
placebo, Outcome 5 WOMAC-VAS (Function) change from baseline at 36 months.
Study or subgroup ASU 300mg Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Maheu 2013 166 1 (30) 179 2 (28) 100% -1[-7.14,5.14]
   
Total *** 166   179   100% -1[-7.14,5.14]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.32(P=0.75)  
Favours ASU 300mg 10050-100 -50 0 Favours placebo
 
 
Analysis 19.6.   Comparison 19 Persea gratissma + Glycine max (ASU
300 mg) versus placebo, Outcome 6 Lequesne algofunctional index.
Study or subgroup ASU 300mg Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
19.6.1 At 3 months  
Appelboom 2001 76 5.5 (3.6) 78 7.8 (3.4) 31.8% -2.3[-3.41,-1.19]
Blotman 1997 80 6.3 (2.8) 83 7.7 (3.3) 33.76% -1.4[-2.34,-0.46]
Subtotal *** 156   161   65.56% -1.8[-2.68,-0.92]
Heterogeneity: Tau2=0.13; Chi2=1.48, df=1(P=0.22); I2=32.35%  
Test for overall effect: Z=4.03(P<0.0001)  
   
19.6.2 At 12 months  
Lequesne 2002 85 9.5 (3.2) 78 9.4 (2.5) 34.44% 0.1[-0.78,0.98]
Subtotal *** 85   78   34.44% 0.1[-0.78,0.98]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.22(P=0.82)  
   
Total *** 241   239   100% -1.17[-2.54,0.2]
Heterogeneity: Tau2=1.22; Chi2=12.02, df=2(P=0); I2=83.37%  
Test for overall effect: Z=1.67(P=0.1)  
Test for subgroup differences: Chi2=9.01, df=1 (P=0), I2=88.91%  
Favours ASU 300mg 52.5-5 -2.5 0 Favours placebo
 
 
Analysis 19.7.   Comparison 19 Persea gratissma + Glycine max
(ASU 300 mg) versus placebo, Outcome 7 Function (various tools).
Study or subgroup ASU 300mg Placebo Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Appelboom 2001 76 5.5 (3.6) 78 7.8 (3.4) 24.59% -0.65[-0.98,-0.33]
Blotman 1997 80 6.3 (2.8) 83 7.7 (3.3) 25.14% -0.45[-0.77,-0.14]
Lequesne 2002 85 9.5 (3.2) 78 9.4 (2.5) 25.29% 0.03[-0.27,0.34]
Maheu 1998 84 33.9 (21.1) 78 47.1 (23) 24.97% -0.6[-0.91,-0.28]
   
Total *** 325   317   100% -0.42[-0.73,-0.11]
Heterogeneity: Tau2=0.07; Chi2=11.64, df=3(P=0.01); I2=74.22%  
Test for overall effect: Z=2.63(P=0.01)  
Favours ASU 300mg 21-2 -1 0 Favours placebo
Oral herbal therapies for treating osteoarthritis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
120
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
 
Analysis 19.8.   Comparison 19 Persea gratissma + Glycine max (ASU 300
mg) versus placebo, Outcome 8 Participants (n) reported adverse events.
Study or subgroup ASU 300mg Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Appelboom 2001 28/86 23/88 2.39% 1.25[0.78,1.98]
Blotman 1997 9/77 10/76 0.73% 0.89[0.38,2.06]
Lequesne 2002 39/85 39/78 5.03% 0.92[0.67,1.26]
Maheu 1998 23/84 20/78 1.95% 1.07[0.64,1.79]
Maheu 2013 168/189 178/209 89.9% 1.04[0.97,1.13]
   
Total (95% CI) 521 529 100% 1.04[0.97,1.12]
Total events: 267 (ASU 300mg), 270 (Placebo)  
Heterogeneity: Tau2=0; Chi2=1.33, df=4(P=0.86); I2=0%  
Test for overall effect: Z=1.09(P=0.28)  
Favours ASU 300mg 100.1 50.2 20.5 1 Favours placebo
 
 
Analysis 19.9.   Comparison 19 Persea gratissma + Glycine max (ASU 300 mg)
versus placebo, Outcome 9 Participants (n) withdrew due to adverse events.
Study or subgroup ASU 300mg Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Maheu 2013 32/189 31/209 100% 1.14[0.73,1.8]
   
Total (95% CI) 189 209 100% 1.14[0.73,1.8]
Total events: 32 (ASU 300mg), 31 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.57(P=0.57)  
Favours ASU 300mg 1000.01 100.1 1 Favours placebo
 
 
Analysis 19.10.   Comparison 19 Persea gratissma + Glycine max (ASU 300 mg)
versus placebo, Outcome 10 Particpants (n) reported serious adverse events.
Study or subgroup ASU 300mg Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Maheu 2013 75/189 68/209 100% 1.22[0.94,1.59]
   
Total (95% CI) 189 209 100% 1.22[0.94,1.59]
Total events: 75 (ASU 300mg), 68 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.48(P=0.14)  
Favours ASU 300 1000.01 100.1 1 Favours placebo
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Analysis 19.11.   Comparison 19 Persea gratissma + Glycine max (ASU
300 mg) versus placebo, Outcome 11 JSW change from baseline.
Study or subgroup ASU 300mg Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
19.11.1 < median group, at 24 months  
Lequesne 2002 30 0.4 (0.5) 25 0.9 (0.6) 34.1% -0.43[-0.73,-0.13]
Subtotal *** 30   25   34.1% -0.43[-0.73,-0.13]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.77(P=0.01)  
   
19.11.2 > median group, at 24 months  
Lequesne 2002 25 0.5 (0.9) 28 0.4 (0.9) 23.19% 0.16[-0.31,0.63]
Subtotal *** 25   28   23.19% 0.16[-0.31,0.63]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
   
19.11.3 At 36 months  
Maheu 2013 166 0.6 (0.9) 179 0.7 (0.9) 42.71% -0.03[-0.22,0.16]
Subtotal *** 166   179   42.71% -0.03[-0.22,0.16]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.31(P=0.75)  
   
Total *** 221   232   100% -0.12[-0.43,0.19]
Heterogeneity: Tau2=0.05; Chi2=6.2, df=2(P=0.05); I2=67.72%  
Test for overall effect: Z=0.77(P=0.44)  
Test for subgroup differences: Chi2=6.2, df=1 (P=0.05), I2=67.72%  
Favours ASU 300mg 21-2 -1 0 Favours placebo
 
 
Comparison 20.   Persea gratissma + Glycine max (ASU 600 mg) versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 1 156 Mean Difference (IV, Random,
95% CI)
-14.2 [-20.82, -7.58]
2 Lequesne algofunctional index 1 156 Mean Difference (IV, Random,
95% CI)
-1.30 [-2.38, -0.22]
3 Participants (n) reported adverse events 1 174 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.66, 1.74]
 
 
Analysis 20.1.   Comparison 20 Persea gratissma + Glycine
max (ASU 600 mg) versus placebo, Outcome 1 Pain VAS 0-100.
Study or subgroup ASU 600mg Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Appelboom 2001 78 28.2 (20.8) 78 42.4 (21.4) 100% -14.2[-20.82,-7.58]
   
Favours ASU 600mg 10050-100 -50 0 Favours placebo
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Study or subgroup ASU 600mg Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Total *** 78   78   100% -14.2[-20.82,-7.58]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.2(P<0.0001)  
Favours ASU 600mg 10050-100 -50 0 Favours placebo
 
 
Analysis 20.2.   Comparison 20 Persea gratissma + Glycine max (ASU
600 mg) versus placebo, Outcome 2 Lequesne algofunctional index.
Study or subgroup ASU 600mg Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Appelboom 2001 78 6.5 (3.5) 78 7.8 (3.4) 100% -1.3[-2.38,-0.22]
   
Total *** 78   78   100% -1.3[-2.38,-0.22]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.35(P=0.02)  
Favours ASU 600mg 105-10 -5 0 Favours placebo
 
 
Analysis 20.3.   Comparison 20 Persea gratissma + Glycine max (ASU 600
mg) versus placebo, Outcome 3 Participants (n) reported adverse events.
Study or subgroup ASU 600mg Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Appelboom 2001 24/86 23/88 100% 1.07[0.66,1.74]
   
Total (95% CI) 86 88 100% 1.07[0.66,1.74]
Total events: 24 (ASU 600mg), 23 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.26(P=0.79)  
Favours ASU 600mg 100.1 50.2 20.5 1 Favours placebo
 
 
Comparison 21.   Persea gratissma + Glycine max (ASU 300 mg) versus chondroitin sulphate
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 WOMAC-VAS (Pain) 1   Mean Difference (IV, Random, 95% CI) Totals not selected
2 WOMAC-VAS (Function) 1   Mean Difference (IV, Random, 95% CI) Totals not selected
3 Participants (n) reported ad-
verse events
1 357 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.59, 1.26]
4 Paricipants (n) reported seri-
ous adverse events
1 357 Risk Ratio (M-H, Random, 95% CI) 2.92 [0.31, 27.78]
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Analysis 21.1.   Comparison 21 Persea gratissma + Glycine max (ASU
300 mg) versus chondroitin sulphate, Outcome 1 WOMAC-VAS (Pain).
Study or subgroup ASU 300mg Chondroitin sulphate Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Pavelka 2010 181 24.3 (19.5) 176 22.9 (20) 1.41[-2.68,5.5]
Favours ASU 300mg 105-10 -5 0 Favours chondroitin
 
 
Analysis 21.2.   Comparison 21 Persea gratissma + Glycine max (ASU 300
mg) versus chondroitin sulphate, Outcome 2 WOMAC-VAS (Function).
Study or subgroup ASU 300mg Chondroitin sulphate Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Pavelka 2010 181 26.8 (19.8) 176 25.1 (20.1) 1.63[-2.51,5.77]
Favours ASU 300mg 105-10 -5 0 Favours chondroitin
 
 
Analysis 21.3.   Comparison 21 Persea gratissma + Glycine max (ASU 300 mg)
versus chondroitin sulphate, Outcome 3 Participants (n) reported adverse events.
Study or subgroup ASU 300mg Chondroitin
sulphate
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pavelka 2010 38/181 43/176 100% 0.86[0.59,1.26]
   
Total (95% CI) 181 176 100% 0.86[0.59,1.26]
Total events: 38 (ASU 300mg), 43 (Chondroitin sulphate)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.77(P=0.44)  
Favours ASU 300mg 1000.01 100.1 1 Favours chondroitin
 
 
Analysis 21.4.   Comparison 21 Persea gratissma + Glycine max (ASU 300 mg) versus
chondroitin sulphate, Outcome 4 Paricipants (n) reported serious adverse events.
Study or subgroup ASU 300mg Chondroitin
sulphate
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pavelka 2010 3/181 1/176 100% 2.92[0.31,27.78]
   
Total (95% CI) 181 176 100% 2.92[0.31,27.78]
Total events: 3 (ASU 300mg), 1 (Chondroitin sulphate)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.93(P=0.35)  
Favours ASU 300 1000.01 100.1 1 Favours chondroitin
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Comparison 22.   Phellondendron amurense + Citrus sinensis (NP 06-1) versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Lequesne algofunctional index 1 45 Mean Difference (IV, Random, 95%
CI)
-3.82 [-7.05, -0.59]
1.1 Normal BMI participants 1 18 Mean Difference (IV, Random, 95%
CI)
-2.2 [-3.37, -1.03]
1.2 Overweight BMI participants 1 27 Mean Difference (IV, Random, 95%
CI)
-5.50 [-6.95, -4.05]
 
 
Analysis 22.1.   Comparison 22 Phellondendron amurense + Citrus sinensis
(NP 06-1) versus placebo, Outcome 1 Lequesne algofunctional index.
Study or subgroup Phellonden-
dron+Citrus
Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
22.1.1 Normal BMI participants  
Oben 2009 7 7.7 (1.4) 11 9.9 (0.9) 50.91% -2.2[-3.37,-1.03]
Subtotal *** 7   11   50.91% -2.2[-3.37,-1.03]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.7(P=0)  
   
22.1.2 Overweight BMI participants  
Oben 2009 14 6.3 (2.3) 13 11.8 (1.5) 49.09% -5.5[-6.95,-4.05]
Subtotal *** 14   13   49.09% -5.5[-6.95,-4.05]
Heterogeneity: Not applicable  
Test for overall effect: Z=7.41(P<0.0001)  
   
Total *** 21   24   100% -3.82[-7.05,-0.59]
Heterogeneity: Tau2=4.99; Chi2=12.04, df=1(P=0); I2=91.69%  
Test for overall effect: Z=2.32(P=0.02)  
Test for subgroup differences: Chi2=12.04, df=1 (P=0), I2=91.69%  
Favours Phellondendron+Citrus 10050-100 -50 0 Favours placebo
 
 
Comparison 23.   Uncaria guianensis + Lepidium meyenii versus glucosamine sulphate
Outcome or subgroup title No. of
studies
No. of par-
ticipants
Statistical method Effect size
1 Participants (n) reported adverse events 1 95 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.18, 3.24]
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Analysis 23.1.   Comparison 23 Uncaria guianensis + Lepidium meyenii versus
glucosamine sulphate, Outcome 1 Participants (n) reported adverse events.
Study or subgroup Uncaria+Le-
pidium
Glucosamine
sulphate
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Mehta 2007 3/47 4/48 100% 0.77[0.18,3.24]
   
Total (95% CI) 47 48 100% 0.77[0.18,3.24]
Total events: 3 ( Uncaria+Lepidium), 4 (Glucosamine sulphate)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.36(P=0.72)  
Favours Uncaria+Lepidium 1000.01 100.1 1 Favours glucosamine
 
 
Comparison 24.   Zingiber o*icinale + Alpinia galanga (EV.EXT77) versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain immediately after walking
50 feet VAS 0-100
1 247 Mean Difference (IV, Random, 95% CI) -9.60 [-16.81, -2.39]
2 WOMAC-VAS (Function) 1   Mean Difference (IV, Random, 95% CI) Totals not selected
3 Participants (n) reported adverse
events
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 24.1.   Comparison 24 Zingiber o*icinale + Alpinia galanga (EV.EXT77)
versus placebo, Outcome 1 Pain immediately aTer walking 50 feet VAS 0-100.
Study or subgroup EV.EXT 77 Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Altman 2001 124 34.6 (29.5) 123 44.2 (28.3) 100% -9.6[-16.81,-2.39]
   
Total *** 124   123   100% -9.6[-16.81,-2.39]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.61(P=0.01)  
Favours EV.EXT 77 10050-100 -50 0 Fvours placebo
 
 
Analysis 24.2.   Comparison 24 Zingiber o*icinale + Alpinia galanga
(EV.EXT77) versus placebo, Outcome 2 WOMAC-VAS (Function).
Study or subgroup EV.EXT 77 Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Altman 2001 124 37.7 (25.3) 123 43.4 (23.7) -5.7[-11.81,0.41]
Favours EV.EXT 77 10050-100 -50 0 Fvours placebo
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Analysis 24.3.   Comparison 24 Zingiber o*icinale + Alpinia galanga (EV.EXT77)
versus placebo, Outcome 3 Participants (n) reported adverse events.
Study or subgroup EV.EXT 77 Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Altman 2001 76/124 49/123 1.54[1.19,1.99]
Favours EV.EXT 77 100.1 50.2 20.5 1 Fvours placebo
 
 
Comparison 25.   SKI306X versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 change from base-
line
1   Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Low dose (600mg) SKI306X 1 47 Mean Difference (IV, Random, 95% CI) -16.1 [-25.19, -7.01]
1.2 Medium dose (1200mg) SKI306X 1 46 Mean Difference (IV, Random, 95% CI) -14.5 [-23.04, -5.96]
1.3 High dose (1800mg) SKI306X 1 46 Mean Difference (IV, Random, 95% CI) -22.3 [-31.82, -12.78]
2 Lequesne algofunctional index
change from baseline
1 139 Mean Difference (IV, Random, 95% CI) -2.73 [-3.71, -1.74]
2.1 Low dose (600mg) SKI306X 1 47 Mean Difference (IV, Random, 95% CI) -2.40 [-4.05, -0.75]
2.2 Medium dose (1200mg) SKI306X 1 46 Mean Difference (IV, Random, 95% CI) -2.8 [-4.62, -0.98]
2.3 High dose (1800mg) SKI306X 1 46 Mean Difference (IV, Random, 95% CI) -3.0 [-4.68, -1.32]
3 Participants (n) reported adverse
events
2 139 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.49, 1.79]
3.1 Low dose (600mg) SKI306X 1 47 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.32, 2.88]
3.2 Medium dose (1200mg) SKI306X 1 46 Risk Ratio (M-H, Random, 95% CI) 1.2 [0.43, 3.38]
3.3 High dose (1800mmg) SKI306X 1 46 Risk Ratio (M-H, Random, 95% CI) 0.6 [0.16, 2.22]
 
 
Analysis 25.1.   Comparison 25 SKI306X versus placebo, Outcome 1 Pain VAS 0-100 change from baseline.
Study or subgroup SKI306X Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
25.1.1 Low dose (600mg) SKI306X  
Jung 2001 24 -23.6 (16.3) 23 -7.5 (15.5) 100% -16.1[-25.19,-7.01]
Subtotal *** 24   23   100% -16.1[-25.19,-7.01]
Heterogeneity: Not applicable  
Favours SKI306X 4020-40 -20 0 Favours placebo
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Study or subgroup SKI306X Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=3.47(P=0)  
   
25.1.2 Medium dose (1200mg) SKI306X  
Jung 2001 23 -22 (14) 23 -7.5 (15.5) 100% -14.5[-23.04,-5.96]
Subtotal *** 23   23   100% -14.5[-23.04,-5.96]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.33(P=0)  
   
25.1.3 High dose (1800mg) SKI306X  
Jung 2001 23 -29.8 (17.4) 23 -7.5 (15.5) 100% -22.3[-31.82,-12.78]
Subtotal *** 23   23   100% -22.3[-31.82,-12.78]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.59(P<0.0001)  
Favours SKI306X 4020-40 -20 0 Favours placebo
 
 
Analysis 25.2.   Comparison 25 SKI306X versus placebo, Outcome
2 Lequesne algofunctional index change from baseline.
Study or subgroup SKI306X Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
25.2.1 Low dose (600mg) SKI306X  
Jung 2001 24 -3.7 (3.4) 23 -1.3 (2.3) 35.7% -2.4[-4.05,-0.75]
Subtotal *** 24   23   35.7% -2.4[-4.05,-0.75]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.84(P=0)  
   
25.2.2 Medium dose (1200mg) SKI306X  
Jung 2001 23 -4.1 (3.8) 23 -1.3 (2.3) 29.62% -2.8[-4.62,-0.98]
Subtotal *** 23   23   29.62% -2.8[-4.62,-0.98]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.02(P=0)  
   
25.2.3 High dose (1800mg) SKI306X  
Jung 2001 23 -4.3 (3.4) 23 -1.3 (2.3) 34.68% -3[-4.68,-1.32]
Subtotal *** 23   23   34.68% -3[-4.68,-1.32]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.5(P=0)  
   
Total *** 70   69   100% -2.73[-3.71,-1.74]
Heterogeneity: Tau2=0; Chi2=0.26, df=2(P=0.88); I2=0%  
Test for overall effect: Z=5.41(P<0.0001)  
Test for subgroup differences: Chi2=0.26, df=1 (P=0.88), I2=0%  
Favours SKI306X 105-10 -5 0 Favours placebo
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Analysis 25.3.   Comparison 25 SKI306X versus placebo, Outcome 3 Participants (n) reported adverse events.
Study or subgroup SKI306X Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
25.3.1 Low dose (600mg) SKI306X  
Jung 2004 5/24 5/23 35.32% 0.96[0.32,2.88]
Subtotal (95% CI) 24 23 35.32% 0.96[0.32,2.88]
Total events: 5 (SKI306X), 5 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.08(P=0.94)  
   
25.3.2 Medium dose (1200mg) SKI306X  
Jung 2001 6/23 5/23 39.76% 1.2[0.43,3.38]
Subtotal (95% CI) 23 23 39.76% 1.2[0.43,3.38]
Total events: 6 (SKI306X), 5 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.34(P=0.73)  
   
25.3.3 High dose (1800mmg) SKI306X  
Jung 2001 3/23 5/23 24.92% 0.6[0.16,2.22]
Subtotal (95% CI) 23 23 24.92% 0.6[0.16,2.22]
Total events: 3 (SKI306X), 5 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.76(P=0.44)  
   
Total (95% CI) 70 69 100% 0.93[0.49,1.79]
Total events: 14 (SKI306X), 15 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.67, df=2(P=0.72); I2=0%  
Test for overall effect: Z=0.21(P=0.83)  
Test for subgroup differences: Chi2=0.67, df=1 (P=0.72), I2=0%  
Favours SKI306X 500.02 100.1 1 Favours placebo
 
 
Comparison 26.   SKI306X (600 mg) versus diclofenac
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 change from baseline 1 249 Mean Difference (IV, Random, 95% CI) 1.31 [-2.78, 5.40]
2 Lequesne algofunctional index change
from baseline
1 249 Mean Difference (IV, Random, 95% CI) 0.77 [0.10, 1.44]
3 Participants (n) reported adverse
events
1 249 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.38, 0.97]
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Analysis 26.1.   Comparison 26 SKI306X (600 mg) versus diclofenac, Outcome 1 Pain VAS 0-100 change from baseline.
Study or subgroup SKI306X Diclofenac Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Jung 2004 125 -14.2 (17.5) 124 -15.5 (15.4) 100% 1.31[-2.78,5.4]
   
Total *** 125   124   100% 1.31[-2.78,5.4]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.63(P=0.53)  
Favours SKI306X 4020-40 -20 0 Favours diclofenac
 
 
Analysis 26.2.   Comparison 26 SKI306X (600 mg) versus diclofenac,
Outcome 2 Lequesne algofunctional index change from baseline.
Study or subgroup SKI306X Diclofenac Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Jung 2004 125 -1.9 (2.8) 124 -2.7 (2.6) 100% 0.77[0.1,1.44]
   
Total *** 125   124   100% 0.77[0.1,1.44]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.25(P=0.02)  
Favours SKI306X 42-4 -2 0 Favours diclofenac
 
 
Analysis 26.3.   Comparison 26 SKI306X (600 mg) versus
diclofenac, Outcome 3 Participants (n) reported adverse events.
Study or subgroup SKI306X Diclofenac Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Jung 2004 22/125 36/124 100% 0.61[0.38,0.97]
   
Total (95% CI) 125 124 100% 0.61[0.38,0.97]
Total events: 22 (SKI306X), 36 (Diclofenac)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.09(P=0.04)  
Favours SKI306X 100.1 50.2 20.5 1 Favours diclofenac
 
 
Comparison 27.   Phytodolor N versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Enduring pain (0 to 3) 1 72 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 Function: mobility limitations (0 to
3)
1 72 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3 Participants (n) reported adverse
events
3 140 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 7.92]
 
 
Analysis 27.1.   Comparison 27 Phytodolor N versus placebo, Outcome 1 Enduring pain (0 to 3).
Study or subgroup Phytodolor N Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bernhardt 1991 36 0.1 (0) 36 0.5 (0)   Not estimable
   
Total *** 36   36   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours Phytodolor N 42-4 -2 0 Favours placebo
 
 
Analysis 27.2.   Comparison 27 Phytodolor N versus placebo, Outcome 2 Function: mobility limitations (0 to 3).
Study or subgroup Phytodolor N Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Bernhardt 1991 36 0.8 (0) 36 1.2 (0)   Not estimable
   
Total *** 36   36   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours Phytodolor N 42-4 -2 0 Favours placebo
 
 
Analysis 27.3.   Comparison 27 Phytodolor N versus placebo, Outcome 3 Participants (n) reported adverse events.
Study or subgroup Phytodolor N Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bernhardt 1991 0/36 1/36 100% 0.33[0.01,7.92]
Huber 1991 0/18 0/20   Not estimable
Schadler 1988 0/15 0/15   Not estimable
   
Total (95% CI) 69 71 100% 0.33[0.01,7.92]
Total events: 0 (Phytodolor N), 1 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.68(P=0.5)  
Favours Phytodolor N 2000.005 100.1 1 Favours placebo
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Comparison 28.   Reumalex versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 AIMS2 arthritis pain score change from
baseline
1 52 Mean Difference (IV, Random, 95% CI) -0.89 [-1.73, -0.05]
2 Participants (n) reported adverse events 1 52 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.40, 2.91]
 
 
Analysis 28.1.   Comparison 28 Reumalex versus placebo,
Outcome 1 AIMS2 arthritis pain score change from baseline.
Study or subgroup Reumalex placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Mills 1996 25 -0.8 (1.7) 27 0.1 (1.4) 100% -0.89[-1.73,-0.05]
   
Total *** 25   27   100% -0.89[-1.73,-0.05]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.08(P=0.04)  
Favours Reumalex 105-10 -5 0 Favours placebo
 
 
Analysis 28.2.   Comparison 28 Reumalex versus placebo, Outcome 2 Participants (n) reported adverse events.
Study or subgroup Reumalex placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Mills 1996 6/25 6/27 100% 1.08[0.4,2.91]
   
Total (95% CI) 25 27 100% 1.08[0.4,2.91]
Total events: 6 (Reumalex), 6 (placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.15(P=0.88)  
Favours Reumalex 1000.01 100.1 1 Favours placebo
 
 
Comparison 29.   Chinese DJW versus diclofenac
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 (total) 1 200 Mean Difference (IV, Random, 95% CI) 11.81 [-9.67, 33.29]
2 Lequesne algofunctional index 1 200 Mean Difference (IV, Random, 95% CI) 0.28 [-0.89, 1.45]
3 Participants (n) reported adverse
events
1 200 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.66, 1.63]
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Analysis 29.1.   Comparison 29 Chinese DJW versus diclofenac, Outcome 1 Pain VAS 0-100 (total).
Study or subgroup DJW Diclofenac Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Teekachunhatean 2004 100 70 (83.9) 100 58.2 (70.4) 100% 11.81[-9.67,33.29]
   
Total *** 100   100   100% 11.81[-9.67,33.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.08(P=0.28)  
Favours DJW 10050-100 -50 0 Favours diclofenac
 
 
Analysis 29.2.   Comparison 29 Chinese DJW versus diclofenac, Outcome 2 Lequesne algofunctional index.
Study or subgroup DJW Diclofenac Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Teekachunhatean 2004 100 8.9 (4.6) 100 8.6 (3.8) 100% 0.28[-0.89,1.45]
   
Total *** 100   100   100% 0.28[-0.89,1.45]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.47(P=0.64)  
Favours DJW 10050-100 -50 0 Favours diclofenac
 
 
Analysis 29.3.   Comparison 29 Chinese DJW versus diclofenac, Outcome 3 Participants (n) reported adverse events.
Study or subgroup DJW Diclofenac Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Teekachunhatean 2004 28/100 27/100 100% 1.04[0.66,1.63]
   
Total (95% CI) 100 100 100% 1.04[0.66,1.63]
Total events: 28 (DJW), 27 (Diclofenac)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.16(P=0.87)  
Favours DJW 1000.01 100.1 1 Favours diclofenac
 
 
Comparison 30.   Chinese BNHS versus Chinese active control
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 (walking) 1 60 Mean Difference (IV, Random, 95%
CI)
2.0 [-7.12, 11.12]
2 WOMAC-VAS (Function) 1 60 Mean Difference (IV, Random, 95%
CI)
-2.0 [-7.57, 3.57]
3 Participants (n) reported adverse events 1 60 Risk Ratio (M-H, Random, 95% CI) 9.00 [0.51, 160.17]
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Analysis 30.1.   Comparison 30 Chinese BNHS versus Chinese active control, Outcome 1 Pain VAS 0-100 (walking).
Study or subgroup BNHS Chinese control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Cao 2005 30 15 (19) 30 13 (17) 100% 2[-7.12,11.12]
   
Total *** 30   30   100% 2[-7.12,11.12]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.43(P=0.67)  
Favours BNHS 10050-100 -50 0 Favours Chinese control
 
 
Analysis 30.2.   Comparison 30 Chinese BNHS versus Chinese active control, Outcome 2 WOMAC-VAS (Function).
Study or subgroup BNHS Chinese control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Cao 2005 30 11 (11) 30 13 (11) 100% -2[-7.57,3.57]
   
Total *** 30   30   100% -2[-7.57,3.57]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.7(P=0.48)  
Favours BNHS 10050-100 -50 0 Favours Chinese control
 
 
Analysis 30.3.   Comparison 30 Chinese BNHS versus Chinese active
control, Outcome 3 Participants (n) reported adverse events.
Study or subgroup BNHS Chinese control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Cao 2005 4/30 0/30 100% 9[0.51,160.17]
   
Total (95% CI) 30 30 100% 9[0.51,160.17]
Total events: 4 (BNHS), 0 (Chinese control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.5(P=0.13)  
Favours BNHS 1000.01 100.1 1 Favours Chinese control
 
 
Comparison 31.   Chinese BNHS versus glucosamine sulphate
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 (walking) 1 60 Mean Difference (IV, Random, 95%
CI)
-2.0 [-6.81, 2.81]
2 WOMAC-VAS (Function) 1 60 Mean Difference (IV, Random, 95%
CI)
0.0 [-2.53, 2.53]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3 Participants (n) reported adverse events 1 60 Risk Ratio (M-H, Random, 95% CI) 9.00 [0.51, 160.17]
 
 
Analysis 31.1.   Comparison 31 Chinese BNHS versus glucosamine sulphate, Outcome 1 Pain VAS 0-100 (walking).
Study or subgroup BNHS Glucosamine
sulphate
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Cao 2005 30 18 (9) 30 20 (10) 100% -2[-6.81,2.81]
   
Total *** 30   30   100% -2[-6.81,2.81]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.81(P=0.42)  
Favours BNHS 10050-100 -50 0 Favours glucosamine
 
 
Analysis 31.2.   Comparison 31 Chinese BNHS versus glucosamine sulphate, Outcome 2 WOMAC-VAS (Function).
Study or subgroup BNHS Glucosamine
sulphate
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Cao 2005 30 12 (5) 30 12 (5) 100% 0[-2.53,2.53]
   
Total *** 30   30   100% 0[-2.53,2.53]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours BNHS 10050-100 -50 0 Favours glucosamine
 
 
Analysis 31.3.   Comparison 31 Chinese BNHS versus glucosamine
sulphate, Outcome 3 Participants (n) reported adverse events.
Study or subgroup BNHS Glucosamine
sulphate
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Cao 2005 4/30 0/30 100% 9[0.51,160.17]
   
Total (95% CI) 30 30 100% 9[0.51,160.17]
Total events: 4 (BNHS), 0 (Glucosamine sulphate)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.5(P=0.13)  
Favours BNHS 1000.01 100.1 1 Favours glucosamine
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Comparison 32.   Ayurvedic A to E versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Adverse event episodes (n) reported 1 454 Risk Ratio (M-H, Random, 95%
CI)
0.95 [0.71, 1.28]
1.1 Formula A versus placebo 1 90 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.63, 1.45]
1.2 Formula B versus placebo 1 108 Risk Ratio (M-H, Random, 95%
CI)
1.35 [0.92, 1.98]
1.3 Formula C versus placebo 1 82 Risk Ratio (M-H, Random, 95%
CI)
0.78 [0.50, 1.21]
1.4 Formula D versus placebo 1 72 Risk Ratio (M-H, Random, 95%
CI)
0.57 [0.34, 0.93]
1.5 Formula E versus placebo 1 102 Risk Ratio (M-H, Random, 95%
CI)
1.22 [0.82, 1.80]
 
 
Analysis 32.1.   Comparison 32 Ayurvedic A to E versus placebo, Outcome 1 Adverse event episodes (n) reported.
Study or subgroup Ayurveda Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
32.1.1 Formula A versus placebo  
Chopra 2011 22/45 23/45 20.45% 0.96[0.63,1.45]
Subtotal (95% CI) 45 45 20.45% 0.96[0.63,1.45]
Total events: 22 (Ayurveda), 23 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.21(P=0.83)  
   
32.1.2 Formula B versus placebo  
Chopra 2011 31/54 23/54 21.6% 1.35[0.92,1.98]
Subtotal (95% CI) 54 54 21.6% 1.35[0.92,1.98]
Total events: 31 (Ayurveda), 23 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.52(P=0.13)  
   
32.1.3 Formula C versus placebo  
Chopra 2011 18/41 23/41 19.41% 0.78[0.5,1.21]
Subtotal (95% CI) 41 41 19.41% 0.78[0.5,1.21]
Total events: 18 (Ayurveda), 23 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.09(P=0.27)  
   
32.1.4 Formula D versus placebo  
Chopra 2011 13/36 23/36 17.21% 0.57[0.34,0.93]
Subtotal (95% CI) 36 36 17.21% 0.57[0.34,0.93]
Total events: 13 (Ayurveda), 23 (Placebo)  
Favours Ayurveda 1000.01 100.1 1 Favours placebo
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Study or subgroup Ayurveda Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=2.24(P=0.03)  
   
32.1.5 Formula E versus placebo  
Chopra 2011 28/51 23/51 21.33% 1.22[0.82,1.8]
Subtotal (95% CI) 51 51 21.33% 1.22[0.82,1.8]
Total events: 28 (Ayurveda), 23 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.98(P=0.33)  
   
Total (95% CI) 227 227 100% 0.95[0.71,1.28]
Total events: 112 (Ayurveda), 115 (Placebo)  
Heterogeneity: Tau2=0.06; Chi2=9.5, df=4(P=0.05); I2=57.89%  
Test for overall effect: Z=0.33(P=0.74)  
Test for subgroup differences: Chi2=9.49, df=1 (P=0.05), I2=57.86%  
Favours Ayurveda 1000.01 100.1 1 Favours placebo
 
 
Comparison 33.   Ayurvedic Antarth versus placebo
Outcome or subgroup title No. of
studies
No. of partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 1 88 Mean Difference (IV, Random, 95% CI) -1.0 [-9.79, 7.79]
 
 
Analysis 33.1.   Comparison 33 Ayurvedic Antarth versus placebo, Outcome 1 Pain VAS 0-100.
Study or subgroup Antarth Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Gupta 2011 44 47 (20) 44 48 (22) 100% -1[-9.79,7.79]
   
Total *** 44   44   100% -1[-9.79,7.79]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.22(P=0.82)  
Favours Antarth 10050-100 -50 0 Favours placebo
 
 
Comparison 34.   Ayurvedic RA-II versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 1 90 Mean Difference (IV, Random, 95%
CI)
-1.03 [-1.18, -0.88]
2 WOMAC 0-4 (Function) 1 90 Mean Difference (IV, Random, 95%
CI)
-5.80 [-6.72, -4.88]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3 Participants (n) reported adverse
events
1 90 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.69, 1.58]
 
 
Analysis 34.1.   Comparison 34 Ayurvedic RA-II versus placebo, Outcome 1 Pain VAS 0-100.
Study or subgroup RA-II Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Chopra 2004 45 -2.8 (0.4) 45 -1.8 (0.4) 100% -1.03[-1.18,-0.88]
   
Total *** 45   45   100% -1.03[-1.18,-0.88]
Heterogeneity: Not applicable  
Test for overall effect: Z=13.2(P<0.0001)  
Favours RA-II 10050-100 -50 0 Favours placebo
 
 
Analysis 34.2.   Comparison 34 Ayurvedic RA-II versus placebo, Outcome 2 WOMAC 0-4 (Function).
Study or subgroup RA-II Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Chopra 2004 45 -12.7 (2.1) 45 -6.9 (2.4) 100% -5.8[-6.72,-4.88]
   
Total *** 45   45   100% -5.8[-6.72,-4.88]
Heterogeneity: Not applicable  
Test for overall effect: Z=12.29(P<0.0001)  
Favours RA-II 5025-50 -25 0 Favours placebo
 
 
Analysis 34.3.   Comparison 34 Ayurvedic RA-II versus placebo, Outcome 3 Participants (n) reported adverse events.
Study or subgroup RA-II Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Chopra 2004 23/45 22/45 100% 1.05[0.69,1.58]
   
Total (95% CI) 45 45 100% 1.05[0.69,1.58]
Total events: 23 (RA-II), 22 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.21(P=0.83)  
Favours RA-II 1000.01 100.1 1 Favours placebo
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Comparison 35.   Ayurvedic SGC versus glucosamine sulphate
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 change from baseline 1 220 Mean Difference (IV, Random, 95% CI) 3.0 [-3.28, 9.28]
2 WOMAC 0-4 (Function) change from
baseline
1 220 Mean Difference (IV, Random, 95% CI) 2.0 [-0.72, 4.72]
3 Participants (n) reported adverse
events
1 210 Odds Ratio (M-H, Random, 95% CI) 1.04 [0.58, 1.86]
 
 
Analysis 35.1.   Comparison 35 Ayurvedic SGC versus glucosamine
sulphate, Outcome 1 Pain VAS 0-100 change from baseline.
Study or subgroup SGC Glucosamine
sulphate
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Chopra 2013 110 -21 (24.8) 110 -24 (22.7) 100% 3[-3.28,9.28]
   
Total *** 110   110   100% 3[-3.28,9.28]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.94(P=0.35)  
Favours SGC 10050-100 -50 0 Favours glucosamine
 
 
Analysis 35.2.   Comparison 35 Ayurvedic SGC versus glucosamine
sulphate, Outcome 2 WOMAC 0-4 (Function) change from baseline.
Study or subgroup SGC Glucosamine
sulphate
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Chopra 2013 110 -6 (9.5) 110 -8 (11) 100% 2[-0.72,4.72]
   
Total *** 110   110   100% 2[-0.72,4.72]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.44(P=0.15)  
Favours experimental 5025-50 -25 0 Favours control
 
 
Analysis 35.3.   Comparison 35 Ayurvedic SGC versus glucosamine
sulphate, Outcome 3 Participants (n) reported adverse events.
Study or subgroup SGC Glucosamine
sulphate
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Chopra 2013 33/102 34/108 100% 1.04[0.58,1.86]
   
Favours experimental 1000.01 100.1 1 Favours control
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Study or subgroup SGC Glucosamine
sulphate
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total (95% CI) 102 108 100% 1.04[0.58,1.86]
Total events: 33 (SGC), 34 (Glucosamine sulphate)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.14(P=0.89)  
Favours experimental 1000.01 100.1 1 Favours control
 
 
Comparison 36.   Ayurvedic SGC versus celecoxib
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 change from baseline 1 220 Mean Difference (IV, Random, 95% CI) -3.0 [-8.98, 2.98]
2 WOMAC 0-4 (Function) change from
baseline
1 220 Mean Difference (IV, Random, 95% CI) 1.0 [-1.60, 3.60]
3 Participants (n) reported adverse
events
1 207 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.56, 1.79]
 
 
Analysis 36.1.   Comparison 36 Ayurvedic SGC versus celecoxib, Outcome 1 Pain VAS 0-100 change from baseline.
Study or subgroup SGC Celecoxib Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Chopra 2013 110 -21 (24.9) 110 -18 (20.1) 100% -3[-8.98,2.98]
   
Total *** 110   110   100% -3[-8.98,2.98]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.98(P=0.33)  
Favours SGC 10050-100 -50 0 Favours celecoxib
 
 
Analysis 36.2.   Comparison 36 Ayurvedic SGC versus celecoxib,
Outcome 2 WOMAC 0-4 (Function) change from baseline.
Study or subgroup SGC Celecoxib Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Chopra 2013 110 -6 (9.5) 110 -7 (10.2) 100% 1[-1.6,3.6]
   
Total *** 110   110   100% 1[-1.6,3.6]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.75(P=0.45)  
Favours SGC 5025-50 -25 0 Favours celecoxib
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Analysis 36.3.   Comparison 36 Ayurvedic SGC versus celecoxib, Outcome 3 Participants (n) reported adverse events.
Study or subgroup SGC Celecoxib Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Chopra 2013 33/102 34/105 100% 1[0.56,1.79]
   
Total (95% CI) 102 105 100% 1[0.56,1.79]
Total events: 33 (SGC), 34 (Celecoxib)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0(P=1)  
Favours SGC 1000.01 100.1 1 Favours celecoxib
 
 
Comparison 37.   Ayurvedic SGCG versus glucosamine sulphate
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 change from baseline 1 220 Mean Difference (IV, Random, 95% CI) 4.0 [-1.42, 9.42]
2 WOMAC 0-4 (Function) change from
baseline
1 220 Mean Difference (IV, Random, 95% CI) 1.38 [-1.40, 4.16]
3 Participants (n) reported adverse
events
1 211 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.47, 1.54]
 
 
Analysis 37.1.   Comparison 37 Ayurvedic SGCG versus glucosamine
sulphate, Outcome 1 Pain VAS 0-100 change from baseline.
Study or subgroup SGCG Glucosamine
sulphate
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Chopra 2013 110 -20 (21) 110 -24 (20) 100% 4[-1.42,9.42]
   
Total *** 110   110   100% 4[-1.42,9.42]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.45(P=0.15)  
Favours SGCG 10050-100 -50 0 Favours glucosamine
 
 
Analysis 37.2.   Comparison 37 Ayurvedic SGCG versus glucosamine
sulphate, Outcome 2 WOMAC 0-4 (Function) change from baseline.
Study or subgroup SGCG Glucosamine
sulphate
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Chopra 2013 110 -6.7 (11) 110 -8.1 (10) 100% 1.38[-1.4,4.16]
   
Total *** 110   110   100% 1.38[-1.4,4.16]
Favours SGCG 5025-50 -25 0 Favours glucosamine
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Study or subgroup SGCG Glucosamine
sulphate
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.97(P=0.33)  
Favours SGCG 5025-50 -25 0 Favours glucosamine
 
 
Analysis 37.3.   Comparison 37 Ayurvedic SGCG versus glucosamine
sulphate, Outcome 3 Participants (n) reported adverse events.
Study or subgroup SGCG Glucosamine
sulphate
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Chopra 2013 29/103 34/108 100% 0.85[0.47,1.54]
   
Total (95% CI) 103 108 100% 0.85[0.47,1.54]
Total events: 29 (SGCG), 34 (Glucosamine sulphate)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.53(P=0.6)  
Favours SGCG 1000.01 100.1 1 Favours glucosamine
 
 
Comparison 38.   Ayurvedic SGCG versus celecoxib
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 change from baseline 1 220 Mean Difference (IV, Random, 95% CI) -2.0 [-7.42, 3.42]
2 WOMAC 0-4 (Function) change from
baseline
1 220 Mean Difference (IV, Random, 95% CI) 0.19 [-2.59, 2.97]
3 Participants (n) reported adverse
events
1 208 Odds Ratio (M-H, Random, 95% CI) 0.82 [0.45, 1.48]
 
 
Analysis 38.1.   Comparison 38 Ayurvedic SGCG versus celecoxib, Outcome 1 Pain VAS 0-100 change from baseline.
Study or subgroup SGCG Celecoxib Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Chopra 2013 110 -20 (21) 110 -18 (20) 100% -2[-7.42,3.42]
   
Total *** 110   110   100% -2[-7.42,3.42]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.72(P=0.47)  
Favours SGCG 10050-100 -50 0 Favours celecoxib
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Analysis 38.2.   Comparison 38 Ayurvedic SGCG versus celecoxib,
Outcome 2 WOMAC 0-4 (Function) change from baseline.
Study or subgroup SGCG Celecoxib Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Chopra 2013 110 -6.7 (11) 110 -6.9 (10) 100% 0.19[-2.59,2.97]
   
Total *** 110   110   100% 0.19[-2.59,2.97]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.13(P=0.89)  
Favours SGCG 5025-50 -25 0 Favours celecoxib
 
 
Analysis 38.3.   Comparison 38 Ayurvedic SGCG versus
celecoxib, Outcome 3 Participants (n) reported adverse events.
Study or subgroup SGCG Celecoxib Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Chopra 2013 29/103 34/105 100% 0.82[0.45,1.48]
   
Total (95% CI) 103 105 100% 0.82[0.45,1.48]
Total events: 29 (SGCG), 34 (Celecoxib)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.66(P=0.51)  
Favours SGCG 1000.01 100.1 1 Favours celecoxib
 
 
Comparison 39.   Japanese Boiogito + loxoprofen versus loxoprofen
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain: Knee Society Rating System
0-100 (knee)
1 47 Mean Difference (IV, Random, 95% CI) -1.30 [-8.90, 6.30]
2 Function: Knee Society Rating System
0-50 (stairs)
1 47 Mean Difference (IV, Random, 95% CI) 3.60 [0.51, 6.69]
3 Participants (n) reported adverse
events
1 47 Risk Ratio (M-H, Random, 95% CI) 2.88 [0.12, 67.29]
 
 
Analysis 39.1.   Comparison 39 Japanese Boiogito + loxoprofen versus
loxoprofen, Outcome 1 Pain: Knee Society Rating System 0-100 (knee).
Study or subgroup Boiogito Ioxoprofen Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Majima 2012 24 85.8 (11.1) 23 87.1 (15.1) 100% -1.3[-8.9,6.3]
   
Favours Boiogito 10050-100 -50 0 Favours ioxoprofen
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Study or subgroup Boiogito Ioxoprofen Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Total *** 24   23   100% -1.3[-8.9,6.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.34(P=0.74)  
Favours Boiogito 10050-100 -50 0 Favours ioxoprofen
 
 
Analysis 39.2.   Comparison 39 Japanese Boiogito + loxoprofen versus
loxoprofen, Outcome 2 Function: Knee Society Rating System 0-50 (stairs).
Study or subgroup Boiogito Ioxoprofen Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Majima 2012 24 40.2 (4.4) 23 36.6 (6.2) 100% 3.6[0.51,6.69]
   
Total *** 24   23   100% 3.6[0.51,6.69]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.29(P=0.02)  
Favours Boiogito 5025-50 -25 0 Favours ioxoprofen
 
 
Analysis 39.3.   Comparison 39 Japanese Boiogito + loxoprofen versus
loxoprofen, Outcome 3 Participants (n) reported adverse events.
Study or subgroup Boiogito Ioxoprofen Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Majima 2012 1/24 0/23 100% 2.88[0.12,67.29]
   
Total (95% CI) 24 23 100% 2.88[0.12,67.29]
Total events: 1 (Boiogito), 0 (Ioxoprofen)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
Favours Boiogito 1000.01 100.1 1 Favours ioxoprofen
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PLANT MEDICINAL PRODUCT DOSE MARKER  
Botanical
name
Part/s Tradename Preparation Drug:Ex-
tract
mg/day Constituent marker Quantity
of marker
References
Medicinal products from single plants
CapWokvelTM 999 boswellic acid
(total organic acids
65%)
40% Kimmatkar 2003,
Sontakke 2007
5-Loxin 100 or 250 AKBA 30% Sengupta 2008
Sengupta 2010
Boswellia
serrata
gum resin
Aflapin
extraction solvent not
stated
not stated
100 AKBA + non-volatile oil 20% Sengupta 2010
Vishal 2011
Curcuma do-
mestica
root study medication ethanolic extract not stated   curcumoids 500mg Kuptniratsaikul 2009
Derris scan-
dens
stem study medication ethanolic (50%) extract not stated 800 genistein derivatve not stated Kuptniratsaikul 2011
Garcinia ko-
la
seed study medication freeze-dried aqueous ex-
tract
not stated 400 not stated   Adegbehingbe 2008
Arthrotabs aqueous extract 1.5-2.5:1 2400 30 mg Schmelz 1997.
Flexiloges ethanolic (60%) extract 4.5-5.5:1 960 <30 mg Frerick 2001, Biller
2002.
Harpago-
phytum
procumbens
root
Harpadol cryoground powder   2610
harpagoside1
60 mg Leblan 2000.
Petiveria al-
liacea
herb Tipi tea aqueous extract 9g / 600 ml 600 ml not stated   Ferraz 1991
  150 45 (90%) Cisar 2008Pinus
pinaster
(synonym
Pinus mariti-
ma)
bark Pycnogenol® polyphenol concentrate
  100
proanthocyanidins
not stated Belcaro 2008
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  150 70% Farid 2007
Ricinus offic-
inalis
seed study medication oil not stated 2,7 ml ricinoleic acid not stated Medhi 2009
Rosa canina
lito
rose hip
and seed
Hyben Vital or Litozin powder   5000 galactolipid 1.5mg Rein 2004a Warholm
2003
Winther 2005
Salix daph-
noides
bark study medication ethanolic (70%) extract 8-14:1 1573 salicin 240 mg Biegert 2004.
Salix
pupurea x
daphnoides
bark study medication ethanolic (70%) extract2 10-20:1 1360 salicin 240 mg Schmid 2000.
Uncaria
guianensis
bark study medication freeze-dried aqueous ex-
tract
not stated 100 not stated   Piscoya 2001.
Vitellaria
paradoxa 
seed study medication patented extract not stated 2250 triterpenes 75% Cheras 2010
Zingiber of-
ficinale3
root EV.EXT 33 acetone extract3 20:1 510 not stated   Bliddal 2000.
Zingiber of-
ficinale
root Zintona EC CO2 extract not stated 1000 gingerol 40 mg Wigler 2003
Medicinal products from two plants
Boswellia
carteri +
Curcuma
longa
gum + root study medication extract, solvent not stat-
ed
not stated not stated boswellic acid 37.5% Badria 2002
Persea
gratissma
(P) + Glycine
max (G)
oils Piascledine 300 unsaponifiable fraction
1/3 P;2/3 G
  300 or 600 not stated   Appelboom 2001,
Blotman 1997,
Lequesne 2002, Ma-
heu 1998, Maheu
2013.
Phellon-
denron
bark NP 06-1 extract, solvent not stat-
ed
not stated 370 mix-
ture
berberine 50% Oben 2009
Table 1.   Herbal medicinal products used for the treatment of OA  (Continued)
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amurense +
Citrus sinen-
sis
peel polymethoxylated
flavones
30%
Uncaria
guianensis
+ Lepidium
meyenii
bark Reparagen® freeze-dried aqueous ex-
tract
not stated 1500
300
not stated   Mehta 2007
Zingiber
officinale
+ Alpinia
galanga
root EV.EXT 77 acetone extract3 20:1 not stated not stated   Altman 2001
Medicinal products from three or more plants
Clematis
mandshuri-
ca + Prunel-
la vulgaris
+ Trichosan-
thes kirilowii
root,
flower,
root; 1:1:2
SKI306X ethanol 30% extracts,
thereafter butanol ex-
traction
7:1 600-1800 oleanolic acid 4%, ros-
marinic acids 0.2%,
ursolic acids 0.5%,
hydroxybenzoic acid
0.03%,
hydroxymethoxyben-
zoic acid 0.03%, trans-
cinnamic
acid 0.05%
  Jung 2001, Jung
2004.
total flavonoids 0.34 - 0.56
mg
Fraxinus ex-
celsior
bark
salicyl alcohol 0.48 - 0.8
mg
Solidago vir-
gaurea
herb isofraxidin 0.67 - 1.1
mg
Populus
tremula
bark and
leaf
Phytodolor fresh plant ethanolic
(45,6%) extract
3:1:1 5-8 ml
salicin 4.8 - 8 mg
Bernhardt 1991, Hu-
ber 1991, Schadler
1988.
Salix alba bark powder   200 salicin 40-80mg
Guaiacun of-
ficinale
resin
Reumalex
powder   80    
Mills 1996
Table 1.   Herbal medicinal products used for the treatment of OA  (Continued)
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Cimicifuga
racemosa
root powder   70    
Smilax
(species not
stated)
root extract, solvent not stat-
ed
4:1 50    
Populus
(species not
stated)
bark extract, solvent not stat-
ed
7:1 34    
Chinese
mixture4
herb Duhuo Jisheng Wan powder   3 x 3 g not stated   Teekachunhatean
2004.
Paeoniae al-
ba
paconiflorin
Gentiana
macrophylla
gentianine
Glycyrrhiza
(species not
stated)
root Chinese mixture:
Blood nourishing,
hard softening (BN-
HS)
extract, solvent not stat-
ed
not stated 3150
not stated
not stated Cao 2005
Auryvedic formaulae5
Zingiber of-
ficinale 
rhizome component of for-
mulae A, B, C, D, and
E
powder 1000 total gingerols not stated
Tinospora
cordifolia
stem component of for-
mulae A, B, C, D, and
E
aqueous extract 220 tinosporosides not stated
Withania
somnifera
root component of for-
mulae B and E
aqueous extract 600 total withanolides not stated
Emblica of-
ficinale
fruit component of for-
mulae C
aqueous extract 500 tannins
galic acid
not stated
Tribulus ter-
restris
fruit component of for-
mulae A and B
aqueous extract
not stated
216 total saponins not stated
Chopra 2011
Table 1.   Herbal medicinal products used for the treatment of OA  (Continued)
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Ayuvedic
formula6
  Antarth3 (for sandhi-
gata vata)
not stated not stated   not stated not stated Gupta 2011
Ayuvedic
formula
  RA-11 not stated not stated   not stated not stated Chopra 2004
Ayuvedic
formula
  SGC           Chopra 2013
Ayuvedic   SGCG           Chopra 2013
Japanese
mixture7
  Boiogito not stated not stated 7.5g not stated not stated Majima 2012
Table 1.   Herbal medicinal products used for the treatment of OA  (Continued)
1. Harpagoside content estimated indirectly and approximately from iridoid glycoside content in daily dose of raw material (Sporer 1999).
2. Ethanolic extract stated in unpublished thesis but not in published paper (Schmid 1998b).
3. Information provided by manufacturer but not reported in paper.
4. Chinese herbal medicine contains 7.75% each of: radix angelicae pubescentiis, radix gentianae macrophyllae, cortex eucommiae, radix achyranthis bidentatae, radix angelicae
sinensis, herba taxilli, radix rehmanniae preparata, rhizoma chuanxiong, cortex cinnamomi, radix ledebouriellae. 5% each of: radix paeoniae alba, radix codonopis, radix
glycyrrhizae, poria. 2.5% herba asari.
5. All Ayurvedic formulae A-E contain Zingiber o)icinale (dried rhizome powder, total gingerols as marker), and Tinospora cordifolia (dried stem aqueous extract, marker
tinosporosides). Some formulae also included Emblica o)icinale, Withania somnifera, or Tribulus terrestris. Drug:extract ratio and marker content not stated.
6. Ayurvedic phytomedicine Antarth contains Boswellia serrata, Commiphora mukul, Curcuma longa and Vitex negundo, Alpinia galangal, Withania somnifera, Tribulus
terrestris, and Tinospora cordifolia.
7. Japanese herbal medicine Boiogito contains Sinomenium acutum, Astragalus (species not stated) root, Atractylodes lancea rhizome, Jujube (probably Ziziphus zizyphus),
Glycyrrhiza (species not stated), and ginger (species not stated, probably Zingiber o)icinale).
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A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE
1     exp osteoarthritis/
2     osteoarthr$.tw.
3     (degenerative adj2 arthritis).tw.
4     arthrosis.tw.
5     or/1-4
6     exp Medicine, Herbal/
7     exp Plants, Medicinal/
8     exp Medicine, Traditional/
9     exp Drugs, Chinese Herbal/
10     herb$.tw.
11     (plant or plants).tw.
12     phytomedicine.tw.
13     botanical.tw.
14     weed$.tw.
15     algae.tw.
16     (fungi or fungus).tw.
17     ((traditional or chinese or herbal) adj medicine).tw.
18     ((oriental or chinese) adj tradition$).tw.
19     or/6-18
20     5 and 19
EMBASE
1     exp osteoarthritis/
2     osteoarthr$.tw.
3     (degenerative adj2 arthritis).tw.
4     arthrosis.tw.
5     or/1-4
6     exp Herbal Medicine/
7     exp Medicinal Plant/
8     exp Traditional Medicine/
9     exp Chinese Medicine/
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10     herb$.tw.
11     (plant or plants).tw.
12     phytomedicine.tw.
13     botanical.tw.
14     weed$.tw.
15     algae.tw.
16     (fungi or fungus).tw.
17     ((traditional or chinese or herbal) adj medicine).tw.
18     ((oriental or chinese) adj tradition$).tw.
19     or/6-18
20     5 and 19
CINAHL
1     exp OSTEOARTHRITIS/
2     osteoarthr$.tw.
3     (degenerative adj2 arthritis).tw.
4     arthrosis.tw.
5     or/1-4
6     exp Medicine, Herbal/
7     exp Plants, Medicinal/
8     Medicine, Traditional/
9     exp Plant Extracts/
10     herb$.tw.
11     (plant or plants).tw.
12     phytomedicine.tw.
13     botanical.tw.
14     weed$.tw.
15     algae.tw.
16     (fungi or fungus).tw.
17     ((traditional or chinese or herbal) adj medicine).tw.
18     ((oriental or chinese) adj tradition$).tw.
19     or/6-18
20     5 and 19
Revised Strategy (EBSOhost)
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S24 S5 and S22
S23 S5 and S22
S22 S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21
S21 ti chinese tradition* or ab chinese tradition*
S20 ti oriental tradition* or ab oriental tradition*
S19 ti herbal medicine or ab herbal medicine
S18 ti chinese medicine or ab chinese medicine
S17 ti traditional medicine or ab traditional medicine
S16 ti fungi or ti fungus or ab fungi or ab fungus
S15 ti algae or ab algae
S14 ti weed* or ab weed*
S13 ti botanical or ab botanical
S12 ti phytomedicine or ab phytomedicine
S11 ti plant or ti plants or ab plant or ab plants
S10 ti herb* or ab herb*
S9 (MH "Plant Extracts+")
S8 (MH "Medicine, Traditional+")
S7 (MH "Plants, Medicinal+")
S6 (MH "Medicine, Herbal+")
S5 S1 or S2 or S3 or S4
S4 ti arthrosis or ab arthrosis
S3 ti degenerative N2 arthritis or ab degenerative N2 arthritis
S2 ti osteoarthr* or ab osteoarthr*
S1 (MH "Osteoarthritis+")
AMED
1     exp Osteoarthritis/
2     osteoarthr$.tw.
3     (degenerative adj2 arthritis).tw.
4     arthrosis.tw.
5     or/1-4
6     exp herbal drugs/
7     exp traditional medicine/
8     exp plant extracts/
9     exp plants medicinal/
10     herb$.tw.
11     (plant or plants).tw.
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12     phytomedicine.tw.
13     botanical.tw.
14     weed$.tw.
15     algae.tw.
16     (fungi or fungus).tw.
17     ((traditional or chinese or herbal) adj medicine).tw.
18     ((oriental or chinese) adj tradition$).tw.
19     or/6-18
20     5 and 19
The Cochrane Library 2008, Issue 4
#1           MeSH descriptor Osteoarthritis explode all trees
#2           osteoarthr*:ti,ab
#3           (degenerative near/2 arthritis):ti,ab
#4           arthrosis:ti,ab
#5           (#1 OR #2 OR #3 OR #4)
#6           MeSH descriptor Medicine, Herbal explode all trees
#7           MeSH descriptor Plants, Medicinal explode all trees
#8           MeSH descriptor Medicine, Traditional explode all trees
#9           MeSH descriptor Drugs, Chinese Herbal explode all trees
#10         herb*:ti,ab
#11         (plant or plants):ti,ab
#12         phytomedicine:ti,ab
#13         botanical:ti,ab
#14         weed*:ti,ab
#15         algae:ti,ab
#16         (fungi or fungus):ti,ab
#17         ((traditional or chinese or herbal) next medicine):ti,ab
#18         ((oriental or chinese) next tradition*):ti,ab
#19         (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18)
#20         (#5 AND #19)
ISI Web of Science
#7 #4 AND #1
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Refined by: Publication Years=( 2009 OR 2007 OR 2004 OR 2001 OR 2010 OR 2005 OR 2003 OR 2000 OR 2008 OR 2006 OR 2002 ) AND Document
Type=( PROCEEDINGS PAPER OR MEETING ABSTRACT )
#6 #4 AND #1
Refined by: Publication Years=( 2009 OR 2007 OR 2004 OR 2001 OR 2010 OR 2005
#5 #4 AND #1
#4 #3 OR #2
#3 Topic=(((oriental or chinese or traditional) and (medicine or therap*)))
#2 Topic=(herb* or plant or plants or phytomedicine or botanical or weed* or algae or fungi or fungus)
#1 Topic=(arthrit* or arthrosis or osteoarthrit* or osteoarthrosis)
Dissertation Abstracts
arthrit* or arthrosis or osteoarthrit* or osteoarthrosis AND
herb* or plant or plants or phytomedicine or botanical or weed* or algae or fungi or fungus or ((oriental or chinese or traditional) and
(medicin* or therap*))
World Health Organization International Clinical Trials Registry Platform
Osteoarthritis in Condition AND
herb* or plant or plants or phytomedicine or botanical or weed* or algae or fungi or fungus or oriental or chinese or traditional in
Intervention
F E E D B A C K
New feedback, 12 November 2015
Summary
Date of Submission: 12-Nov-2015
Name: Bernd Kerschner
Email Address: bernd.kerschner@donau-uni.ac.at
ADiliation: Cochrane Austria
Role: medical journalist
Comment: Dear editors and authors,
the conclusions in the present review on oral herbal therapies for treating osteoarthritis are very confusing and in part contradictory when
it comes to the eDicacy of Boswellia extract.
While the Author's conclusions state:
"Several other medicinal plant products, including extracts of Boswellia serrata, show trends of benefits that warrant further investigation
in light of the fact that the risk of adverse events appear low."
the plain language summary however says:
"There is high-quality evidence that in people with osteoarthritis Boswellia serrata slightly improved pain and function. Further research
is unlikely to change the estimates."
When trying to interprete the results from the summary of findings tables on the diDerent dosages of Boswellia extract (999mg, 100 mg
enriched, 250 mg enriched and 100 mg enriched + volatile oils) it appears to me that there is indeed all in all HIGH evidence for the principle
eDicacy of Boswellia.
with best regards,
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Bernd Kerschner, Krems, Austria
I agree with the conflict of interest statement below:
I certify that I have no aDiliations with or involvement in any organization or entity with a financial interest in the subject matter of my
feedback.
Reply
Thank you for your feedback.
Indeed, the statements in the conclusions, Re: Boswellia serrata, seemingly contradict the summary of evidence in summary of findings
table 2, and the plain language summary. Upon reflection, we believe the evidence for improved pain and function with Boswellia is
moderate-quality - there is a potential for imprecision due to the small number of participants contributing to these outcomes. This is
also reflected in the lower 95% confidence intervals around the eDect estimates for pain and function, which include a small and possibly
clinically insignificant improvement in pain and function. Thus, further research may change the estimates, and will likely improve the
precision of the findings. We have altered the text in the plain language summary, abstract, text and the summary of findings tables to
reflect the judgement of moderate-quality evidence for improved pain and function with treatment with Boswellia serrata.
We will be updating the review, and splitting into separate reviews for individual herbs. Thus, we may find new studies to add to the body
of evidence for assessing the benefits and possible harms of Boswellia serrata and other herbs
Contributors
Melainie Cameron, Author.
Renea Johnston, Managing Editor.
W H A T ' S   N E W
 
Date Event Description
7 March 2016 Feedback has been incorporated Responded to feedback
 
H I S T O R Y
Review first published: Issue 1, 2001
 
Date Event Description
25 September 2013 New citation required and conclusions
have changed
Substantive update including changed conclusions; new authors
added.
Change in conclusions on update: small, statistically signifi-
cant benefits in terms of pain and function now reported for two
herbal preparations, Boswellia serrata extracts and avocado-soy-
abean unsaponifiables. Many other herbal preparations includ-
ed.
Methods were updated in accordance with current Cochrane Col-
laboration recommendations: risk of bias assessment and sum-
mary of findings tables were added, and substantial re-writing
was performed in the reporting of the methods and results to
align with the standards recommended by the Cochrane Collab-
oration's Methodological Expectations of Cochrane Intervention
Reviews (MECIR) project.
29 August 2013 New search has been performed An additional 45 studies were added to this review update, plus
four studies were included from the original review.
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Date Event Description
The updated review is now divided into two parts: oral and top-
ical herbal therapies for treating osteoarthritis. This review cov-
ers oral herbal therapies only. Inclusion criteria have been nar-
rowed to strictly apply the World Health Organization (WHO) de-
finition of herbal medicines, thereby excluding studies of inter-
ventions that include non-herbal components (for example zinc,
magnesium), or extracted or synthetic single compounds.
10 May 2008 Amended CMSG ID A008R
 
C O N T R I B U T I O N S   O F   A U T H O R S
SC and MC contributed to the paper selection and data extraction. MC and SG completed the data analysis and interpretation, and wrote,
checked, proof-read, and approved the updated review.
D E C L A R A T I O N S   O F   I N T E R E S T
None known
S O U R C E S   O F   S U P P O R T
Internal sources• Victoria University, Australia.
Victoria University provided one author with time release from normal duties (2004-2009) for review training and to undertake this
review.• University of Freiburg, Germany.
University of Freiburg provided one author with time release from normal duties to complete the review. A staD member of the Cochrane
Centre Germany, based at the University of Frieburg, assisted with data extraction from German lanugage manucripts.• Australian Catholic University, Australia.
The Australian Catholic University provided one author with time release from normal duties (2010-2011) to undertake this review.
Librarians from the Australian Catholic University assisted with the acquisition of full manuscripts of studies included in this review.• University of the Sunshine Coast, Australia.
The University of the Sunshine Coast provided one author with time release from normal duties (2012) to complete this review.
External sources• National Center for Complementary and Alternative Medicine, USA.
This work was partially funded by Grant Number R24 AT001293 from the National Center for Complementary and Alternative Medicine
(NCCAM). The contents of this systematic review are solely the responsibility of the authors and do not necessarily represent the oDicial
views of the NCCAM or the National Institutes of Health.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
For this review update, we expanded the inclusion criteria so studies that included an active control as well as placebo controls,
unpublished reports of randomised controlled trials, and trials in any language were eligible for inclusion. Changes to the methods of
quality assessment (replaced by assessment of 'risk of bias') and analysis and presentation of results are consistent with updated Cochrane
Collaboration and Cochrane Musculoskeletal Group methods introduced since the original review. We restricted included studies to those
investigations of interventions that strictly satisfied the WHO guidelines for herbal medicines. This updated review is limited to oral
medicinal plant products. In the original review, studies of the same herbal therapy that used the same outcome measure were pooled
regardless of the length of the intervention period. In this update, these data and comparisons are subgrouped according to intervention
time, rather than pooled. The table of herbal interventions has been extensively revised so that it oDers detailed information about the
herbal medicines, including full botanical names, part/s of the plant used, details of extraction methods, drug:extract ratios, and active
principles
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I N D E X   T E R M S
Medical Subject Headings (MeSH)
Administration, Oral;  Boswellia;  Chronic Disease;  Drug Combinations;  Osteoarthritis  [*drug therapy];  Phytosterols  [therapeutic use]; 
Phytotherapy  [*methods];  Plant Extracts  [therapeutic use];  Randomized Controlled Trials as Topic;  Vitamin E  [therapeutic use]
MeSH check words
Humans
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